

10/527,435

=> ....Testing the current file.... screen


ENTER SCREEN EXPRESSION OR (END):end

=> screen 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L1 SCREEN CREATED

=>

Uploading C:\Program Files\Stnexp\Queries\10527435 (a).str



chain nodes :

12 13

ring nodes :

1 2 3 4 5 6 7 8 9 10 11

ring/chain nodes :

14

chain bonds :

2-14 8-12 11-13

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 5-11 7-8 8-9 9-10 10-11

exact/norm bonds :

2-14 8-12 11-13

exact bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 5-11 7-8 8-9 9-10 10-11

isolated ring systems :

containing 1 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom

11:Atom 12:CLASS 13:CLASS 14:CLASS

L2 STRUCTURE UPLOADED

=> que L2 NOT L1

L3 QUE L2 NOT L1


10/527,435

=> d 13

L3 HAS NO ANSWERS

L1 SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L2 STR



Structure attributes must be viewed using STN Express query preparation.

L3 QUE L2 NOT L1

=> s 13 sss sam

SAMPLE SEARCH INITIATED 23:35:39 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 96 TO ITERATE

100.0% PROCESSED 96 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 1333 TO 2507

PROJECTED ANSWERS: 0 TO 0

L4 0 SEA SSS SAM L2 NOT L1

=> ....Testing the current file.... screen


ENTER SCREEN EXPRESSION OR (END):end

=> screen 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L5 SCREEN CREATED

=>

Uploading C:\Program Files\Stnexp\Queries\10527435 (b).str



```

chain nodes :
12 13
ring nodes :
1 2 3 4 5 6 7 8 9 10 11
ring/chain nodes :
14
chain bonds :
2-14 8-12 11-13
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 5-11 7-8 8-9 9-10 10-11
exact/norm bonds :
2-14 5-7 5-11 7-8 8-9 8-12 9-10 10-11 11-13
exact bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 :

```

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:CLASS 13:CLASS 14:CLASS

```

L6 STRUCTURE UPLOADED

=> que L6 NOT L5

L7 QUE L6 NOT L5


=> d 17

L7 HAS NO ANSWERS

L5 SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L6 STR

10/527,435



Structure attributes must be viewed using STN Express query preparation.  
L7                    QUE   L6 NOT L5

=> s 17 sss sam  
SAMPLE SEARCH INITIATED 23:38:31 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED -        537 TO ITERATE

100.0% PROCESSED            537 ITERATIONS                    50 ANSWERS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:    ONLINE    \*\*COMPLETE\*\*  
                              BATCH    \*\*COMPLETE\*\*  
PROJECTED ITERATIONS:        9350 TO    12130  
PROJECTED ANSWERS:            4524 TO    6516

L8                    50 SEA SSS SAM L6 NOT L5

=> => ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=> screen 1839


L9        SCREEN CREATED

=> screen 2016 OR   2026 OR   2039 OR   2040 OR   2045 OR   2047

L10       SCREEN CREATED

=>  
Uploading C:\Program Files\Stnexp\Queries\10527435 (c).str





```

chain nodes :
12 13 16
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 17 18 19 20 21 22
ring/chain nodes :
14
chain bonds :
2-14 8-12 9-16 11-13 14-22
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 5-11 7-8 8-9 9-10 10-11 17-18 17-22 18-19
19-20 20-21 21-22
exact/norm bonds :
5-7 5-11 7-8 8-9 8-12 9-10 10-11 11-13
exact bonds :
1-2 1-6 2-3 2-14 3-4 4-5 5-6 9-16 14-22
normalized bonds :
17-18 17-22 18-19 19-20 20-21 21-22
isolated ring systems :
containing 1 : 17 :

```

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:CLASS 13:CLASS 14:CLASS 16:CLASS 17:Atom 18:Atom 19:Atom 20:Atom
21:Atom 22:Atom

```

L11 STRUCTURE UPLOADED

=> que L11 AND L9 NOT L10

L12 QUE L11 AND L9 NOT L10

=> d l12

L12 HAS NO ANSWERS

L9 SCR 1839

L10 SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L11 STR

10/527,435

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

Structure attributes must be viewed using STN Express query preparation.  
L12                    QUE   L11 AND L9 NOT L10

=> s l12 sss sam  
SAMPLE SEARCH INITIATED 23:47:20 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED -        236 TO ITERATE

100.0% PROCESSED        236 ITERATIONS                    50 ANSWERS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:   ONLINE   \*\*COMPLETE\*\*  
                             BATCH   \*\*COMPLETE\*\*  
PROJECTED ITERATIONS:       3799 TO       5641  
PROJECTED ANSWERS:         1503 TO       2737

L13                    50 SEA SSS SAM L11 AND L9 NOT L10

=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=> screen 1839


L14    SCREEN CREATED

=> screen 2016 OR   2026 OR   2039 OR   2040 OR   2045 OR   2047

L15    SCREEN CREATED

=>

Uploading C:\Program Files\Stnexp\Queries\10527435 (d).str



chain nodes :  
12 13 16 23 24

ring nodes :  
1 2 3 4 5 6 7 8 9 10 11 17 18 19 20 21 22

```

ring/chain nodes :
14
chain bonds :
2-14  7-23  8-12  9-16  11-13  14-22  16-24
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  5-7  5-11  7-8  8-9  9-10  10-11  17-18  17-22  18-19
  19-20  20-21  21-22
exact/norm bonds :
5-7  5-11  7-8  7-23  8-9  8-12  9-10  10-11  11-13  16-24
exact bonds :
1-2  1-6  2-3  2-14  3-4  4-5  5-6  9-16  14-22
normalized bonds :
17-18  17-22  18-19  19-20  20-21  21-22
isolated ring systems :
containing 1 : 17 :

```

```

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom
11:Atom 12:CLASS 13:CLASS 14:CLASS 16:CLASS 17:Atom 18:Atom 19:Atom 20:Atom
21:Atom 22:Atom 23:CLASS 24:CLASS

```

L16        STRUCTURE UPLOADED

=> que L16 AND L14 NOT L15

L17    QUE L16 AND L14 NOT L15

=> d l17

L17 HAS NO ANSWERS

L14                SCR 1839

L15                SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L16                STR

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

Structure attributes must be viewed using STN Express query preparation.

L17                QUE    L16 AND L14 NOT L15

=> s l17 sss sam

SAMPLE SEARCH INITIATED 23:52:08 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED -                89 TO ITERATE

```

100.0% PROCESSED                89 ITERATIONS                50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

```

```

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                          BATCH  **COMPLETE**

```

PROJECTED ITERATIONS:                1214 TO                2346

PROJECTED ANSWERS:                704 TO                1616

L18                50 SEA SSS SAM L16 AND L14 NOT L15

10/527,435

```
=> => s 117 sss ful
FULL SEARCH INITIATED 23:52:58 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      1631 TO ITERATE
```

```
100.0% PROCESSED      1631 ITERATIONS      1022 ANSWERS
SEARCH TIME: 00.00.01
```

```
L19      1022 SEA SSS FUL L16 AND L14 NOT L15
```

```
=> => s 119
L20      59 L19
```

```
=> d 120 1-59 bib,ab,hitstr
```

L20 ANSWER 1 OF 59 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2007:1165535 CAPLUS

DN 147:446637

TI V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies

AU Laakso, Meg M.; Lee, Fang-Hua; Haggarty, Beth; Agrawal, Caroline; Nolan, Katrina M.; Biscione, Mark; Romano, Josephine; Jordan, Andrea P. O.; Leslie, George J.; Meissner, Eric G.; Su, Lishan; Hoxie, James A.; Doms, Robert W.

CS Department of Microbiology, University of Pennsylvania School of Medicine, Philadelphia, PA, USA

SO PLoS Pathogens (2007), 3(8), 1118-1128

CODEN: PPLACN; ISSN: 1553-7374

PB Public Library of Science

DT Journal; (online computer file)

LA English

AB The V1/V2 region and the V3 loop of the human immunodeficiency virus type I (HIV-1) envelope (Env) protein are targets for neutralizing antibodies and also play an important functional role, with the V3 loop largely determining

whether a virus uses CCR5 (R5), CXCR4 (X4), or either coreceptor (R5X4) to infect cells. While the sequence of V3 is variable, its length is highly conserved. Structural studies indicate that V3 length may be important for interactions with the extracellular loops of the coreceptor. Consistent with this view, genetic truncation of the V3 loop is typically associated with loss of Env function. We removed approx. one-half of the V3 loop from three different HIV-1 strains, and found that only the Env protein from the R5X4 strain R3A retained some fusion activity. Loss of V1/V2 ( $\Delta$ V1/V2) was well tolerated by this virus. Passaging of virus with the truncated V3 loop resulted in the derivation of a virus strain that replicated with wild-type kinetics. This virus, termed TA1, retained the V3 loop truncation and acquired several adaptive changes in gp120 and gp41. TA1 could use CCR5 but not CXCR4 to infect cells, and was extremely sensitive to neutralization by HIV-1 pos. human sera, and by antibodies to the CD4 binding site and to CD4-induced epitopes in the bridging sheet region of gp120. In addition, TA1 was completely resistant to CCR5 inhibitors, and was more dependent upon the N-terminal domain of CCR5, a region of the receptor that is thought to contact the bridging sheet of gp120 and the base of the V3 loop, and whose conformation may not be greatly affected by CCR5 inhibitors. These studies suggest that the V3 loop protects HIV from neutralization by antibodies prevalent in infected humans, that CCR5 inhibitors likely act by disrupting interactions between the V3 loop and the coreceptor, and that altered use of CCR5 by HIV-1 associated with increased sensitivity to changes in the N-terminal domain can be linked to high levels of resistance to these antiviral compds.

IT 461443-59-4, Aplaviroc

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies)

RN 461443-59-4 CAPLUS

CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]- (CA INDEX NAME)

Absolute stereochemistry.

10/527,435



L20 ANSWER 2 OF 59 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2007:1064150 CAPLUS  
 DN 147:385768  
 TI Diketo acids with nucleobase scaffolds: anti-HIV replication inhibitors  
 targeted at HIV integrase in combination therapy  
 IN Nair, Vasu; Chi, Guochen; Uchil, Vinod R.  
 PA University of Georgia Research Foundation, Inc., USA  
 SO PCT Int. Appl., 110pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007106450	A2	20070920	WO 2007-US6245	20070309
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				


PRAI US 2006-781520P P 20060310

OS MARPAT 147:385768

AB A new class of diketo acids constructed on nucleobase scaffolds, e.g., I  
 [R1, R2 = (un)substituted CH<sub>2</sub>Ph whereby Ph is substituted with 1 to 3  
 substituents selected from halogen, OH, OMe, Me, Et, Pr, CF<sub>3</sub>, CH<sub>2</sub>Rb; Rb =  
 5- or 6-membered heteroarom.; R3 = H, C1-6-alkyl, halogen, (un)susbtituted  
 CH<sub>2</sub>Ph, (un)substituted SPh, whereby Ph is substituted with 1 to 3  
 substituents selected from halogen, OH, OMe, Me, Et, Pr, CF<sub>3</sub>; R4 = CO<sub>2</sub>R; R  
 = H, C1-6-alkyl] and II, designed as inhibitors of HIV replication through  
 inhibition of HIV integrase, is described. Thus, 4-(1,3-dibenzyl-1,2,3,4-  
 tetrahydro-2,4-dioxypyrimidin-5-yl)-2-hydroxy-4-oxo-2-butenic acid (III)  
 was prepd from 5-acetyluracil via dibenzylation with PhCH<sub>2</sub>Br in DMF containing  
 K<sub>2</sub>CO<sub>3</sub>, condensation with MeO<sub>2</sub>CCO<sub>2</sub>Me in THF containing NaOCMe<sub>3</sub>, and acid  
 hydrolysis with aqueous HCl in dioxane. These compds. are useful in the  
 prevention or treatment of infection by HFV and in the treatment of AIDS  
 and ARC, either as the compds., or as pharmaceutically acceptable salts,  
 with pharmaceutically acceptable carriers, in combination with antivirals,  
 immunomodulators, antibiotics, vaccines, and other therapeutic agents,  
 especially other anti-HIV compds. (including other anti-HIV integrase agents),  
 which can be used to create combination anti- HIV cocktails as disclosed  
 herein. Methods of treating AIDS and ARC and methods of treating or  
 preventing infection by HIV are also described. Compds. of the present  
 application include those of I and include tautomers, regioisomers,  
 geometric isomers, and where applicable, optical isomers thereof, and  
 pharmaceutically acceptable salts thereof, wherein the nucleobase scaffold  
 and R groups are as otherwise defined in the specification. These are  
 combined with any number of typical other anti-HIV agents to provide an  
 effective treatment modality for HIV infections, including AIDS and ARC.  
 The bioactivity of III was determined [IC<sub>50</sub> = 0.02  $\mu$ M; CC<sub>50</sub> = >2000  $\mu$ M;  
 Therapeutic Index = >10,000 vs. HIV integrase in vitro].

IT 461443-59-4, AK602  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)  
 (novel diketo acids constructed on nucleobase scaffolds as inhibitors  
 of HIV replication through inhibition of HIV integrase useful in  
 prevention and combination therapy of infections)  
 RN 461443-59-4 CAPLUS  
 CN Benzoic acid, 4-[4-[[ (3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-  
 dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]- (CA INDEX NAME)

Absolute stereochemistry.





L20 ANSWER 3 OF 59 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2007:941806 CAPLUS  
 DN 147:292172  
 TI Sequential use of viral entry inhibitors to prevention the infection of T lymphocytes by human immunodeficiency virus  
 IN Duensing, Thomas; Fung, Sek Chung Michael; Stanley, Lewis  
 PA Tanox, Inc., USA  
 SO PCT Int. Appl., 42pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007094983	A2	20070823	WO 2007-US2991	20070203
WO 2007094983	A3	20071206		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			

PRAI US 2006-764840P P 20060203  
 US 2006-837975P P 20060816

AB The present invention is based upon the surprising discovery that exposure of a non-resistant human immunodeficiency virus (HIV) to a first entry inhibitor, such as an anti-CD4 antibody or a co-receptor inhibitor, which like all current HIV drugs selects for mutations that result in a resistant HIV, surprisingly results in HIV viruses much more susceptible to neutralization by a second entry inhibitor, such as soluble CD4 (sCD4) or an HIV gp41 inhibitor. Therefore, the present invention provides methods and compns. for inhibiting HIV-I infection in a subject that overcomes the problem of drug resistance.

IT 461443-59-4


RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (as HIV entry inhibitor; sequential use of viral entry inhibitors to prevention infection of T lymphocytes by human immunodeficiency virus)

RN 461443-59-4 CAPLUS

CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]- (CA INDEX NAME)

Absolute stereochemistry.

10/527,435



L20 ANSWER 4 OF 59 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2007:874552 CAPLUS

DN 147:257932

TI Cationic steroid antimicrobial compositions and methods of use

IN Savage, Paul B.; Unutmaz, Derya

PA Brigham Young University, USA; Vanderbilt University

SO PCT Int. Appl., 111pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007089907	A2	20070809	WO 2007-US2794	20070131
	WO 2007089907	A3	20071101		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, EA, EP, OA

US 2007190067	A1	20070816	US 2007-669785	20070131
---------------	----	----------	----------------	----------

PRAI US 2006-763999P P 20060201

OS MARPAT 147:257932

AB Steroids, such as I [R = (CH<sub>2</sub>)mOH, m = 0, 1, 2, 3, (CH<sub>2</sub>)<sub>3</sub>NH<sub>2</sub>, (CH<sub>2</sub>)<sub>3</sub>OSO<sub>3</sub>H, (CH<sub>2</sub>)<sub>3</sub>O(CH<sub>2</sub>)<sub>3</sub>NH<sub>2</sub>, (CH<sub>2</sub>)<sub>3</sub>O(CH<sub>2</sub>)nMe, n = 0, 2, 4, 7, (CH<sub>2</sub>)<sub>3</sub>NH(CH<sub>2</sub>)<sub>7</sub>Me, (CH<sub>2</sub>)<sub>3</sub>NH(CH<sub>2</sub>)<sub>3</sub>NH<sub>2</sub>], were prepared for therapeutic use in cationic steroid antimicrobial compns. which decrease or inhibit human immunodeficiency virus (HIV) infection or pathogenesis (e.g., illness) of a cell in vitro, ex vivo or in vivo, a symptom or pathol. associated with human immunodeficiency virus (HIV) infection or pathogenesis (e.g., illness) in vitro, ex vivo or in vivo, or an adverse side effect of human immunodeficiency virus (HTV) infection or pathogenesis (e.g., illness) in vitro, ex vivo or in vivo. Thus, steroid amines I [R = (CH<sub>2</sub>)<sub>3</sub>O(CH<sub>2</sub>)<sub>7</sub>Me, (CH<sub>2</sub>)<sub>3</sub>OH] were via a multistep synthetic sequence starting from Me cholate, allyl bromide and octyl bromide. The prepared cationic steroids were tested for inhibition of HIV and were claimed for therapeutic use in combination with a protease inhibitor, a reverse transcriptase inhibitor, a virus fusion inhibitor or a virus entry inhibitor.

IT 461443-59-4, AK 602

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(preparation of cationic steroid antimicrobial agents derived from cholic acid and analogs for therapeutic use in the treatment of HIV infection)

RN 461443-59-4 CAPLUS

CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]- (CA INDEX NAME)


Absolute stereochemistry.

10/527,435



L20 ANSWER 5 OF 59 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2007:848300 CAPLUS  
 DN 147:313878  
 TI CCR5 inhibitors: promising yet challenging  
 AU Clotet, Bonaventura  
 CS AIDS Care Unit and irsiCaixa Retrovirology Laboratory, Hospital Germans  
 Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain  
 SO Journal of Infectious Diseases (2007), 196(2), 178-180  
 CODEN: JIDIAQ; ISSN: 0022-1899  
 PB University of Chicago Press  
 DT Journal; General Review  
 LA English  
 AB A review. The research of Gulick et al. (2007) entitled "Phase 2 study of  
 the safety and efficacy of vicriviroc, a CCR5 inhibitor, in  
 HIV-1-infected, treatment-experienced patients: AIDS Clin. Trials Group  
 5211" is reviewed with commentary and refs. Previous studies conducted  
 with maraviroc plus optimized background therapy (OBT) in a  
 treatment-experienced population, harboring only CCR5 tropic virus, have  
 shown significantly superior virol. control and increases in CD4 cell  
 count compared with placebo plus OBT. Gulick et al. also reported a  
 potent virol. suppression through 24 wk, further supporting the anti-HIV-1  
 activity of the CCR5 inhibitor family. However, a slightly larger number of  
 malignancies in antiretroviral (ARV)-experienced subjects receiving an  
 optimized ARV regimen (OR) plus vicriviroc than in those treated with an  
 OR plus placebo were observed. These findings helped to clarify the role of  
 CCR5 entry inhibitors in HIV therapeutics.  
 IT 461443-59-4, Aplaviroc  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)  
 (chemokine receptor 5 inhibitor aplaviroc might be effective in patient  
 infected with human immunodeficiency virus)  
 RN 461443-59-4 CAPLUS  
 CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-  
 dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 6 OF 59 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2007:845813 CAPLUS  
 DN 147:227133  
 TI Synergistic compositions for treating HIV  
 IN Ji, Changhua; Sankuratri, Suryanarayana  
 PA F. Hoffmann-La Roche A.-G., Switz.  
 SO PCT Int. Appl., 42pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007085567	A2	20070802	WO 2007-EP50527	20070119
	WO 2007085567	A3	20071011		
	W:				
	AE, AG, AL, AM, AN, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW:				
	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				

PRAI US 2006-772094P P 20060130

OS MARPAT 147:227133

AB Synergistic pharmaceutical compns. for treating or preventing HIV-1 infections comprising anti-CCR5 monoclonal antibodies and CCR5 antagonists, viral fusion inhibitors or viral attachment inhibitors are disclosed. The compns. exhibit significant greater activity than is anticipated from the activity of either component alone. Also provided are methods for treating or preventing HIV-1 using the same.

IT 461443-59-4, ONO 4128


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(synergistic compns. for treating HIV-1 infections using anti-CCR5 monoclonal antibodies and CCR5 antagonists and viral fusion and attachment inhibitors)

RN 461443-59-4 CAPLUS

CN Benzoic acid, 4-[4-[[ (3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]- (CA INDEX NAME)


Absolute stereochemistry.



10/527,435

L20 ANSWER 7 OF 59 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2007:804429 CAPLUS  
 DN 147:313780  
 TI CCR5 antagonists: from discovery to clinical efficacy  
 AU Pulley, Shon R.  
 CS Lilly Corporate Center, Discovery Chemistry & Research Technologies, Eli Lilly and Company, Indianapolis, IN, 46285, USA  
 SO Chemokine Biology--Basic Research and Clinical Application (2007), Volume 2, 145-163. Editor(s): Moser, Bernhard; Letts, Gordon L.; Neote, Kuldeep. Publisher: Birkhaeuser Verlag, Basel, Switz. CODEN: 69HVZO  
 DT Conference; General Review  
 LA English  
 AB A review on CCR5 antagonists prior to human efficacy studies and CCR5 antagonists reaching human efficacy studies. The important role of CCR5 in a number of disease states warrants further pursuit of safe and efficacious CCR5 antagonists. The results from ongoing AIDS clin. trials and planned trials in immune mediated diseases will ultimately reveal the therapeutic utility of CCR5 antagonists.  
 IT 461443-59-4, Aplaviroc  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (CCR5 antagonists)  
 RN 461443-59-4 CAPLUS  
 CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 78 THERE ARE 78 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT



L20 ANSWER 8 OF 59 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2007:748017 CAPLUS

DN 147:291401

TI CCR5 small-molecule antagonists and monoclonal antibodies exert potent synergistic antiviral effects by cobinding to the receptor

AU Ji, Changhua; Zhang, Jun; Dioszegi, Marianna; Chiu, Sophie; Rao, Eileen; de Rosier, Andre; Cammack, Nick; Brandt, Michael; Sankuratri, Surya

CS Department of Viral Diseases, Roche Palo Alto, Palo Alto, CA, USA

SO Molecular Pharmacology (2007), 72(1), 18-28

CODEN: MOPMA3; ISSN: 0026-895X

PB American Society for Pharmacology and Experimental Therapeutics

DT Journal

LA English

AB A panel of four CCR5 monoclonal antibodies (mAbs) recognizing different epitopes on CCR5 was examined in CCR5-mediated cell-cell fusion assay, alone or in combination with a variety of small mol. CCR5 antagonists. Although no antagonism was observed between any of the CCR5 inhibitors, surprisingly potent synergy was observed between CCR5 mAbs and antagonists, and the synergistic activity was confirmed in other antiviral assays. Strong synergy was also observed between CCR5 inhibitors and the human immunodeficiency virus (HIV) fusion inhibitor enfuvirtide. There was no synergy observed between small mol. CCR5 inhibitors; however, potent synergy was observed between mAbs recognizing different parts of CCR5. In all synergistic combinations, greater synergy was achieved at higher percent inhibition levels. A neg. correlation was found between the degree of synergy between the two classes of CCR5 inhibitors and the ability to compete each other for binding to the receptor. For example, the greatest synergy, observed between the mAb ROAb13 and the small mol. inhibitor maraviroc, did not interfere with binding to CCR5 for either inhibitor, whereas no synergy was found between mAb 45523 and maraviroc, which do compete for binding to CCR5. In addition, in contrast to a recent report, the CCR5 inhibitors tested here were found to inhibit the same stage of HIV entry. Based on the data presented here, we hypothesize that CCR5 inhibitors exert synergistic antiviral actions through a cobinding mechanism.

IT 461443-59-4, Aplaviroc


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(CCR5 small-mol. antagonists and monoclonal antibodies exert potent synergistic antiviral effects by cobinding to the receptor)

RN 461443-59-4 CAPLUS

CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD

10/527,435

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 9 OF 59 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2007:642553 CAPLUS  
 DN 147:72745  
 TI Preparation of novel spiropiperidine compounds for the modulation of  
 chemokine receptor activity  
 IN Moinet, Christophe; Courchesne, Marc  
 PA Virochem Pharma Inc., Can.  
 SO PCT Int. Appl., 81pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007065256	A1	20070614	WO 2006-CA1981	20061205
W: AE, AG, AL, AM, AN, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRAI US 2005-742545P P 20051206

OS MARPAT 147:72745

AB The title compds. I [ring containing W, X, Y and Z = II, III, etc.; R1 = NR6C(O)R7, NR6C(O)OR7, etc.; R2 = alkyl, alkenyl, aryl, etc.; R3 = H, alkyl, aryl; R4, R5, R51, R52 = H, alkyl, aryl, etc.; R6 = H, alkyl, alkenyl, alkynyl; R7 = H, alkyl, alkenyl, aryl, etc.], useful for the modulation of CCR5 chemokine receptor activity, particularly in the prevention or treatment of inflammatory diseases, immunoregulatory diseases, organ transplantation reactions and infectious diseases such as HIV infections, were prepared and claimed. E.g., a multi-step synthesis of (S)-IV, starting from tert-Bu 2-oxo-1-oxa-3,8-diaza-spiro[4.5]decane-8-carboxylate and 4-methoxybenzyl chloride, was given. Compds. I have been found to have activity in binding to the CCR5 receptor, generally with an IC50 value of less than 25  $\mu$ M. Certain compds. I have also been tested in an assay for HIV activity and generally having an IC50 value of less than 1  $\mu$ M.

IT 461443-59-4, GW873140

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL


(Biological study); USES (Uses)

(codrug; preparation of novel spiropiperidine compds. as chemokine receptor modulators useful in treatment and prevention of diseases)

RN 461443-59-4 CAPLUS

CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 10 OF 59 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2007:502501 CAPLUS  
 TI Assessment of cryopreserved hepatocytes as an alternative to fresh hepatocytes for comparative interspecies metabolism studies with suitable acceptance criteria  
 AU Cheng, Ziqiang; Herron, Christine E.; Bowers, Gary; de Serres, Mark  
 CS Department of World-wide Drug Metabolism and Pharmacokinetics, GlaxoSmithKline, Research Triangle Park, NC, 27709, USA  
 SO Drug Metabolism Letters (2007), 1(2), 109-120  
 CODEN: DMLRBM; ISSN: 1872-3128  
 PB Bentham Science Publishers Ltd.  
 DT Journal  
 LA English  
 AB Fresh hepatocytes have been the choice for interspecies comparative drug metabolism studies. Cryopreserved hepatocytes represent a readily available alternative when combined with acceptance limits based on the metabolic turnover of 7-ethoxycoumarin. Results for the ten NCEs examined show that the metabolites formed were strongly correlated in fresh and cryopreserved hepatocytes.  
 IT INDEXING IN PROGRESS  
 IT 461443-59-4, GW 873140  
 RL: BSU (Biological study, unclassified); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses) (14C-labeled; assessment of cryopreserved hepatocytes as an alternative to fresh hepatocytes for comparative interspecies metabolism studies with suitable acceptance criteria)  
 RN 461443-59-4 CAPLUS  
 CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 11 OF 59 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2007:329882 CAPLUS  
 DN 146:351292  
 TI Use of indirubin and its derivatives in the treatment of HIV infection and heart failure  
 IN Redfield, Robert; Heredia, Alonso; Davis, Charles E.  
 PA University of Maryland Biotechnology Institute Off. of Research Admin/Tech. Dev., USA  
 SO PCT Int. Appl., 36pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007033208	A2	20070322	WO 2006-US35559	20060912
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRAI US 2005-716097P P 20050912


AB Indirubin and its derivs. are described for reduction of replication of human immunodeficiency virus. Indirubin and its derivs. are also described for reducing the effects of heart failure, by administration of indirubin or a functionally active derivative thereof to modify cardiac muscle cell hypertrophy. Indirubin and its functional derivs. may also be employed in antiviral combination therapy compns. containing therapeutically effective chimeric polypeptides containing a virus coat polypeptide sequence and a viral receptor polypeptide sequence wherein the virus coat polypeptide sequence and the viral receptor polypeptide sequence are linked and exhibit ligand/receptor binding affinity.

IT 461443-59-4, AK602 461443-59-4D, AK 602, analogs  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (indirubin and derivs. for treatment of HIV infection and heart failure, and use with other agents)

RN 461443-59-4 CAPLUS

CN Benzoic acid, 4-[4-[[ (3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 461443-59-4 CAPLUS

CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]- (CA INDEX NAME)

Absolute stereochemistry.



L20 ANSWER 12 OF 59 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2007:287045 CAPLUS  
 DN 146:288407  
 TI Chloroquine combination drugs and methods for their synthesis  
 IN Kosak, Kenneth M.  
 PA USA  
 SO U.S. Pat. Appl. Publ., 48pp., Cont.-in-part of U.S. Ser. No. 323,389,  
 abandoned.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2007060499	A1	20070315	US 2006-360111	20060222
	WO 2007040469	A2	20070412	WO 2005-US33310	20050915
	WO 2007040469	A3	20070712		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
	US 2007166281	A1	20070719	US 2007-709965	20070222
PRAI	WO 2005-US33310	A2	20050915		
	US 2005-323389	B2	20051229		
	US 2004-923112	A2	20040821		
	US 2006-360111	A2	20060222		

AB This invention discloses compns. of chloroquine-coupled active agents, including methods for their preparation. The prior art has shown that chloroquines given as free drug in high enough concentration, enhances the release of various agents from cellular endosomes into the cytoplasm. The purpose of these compns. is to provide a controlled amount of chloroquine at the same site where the active agent is delivered, thereby reducing the overall dosage needed. The compns. comprise a chloroquine substance coupled to an active agent directly or through a variety of pharmaceutical carrier substances. The carrier substances include polysaccharides, synthetic polymers, proteins, micelles and other substances for carrying and releasing the chloroquine compns. in the body for therapeutic effect. The compns. can also include a biocleavable linkage for carrying and releasing active agents for therapeutic or other medical uses. The invention also discloses carrier compns. that are coupled to targeting mols. for targeting the delivery of chloroquine substances and active agents to their site of action.

IT 461443-59-4, Aplaviroc


RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (chloroquine combination drugs and methods for their synthesis)

RN 461443-59-4 CAPLUS

CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]- (CA INDEX NAME)




Absolute stereochemistry.



L20 ANSWER 13 OF 59 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2007:207313 CAPLUS  
 DN 146:329986  
 TI Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry  
 AU Westby, Mike; Smith-Burchnell, Caroline; Mori, Julie; Lewis, Marilyn; Mosley, Michael; Stockdale, Mark; Dorr, Patrick; Ciaramella, Giuseppe; Perros, Manos  
 CS Pfizer Global Research and Development, Sandwich, UK  
 SO Journal of Virology (2007), 81(5), 2359-2371  
 CODEN: JOVIAM; ISSN: 0022-538X  
 PB American Society for Microbiology  
 DT Journal  
 LA English  
 AB Maraviroc is a CCR5 antagonist in clin. development as one of a new class of antiretrovirals targeting human immunodeficiency virus type 1 (HIV-1) coreceptor binding. We investigated the mechanism of HIV resistance to maraviroc by using in vitro sequential passage and site-directed mutagenesis. Serial passage through increasing maraviroc concns. failed to select maraviroc-resistant variants from some laboratory-adapted and clin. isolates of HIV-1. However, high-level resistance to maraviroc was selected from three of six primary isolates passaged in peripheral blood lymphocytes (PBL). The SF162 strain acquired resistance to maraviroc in both treated and control cultures; all resistant variants were able to use CXCR4 as a coreceptor. In contrast, maraviroc-resistant virus derived from isolates CC1/85 and RU570 remained CCR5 tropic, as evidenced by susceptibility to the CCR5 antagonist SCH-C, resistance to the CXCR4 antagonist AMD3100, and an inability to replicate in CCR5 Δ32/Δ32 PBL. Strain-specific mutations were identified in the V3 loop of maraviroc-resistant CC1/85 and RU570. The envelope-encoding region of maraviroc-resistant CC1/85 was inserted into an NL4-3 background. This recombinant virus was completely resistant to maraviroc but retained susceptibility to aplaviroc. Reverse mutation of gp120 residues 316 and 323 in the V3 loop (numbering from HXB2) to their original sequence restored wild-type susceptibility to maraviroc, while reversion of either mutation resulted in a partially sensitive virus with reduced maximal inhibition (plateau). The plateaus are consistent with the virus having acquired the ability to utilize maraviroc-bound receptor for entry. This hypothesis was further corroborated by the observation that a high concentration of maraviroc blocks the activity of aplaviroc against maraviroc-resistant virus.  
 IT 461443-59-4, Aplaviroc  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry)  
 RN 461443-59-4 CAPLUS  
 CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 14 OF 59 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2007:175576 CAPLUS  
 DN 146:258964

TI Method for augmentation of intraepithelial and systemic exposure of  
 therapeutic agents having substrate activity for cytochrome p450 enzymes  
 and membrane efflux systems following vaginal and oral cavity  
 administration

IN Pauletti, Giovanni M.; Harrison, Donald C.; Desai, Kishorkumar J.

PA USA

SO U.S. Pat. Appl. Publ., 24pp., Cont.-in-part of U.S. Ser. No. 208,209.  
 CODEN: USXXCO

DT Patent

LA English

FAN.CNT 12

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2007036834	A1	20070215	US 2006-522126	20060915
	AU 765269	B2	20030911	AU 2001-54192	20010703
	US 2003049302	A1	20030313	US 2002-226667	20020821
	US 6982091	B2	20060103		
	US 2006002966	A1	20060105	US 2005-208209	20050818
	WO 2007035515	A2	20070329	WO 2006-US36087	20060915
	WO 2007035515	A3	20070927		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,  
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,  
 GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,  
 KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN,  
 MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS,  
 RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ,  
 UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,  
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,  
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
 KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRAI	US 2001-315877P	P	20010829		
	US 2002-226667	A1	20020821		
	US 2005-208209	A2	20050818		
	US 2005-717680P	P	20050915		
	AU 1998-76976	A3	19980610		

AB The present invention relates to a method for augmentation of epithelial  
 concentration and systemic exposure of therapeutic agents having a substrate  
 affinity for cytochrome P 450 enzymes and membrane efflux transporter  
 systems by using a vaginal or buccal drug delivery compns. and/or devices.  
 Specifically, the invention relates to a method for augmentation of  
 intraepithelial concentration and/or systemic bioavailability for delivery of  
 anti-viral and/or anti-cancer therapeutic agents having a substrate  
 affinity for cytochrome P 450 enzymes and membrane efflux systems by using  
 a vaginal or buccal drug delivery of these drugs into the systemic  
 circulation by delivering such drug to a subject in need thereof vaginally  
 or buccally in an especially formulated composition increasing the drug's  
 bioavailability by providing means for increasing the drug solubility and  
 permeability through the vaginal or buccal mucosa.

IT 461443-59-4, GSK 873140

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(AK602; method for augmentation of intraepithelial and systemic  
 exposure of therapeutic agents having substrate activity for cytochrome


10/527,435

P 450 enzymes and membrane efflux systems following vaginal and oral cavity administration)

RN 461443-59-4 CAPLUS

CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]- (CA INDEX NAME)

Absolute stereochemistry.




L20 ANSWER 15 OF 59 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2007:119657 CAPLUS  
 DN 146:182972  
 TI Methods for reducing viral load in HIV-1-infected patients  
 IN Olson, William C.; Maddon, Paul J.; Pevear, Daniel C.; Israel, Robert J.;  
 Murga, Jose D.  
 PA Progenics Pharmaceuticals, Inc., USA  
 SO PCT Int. Appl., 97pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007014114	A2	20070201	WO 2006-US28565	20060721
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 2007026441	A1	20070201	US 2006-491330	20060721
PRAI US 2005-702064P	P	20050722		
US 2005-701889P	P	20050723		
US 2005-711528P	P	20050826		
US 2005-715619P	P	20050909		
AB The authors disclose a method for reducing viral load in an HIV-1-infected human subject. The method comprises the administration at a predefined intervals of (a) a humanized antibody designated PRO 140, or of (b) an anti-CCR5 receptor monoclonal antibody. The authors also disclose a treatment comprising the administration of (a) a monoclonal antibody which (i) binds to a CCR5 receptor on the surface of the subject's CD4+ cells and (ii) inhibits fusion of HIV-1 to CCR5+CD4+ cells, and (b) a non-antibody CCR5 receptor antagonist, in therapeutic amts.				
IT 461443-59-4, GW873140 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (with anti-CCR5 antibody for combination therapy in human immunodeficiency virus infection)				
RN 461443-59-4 CAPLUS				
CN Benzoic acid, 4-[4-[[ (3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5- dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]- (CA INDEX NAME)				


Absolute stereochemistry.

10/527,435



L20 ANSWER 16 OF 59 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2007:81249 CAPLUS  
 DN 146:329879  
 TI Spirodiketopiperazine-based CCR5 antagonists: Lead optimization from biologically active metabolite  
 AU Nishizawa, Rena; Nishiyama, Toshihiko; Hisaichi, Katsuya; Matsunaga, Naoki; Minamoto, Chiaki; Habashita, Hiromu; Takaoka, Yoshikazu; Toda, Masaaki; Shibayama, Shiro; Tada, Hideaki; Sagawa, Kenji; Fukushima, Daikichi; Maeda, Kenji; Mitsuya, Hiroaki  
 CS Medicinal Chemistry Research Laboratories, Ono Pharmaceutical Co. Ltd., Osaka, 618-8585, Japan  
 SO Bioorganic & Medicinal Chemistry Letters (2007), 17(3), 727-731  
 CODEN: BMCLE8; ISSN: 0960-894X  
 PB Elsevier Ltd.  
 DT Journal  
 LA English  
 OS CASREACT 146:329879  
 AB Hydroxylated derivs. were designed and synthesized based on the information of oxidative metabolites. Compds. derived from  $\beta$ -substituted (2R,3R)-2-amino-3-hydroxypropionic acid showed improved inhibitory activities against the binding of MIP-1 $\alpha$  to human CCR5, compared with the nonhydroxylated derivs. and the other isomers.  
 IT 343277-06-5P 461022-95-7P  
 RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (lead optimization from biol. active metabolite of spirodiketopiperazine-based CCR5 antagonists)  
 RN 343277-06-5 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-9-[(4-phenoxyphenyl)methyl]-, hydrochloride (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 461022-95-7 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[(4-phenoxyphenyl)methyl]-, hydrochloride (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.






● HCl

IT 343272-98-0P 343272-99-1P 343277-02-1P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (lead optimization from biol. active metabolite of spirodiketopiperazine-based CCR5 antagonists)  
 RN 343272-98-0 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-9-[(4-phenoxyphenyl)methyl]-, hydrochloride (1:1), (3S)-(CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 343272-99-1 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(1S)-1-hydroxy-2-methylpropyl]-9-[(4-phenoxyphenyl)methyl]-, hydrochloride (1:1), (3R)-(CA INDEX NAME)

Absolute stereochemistry.

10/527,435




● HCl

RN 343277-02-1 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(1S)-1-hydroxy-2-methylpropyl]-9-[(4-phenoxyphenyl)methyl]-, hydrochloride (1:1), (3S)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

IT 461019-79-4P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(lead optimization from biol. active metabolite of spirodiketopiperazine-based CCR5 antagonists)

RN 461019-79-4 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-9-(phenylmethyl)-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.




10/527,435

RE.CNT 19      THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 17 OF 59 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2006:1353988 CAPLUS  
 DN 146:75294  
 TI Antifugetactic agents for immune response enhancement  
 IN Poznansky, Mark C.; Potts, John T., Jr.; Vianello, Fabrizio; Papeta, Natalia  
 PA The General Hospital Corporation, USA  
 SO PCT Int. Appl., 92pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006137934	A2	20061228	WO 2005-US40218	20051104
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	CA 2586765	A1	20061228	CA 2005-2586765	20051104
	EP 1814587	A2	20070808	EP 2005-858305	20051104
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
PRAI	US 2004-625733P	P	20041105		
	WO 2005-US40218	W	20051104		
AB	This invention provides methods and compns. for modulating movement of eukaryotic cells with migratory capacity. More specifically, the invention provides anti-fugetactic agents and methods for the use thereof in enhancing an immune response. Stromal-derived factor-1 (SDF-1) mediated immune evasion of melanoma cells was abrogated by CXCR4 antagonist AMD3100.				
IT	461443-59-4, AK602 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (antifugetactic agents for immune response enhancement)				
RN	461443-59-4 CAPLUS				
CN	Benzoic acid, 4-[4-[[ (3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]- (CA INDEX NAME)				

Absolute stereochemistry.



L20 ANSWER 18 OF 59 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2006:1283330 CAPLUS  
 DN 146:41897  
 TI Synergic combinations comprising a styrylquinoline compound and other HIV infection therapeutic agents  
 IN Leh, Herve; Zouhiri, Fatima; Mouscadet, Jean-Francois; Thomas, Claire-Marie  
 PA Bioalliance Pharma, Fr.; Centre National De La Recherche Scientifique (C.N.R.S); Ecole Normale Supérieure De Cachan; Université De Paris 11 - Paris Sud  
 SO PCT Int. Appl., 57pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006129134	A1	20061207	WO 2005-IB1538	20050601
W: AE, AG, AL, AM, AN, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				


PRAI WO 2005-IB1538 20050601

OS MARPAT 146:41897

AB The invention relates to a combination comprising a quinoline compound or its salt and at least one HIV infection therapeutic agent selected from the group consisting of entry inhibitors, reverse-transcriptase inhibitors, strand-transfer inhibitors, protease inhibitors, and maturation inhibitors. The combination has therapeutic synergy in the treatment of an HIV infection compared with the quinoline compound or HIV infection therapeutic agent alone. Thus, synergic interactions between 8-hydroxy-2-[2-[(3,4-dihydroxy-5-methoxyphenyl)ethenyl]]-7-quinoline carboxylic acid (BA011FZ041) and either reverse transcriptase (zidovudine and nevirapine) or integrase inhibitors (L-731988) were investigated using a NL43 HIV-1 laboratory strain replication assay. Inhibition by combination of BA011FZ041 and other inhibitors was evaluated at three fixed molar BA011FZ041/inhibitor ratios (1:1, 1:2, and 2:1). Combination of BA011FZ041 with nevirapine led to a synergistic effect at ED (ED)75 and ED90 for all three ratios. Combination of BA011FZ041 with zidovudine demonstrated synergy at ED90 for all three ratios and a synergic effect at the ED75 for ratios 1:2 and 2:1. For nevirapine and zidovudine, IC50 of these drugs in combination with BA011FZ041 were decreased by a factor 2 to 6 as compared to IC50 for the drugs alone. Furthermore, combination of the two integrase inhibitors led also to synergistic effect at ED75 and ED90 for the ratios 1:1 and 2:1. For the ratio 1:2, a synergic effect was found at ED90 although a mere additive effect was detected at ED75. Finally, IC50 of L-731988 was significantly decreased by a factor 7 when it was present in combination with quinoline compds., thus emphasizing the complementarities of both classes of anti-integrase agents.

IT 461443-59-4, GSK 873140  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)  
 (synergic combinations comprising styrylquinoline compound and other HIV  
 infection therapeutic agents)  
 RN 461443-59-4 CAPLUS  
 CN Benzoic acid, 4-[4-[[ (3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-  
 dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 19 OF 59 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2006:1098080 CAPLUS  
 DN 146:155353  
 TI Resistance profile of a neutralizing anti-HIV monoclonal antibody, KD-247,  
 that shows favourable synergism with anti-CCR5 inhibitors  
 AU Yoshimura, Kazuhisa; Shibata, Junji; Kimura, Tetsuya; Honda, Akiko; Maeda,  
 Yosuke; Koito, Atsushi; Murakami, Toshio; Mitsuya, Hiroaki; Matsushita,  
 Shuzo  
 CS Division of Clinical Retrovirology and Infectious Diseases, Center for  
 AIDS Research, Graduate School of Medical Sciences, Kumamoto University,  
 Kumamoto, Japan  
 SO AIDS (Hagerstown, MD, United States) (2006), 20(16), 2065-2073  
 CODEN: AIDSET; ISSN: 0269-9370  
 PB Lippincott Williams & Wilkins  
 DT Journal  
 LA English  
 AB The high-affinity humanized monoclonal antibody (MAb) KD-247 reacts with a  
 tip region in gp120-V3 and cross-neutralizes primary isolates with a  
 matching neutralization sequence motif. We induced an HIV-1 variant that  
 was resistant to KD-247 by exposing the JR-FL virus to increasing concns.  
 of KD-247 in PM1/CCR5 cells, which expressed high levels of CCR5 in vitro.  
 We determined the amino acid sequence of the gp120-encoding region of the JR-FL  
 escape mutant from KD-247. To confirm that this substitution was  
 responsible for the KD-247-resistance, a single-round replication assay  
 was performed. We further evaluated the anti-HIV-1 interactions between  
 KD-247 and various CCR5 inhibitors in vitro. At passage 8 of the culture  
 in the presence of 1000 µg/mL KD-247, one amino acid substitution, Gly  
 to Glu at position 314 (G314E), was identified in the V3-tip of gp120. A  
 pseudotyped virus with the G314E mutation was highly resistant to KD-247.  
 Unexpectedly, this mutant virus was sensitive to CCR5 inhibitors, RANTES,  
 recombinant human soluble CD4 (rsCD4) and an anti-CCR5 MAb, but resistant to  
 an anti-CD4 MAb, compared with the wild-type virus. We also found that  
 combinations of KD-247 and CCR5 inhibitors were highly synergistic. The  
 present data suggest that KD-247 has certain advantages for possible  
 passive immunotherapy. High concns. of KD-247 are needed for viral  
 acquisition of KD-247 resistance; the escape variants are more sensitive  
 to CCR5 inhibitors and rsCD4; and there are high levels of synergism  
 between KD-247 and CCR5 inhibitors at all concns. tested.  
 IT 461443-59-4, AK-602  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)  
 (resistance profile of neutralizing anti-HIV monoclonal antibody,  
 KD-247 showed favorable synergism with anti-CCR5 inhibitors)  
 RN 461443-59-4 CAPLUS  
 CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-  
 dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]- (CA INDEX NAME)

Absolute stereochemistry.




10/527,435



RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 20 OF 59 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2006:1055159 CAPLUS  
 DN 146:492646  
 TI The effects of ritonavir and lopinavir/ritonavir on the pharmacokinetics of a novel CCR5 antagonist, aplaviroc, in healthy subjects  
 AU Adkison, Kimberly K.; Shachoy-Clark, Anne; Fang, Lei; Lou, Yu; Otto, Vicky R.; Berrey, M. Michelle; Piscitelli, Stephen C.  
 CS GlaxoSmithKline, Research Triangle Park, NC, USA  
 SO British Journal of Clinical Pharmacology (2006) 62(3), 336-344  
 CODEN: BCPHBM; ISSN: 0306-5251  
 PB Blackwell Publishing Ltd.  
 DT Journal  
 LA English  
 AB Aims: This study assessed the effects of the CYP3A inhibitors lopinavir/ritonavir (LPV/r) on the steady-state pharmacokinetics (PK) of aplaviroc (APL), a CYP3A4 substrate, in healthy subjects. Methods: In Part 1, APL PK was determined in eight subjects who received a single oral 50-mg APL test dose with/without a single dose of 100 mg ritonavir (RTV). Part 2 was conducted as an open-label, single-sequence, three-period repeat dose study in a cohort of 24 subjects. Subjects received APL 400 mg every 12 h (b.i.d.) for 7 days (Period 1), LPV/r 400/100 mg b.i.d. for 14 days (Period 2) and APL 400 mg +LPV/r 400/100 mg b.i.d. for 7 days (Period 3). All doses were administered with a moderate fat meal. PK sampling occurred on day 7 of Periods 1 and 3 and day 14 of Period 2. Results: In Part 1, a single RTV dose increased the APL AUC<sub>0-∞</sub> by 2.1-fold [90% confidence interval (CI) 1.9, 2.4]. Repeat dose coadministration of APL with LPV/r increased APL exposures to a greater extent with the geometric least squares mean ratios (90% CI) being 7.7 (6.4, 9.3), 6.2 (4.8, 8.1) and 7.1 (5.6, 9.0) for the APL AUC, C<sub>max</sub>, and C<sub>min</sub>, resp. No change in LPV AUC or C<sub>max</sub> and a small increase in RTV AUC and C<sub>max</sub> (28% and 32%) were observed. The combination of APL and LPV/r was well tolerated and adverse events were mild in severity with self-limiting gastrointestinal complaints most commonly reported. Conclusions: Coadministration of APL and LPV/r was well tolerated and resulted in significantly increased APL plasma concns.  
 IT 461443-59-4, Aplaviroc  
 RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (coadministration of aplaviroc and Kaletra was well tolerated and increased pharmacokinetics parameter of aplaviroc in healthy human)  
 RN 461443-59-4 CAPLUS  
 CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]- (CA INDEX NAME)

Absolute stereochemistry.



10/527,435

RE.CNT 17      THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 21 OF 59 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2006:769177 CAPLUS  
 DN 145:180928  
 TI Human neutrophil  $\alpha$ -defensin 4 inhibition of HIV-1  
 IN Lu, Wuyuan; Cocchi, Fiorenza; Wu, Zhibin  
 PA USA  
 SO U.S. Pat. Appl. Publ., 7pp.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2006172945	A1	20060803	US 2006-347538	20060203
PRAI	US 2005-649873P	P	20050203		

AB A method to reduce replication of HIV-1, involving administering a therapeutically effective amount of recombinant HNP4 to a subject in need thereof to combat HIV-1 infection. The HNP4 agent may be utilized in pharmaceutical compns. including a pharmaceutically acceptable carrier and an anti-viral agent, e.g., an anti-viral agent, or combination of such agents, such as nucleoside RT inhibitors, CCR5 inhibitors/antagonists, viral entry inhibitors, and functional analogs thereof.

IT 461443-59-4, AK602


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(human neutrophil  $\alpha$ -defensin 4 inhibition of HIV-1)

RN 461443-59-4 CAPLUS

CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]- (CA INDEX NAME)

Absolute stereochemistry.



L20 ANSWER 22 OF 59 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2006:676597 CAPLUS  
 DN 145:117362  
 TI Compositions for down-regulation of CCR5 expression and methods of use  
 thereof  
 IN Redfield, Robert R.; Amoroso, Anthony; Davis, Charles E.; Heredia, Alonso  
 PA University of Maryland Biotechnology Institute, USA  
 SO U.S. Pat. Appl. Publ., 35 pp.  
 CODEN: USXXCO  
 DT Patent  
 LA English same as # 54  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2006154857	A1	20060713	US 2005-281195	20051116
	WO 2005001027	A2	20050106	WO 2004-US15681	20040517
	WO 2005001027	A3	20060126		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRAI US 2003-471453P P 20030516  
 WO 2004-US15681 A2 20040517

AB The present invention relates to the downregulation of surface receptor CCR5 expression through manipulation of the cell cycle in activated lymphocytes by administering a composition that arrests the G1 phase of the cell cycle, thereby reducing receptor sites for entry of HIV into T cells, and thus, the effects of HIV. Further, compns. are disclosed that include at least one G1 phase arresting agent and at least one antiviral agent, wherein the combination of agents synergistically enhances the activity of the antiviral agent.


IT 461443-59-4, AK602  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (compns. for down-regulation of CCR5 expression by arresting G1 phase of cell cycle of activated lymphocytes and decreasing HIV virus entry and combination with other antiviral agents)

RN 461443-59-4 CAPLUS

CN Benzoic acid, 4-[4-[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]- (CA INDEX NAME)

Absolute stereochemistry.

10/527,435



L20 ANSWER 23 OF 59 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2006:578211 CAPLUS

DN 145:62897

TI Preparation of spirotropane compounds and therapeutic use as modulators of chemokine receptor activity

IN Chan Chun Kong, Laval; Moinet, Christophe; Courchesne, Marc; Vaillancourt, Louis; Blais, Charles; Bubenik, Monica

PA Virochem Pharma Inc., Can.

SO PCT Int. Appl., 145 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006060919	A1	20060615	WO 2005-CA1878	20051209
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	AU 2005313813	A1	20060615	AU 2005-313813	20051209
	CA 2587508	A1	20060615	CA 2005-2587508	20051209
	EP 1831222	A1	20070912	EP 2005-819431	20051209
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
	CN 101098871	A	20080102	CN 2005-80046172	20051209
	IN 2007KN02150	A	20070817	IN 2007-KN2150	20070612
	KR 2007095310	A	20070928	KR 2007-715147	20070702
PRAI	US 2004-634266P	P	20041209		
	US 2005-693051P	P	20050623		
	WO 2005-CA1878	W	20051209		


OS CASREACT 145:62897; MARPAT 145:62897

AB Spiro compds. according to formula (I) are claimed: wherein R1 = NR7R9; R2 = (un)substituted C1-10 alkyl, C2-10 alkenyl, 3-10 membered heterocycle, etc.; R3 = H, (un)substituted C1-10 alkyl or C6-12 aryl; R7 = H, (un)substituted C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl; R9 = H or (un)substituted C1-10-alkyl; and ring A represents a 5 or 6 membered heteroring substituted once or twice with a keto substituent. These compds. and their pharmaceutical acceptable salts are used in combinations or in pharmaceutical compns. and are useful in the modulation of CCR5 chemokine receptor activity (no data given). I are useful in the prevention or treatment of certain inflammatory diseases, immunoregulatory diseases, organ transplantation reactions and in the prevention and treatment of infectious diseases such as HIV infections. Preparation of I is exemplified. For example, II was prepared from 4,4-difluorocyclohexanecarboxylic acid ((S)-3-oxo-1-phenylpropyl)amide and 3-(4-methanesulfonylbenzyl)bicyclo[3.2.1]-1 $\alpha$ ,3,8-triazaspiro[4.5]dodecan-2,4-dione hydrochloride (preparation given).

10/527,435

IT	461443-59-4, GW873140
	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
	(Biological study); USES (Uses)
	(addnl. therapeutic agent; preparation of spirotropane compds. and
	therapeutic use as modulators of chemokine receptor activity)
RN	461443-59-4 CAPLUS
CN	Benzoic acid, 4-[4-[[ (3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-
	dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 3        THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE.FORMAT



L20 ANSWER 24 OF 59 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2006:558325 CAPLUS  
 DN 145:62894  
 TI Preparation of spirotropane compounds and methods for the modulation of  
 chemokine receptor activity to block cellular entry of HIV  
 IN Chan Chun Kong, Laval; Moinet, Christophe; Courchesne, Marc; Vaillancourt,  
 Louis; Bubenik, Monica  
 PA Virochem Pharma Inc., Can.  
 SO PCT Int. Appl., 153 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006060918	A1	20060615	WO 2005-CA1877	20051209
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM CA 2590737 A1 20060615 CA 2005-2590737 20051209 EP 1824853 A1 20070829 EP 2005-819950 20051209 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU PRAI US 2004-634257P P 20041209 WO 2005-CA1877 W 20051209				

OS MARPAT 145:62894

AB Comps. according to formula I (wherein the R1= (un)substituted alkyl,  
 alkenyl, etc.; R2 = H, cycloalkylcarbonyl, ester, etc.; and A = a 5 or 6  
 membered heteroring involving a nitrogen or oxygen atom and one or two  
 keto substituent) are claimed. These compds. and their pharmaceutical  
 acceptable salt are used in combinations or pharmaceutical compns. and are  
 useful in modulation of CCR5 chemokine receptor activity and blocking  
 cellular entry of HIV (no biol. data given). Preparation of I is exemplified.  
 For example, II was prepared from 3-(4-methanesulfonylbenzyl)bicyclo[3.2.1]-  
 1a,3,8-triazaspiro[4.5]dodecan-2,4-dione hydrochloride (preparation given) and  
 (3R,4S)-3-formyl-4-phenylpyrrolidine-1-carboxylic acid tert-Bu ester  
 (preparation given).

IT 461443-59-4, GW873140


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)

(addnl. therapeutic agent; preparation of spirotropane compds. and methods  
 for modulation of chemokine receptor activity to block cellular entry  
 of HIV)

RN 461443-59-4 CAPLUS

CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-  
 dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 25 OF 59 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2006:542321 CAPLUS  
 DN 144:481019  
 TI Method for treating HIV infection through co-administration of tipranavir and GW873140  
 IN Kraft, Michael Friedrich; Mayers, Douglas Lytle  
 PA Boehringer Ingelheim International G.m.b.H., Germany  
 SO PCT Int. Appl., 11 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006060177	A1	20060608	WO 2005-US41757	20051117
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM CA 2586384 A1 20060608 CA 2005-2586384 20051117 US 2006160859 A1 20060720 US 2005-281020 20051117 EP 1819333 A1 20070822 EP 2005-824149 20051117 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR PRAI US 2004-632565P P 20041201 WO 2005-US41757 W 20051117				
AB	Method is disclosed for treating HIV infection through co-administration of tipranavir and GW873140.			
IT	461443-59-4, GW 873140 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (method for treating HIV infection by co-administration of tipranavir and GW873140)			
RN	461443-59-4 CAPLUS			
CN	Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]- (CA INDEX NAME)			

Absolute stereochemistry.



10/527,435

RE.CNT 4      THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 26 OF 59 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2006:479520 CAPLUS

DN 145:327740

TI Evaluation of the drug interaction potential of aplaviroc, a novel human immunodeficiency virus entry inhibitor, using a modified Cooperstown 5 + 1 cocktail

AU Johnson, Brendan M.; Song, Ivy H.; Adkinson, Kimberly K.; Borland, Julie; Fang, Lei; Lou, Yu; Berrey, M. Michelle; Nafziger, Anne M.; Piscitelli, Stephen C.; Bertino, Joseph S., Jr.

CS GlaxoSmithKline, Research Triangle Park, NC, USA

SO Journal of Clinical Pharmacology (2006), 46(5), 577-587

CODEN: JCPCBR; ISSN: 0091-2700

PB Sage Publications

DT Journal

LA English

AB Aplaviroc is a novel CCR5 antagonist, a class of compds. under investigation as viral entry inhibitors for the treatment of human immunodeficiency virus infection. A modified Cooperstown 5+1 cocktail was used to assess the drug interaction potential of aplaviroc. Fifteen healthy subjects were administered single oral doses of caffeine (CYP1A2), warfarin (CYP2C9), omeprazole (CYP2C19), dextromethorphan (CYP2D6), and midazolam (CYP3A) alone (reference treatment) and during steady-state administration of aplaviroc (400 mg every 12 h, test treatment). Metabolite-to-parent area under the plasma concentration vs. time curve (AUC) ratios (paraxanthine/caffeine and 5-hydroxyomeprazole/omeprazole), oral clearance (S-warfarin), AUC (midazolam), and metabolite-to-parent urinary excretion ratio (dextrothorphan/dextromethorphan) were determined. The test-to-reference treatment ratios (geometric mean ratio and 90% confidence interval) were caffeine, 1.06 (0.97-1.17); S-warfarin, 0.93 (0.76-1.15); omeprazole, 1.07 (0.98-1.16); dextromethorphan, 1.17 (0.97-1.42); midazolam, 1.30 (1.04-1.63). No significant inhibition of CYP1A2, CYP2C9, CYP2C19, or CYP2D6 enzyme activity was observed. Mild inhibition of CYP3A isoenzymes should not preclude the use of concomitant CYP3A substrates in future clin. studies with aplaviroc.

IT 461443-59-4, Aplaviroc


RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(aplaviroc was well tolerated in healthy subjects, did not inhibit CYP1A2, CYP2C9, CYP2C19, CYP2D6 enzyme activity, while inhibition of CYP3A isoenzymes was mild evident)

RN 461443-59-4 CAPLUS

CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD

10/527,435

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 27 OF 59 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2006:396751 CAPLUS  
 DN 144:466332  
 TI Structural and Molecular Interactions of CCR5 Inhibitors with CCR5  
 AU Maeda, Kenji; Das, Debananda; Ogata-Aoki, Hiromi; Nakata, Hirotomo;  
 Miyakawa, Toshikazu; Tojo, Yasushi; Norman, Rachael; Takaoka, Yoshikazu;  
 Ding, Jianping; Arnold, Gail F.; Arnold, Eddy; Mitsuya, Hiroaki  
 CS Department of Hematology and Department of Infectious Diseases, Kumamoto  
 University Graduate School of Medical and Pharmaceutical Sciences,  
 Kumamoto, 860-8556, Japan  
 SO Journal of Biological Chemistry (2006), 281(18), 12688-12698  
 CODEN: JBCHA3; ISSN: 0021-9258  
 PB American Society for Biochemistry and Molecular Biology  
 DT Journal  
 LA English  
 AB The authors have characterized the structural and mol. interactions of  
 CC-chemokine receptor 5 (CCR5) with three CCR5 inhibitors active against  
 R5 human immunodeficiency virus type 1 (HIV-1) including the potent in  
 vitro and in vivo CCR5 inhibitor aplaviroc (AVC). The data obtained with  
 saturation binding assays and structural analyses delineated the key  
 interactions responsible for the binding of CCR5 inhibitors with CCR5 and  
 illustrated that their binding site is located in a predominantly  
 lipophilic pocket in the interface of extracellular loops and within the  
 upper transmembrane (TM) domain of CCR5. Mutations in the CCR5 binding  
 sites of AVC decreased gp120 binding to CCR5 and the susceptibility to  
 HIV-1 infection, although mutations in TM4 and TM5 that also decreased  
 gp120 binding and HIV-1 infectivity had less effects on the binding of  
 CC-chemokines, suggesting that CCR5 inhibition targeting appropriate  
 regions might render the inhibition highly HIV-1-specific while preserving  
 the CC chemokine-CCR5 interactions. The present data delineating residue  
 by residue interactions of CCR5 with CCR5 inhibitors should not only help  
 design more potent and more HIV-1-specific CCR5 inhibitors, but also give  
 new insights into the dynamics of CC-chemokine-CCR5 interactions and the  
 mechanisms of CCR5 involvement in the process of cellular entry of HIV-1.  
 IT 461443-59-4, Aplaviroc  
 RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic  
 use); BIOL (Biological study); USES (Uses)  
 (structural and mol. interactions of CCR5 inhibitors with CCR5)  
 RN 461443-59-4 CAPLUS  
 CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-  
 dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/527,435



L20 ANSWER 28 OF 59 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2006:254138 CAPLUS  
 DN 145:201842  
 TI Development of a novel dual CCR5-dependent and CXCR4-dependent cell-cell fusion assay system with inducible gp160 expression  
 AU Ji, Changhua; Zhang, Jun; Cammack, Nick; Sankuratri, Surya  
 CS Viral Diseases, Roche Palo Alto, Palo Alto, CA, USA  
 SO Journal of Biomolecular Screening (2006), 11(1), 65-74  
 CODEN: JBISF3; ISSN: 1087-0571  
 PB Sage Publications  
 DT Journal  
 LA English  
 AB In the current study, a novel coreceptor-specific cell-cell fusion (CCF) assay system is reported. The system possesses the following features: dual CCR5-dependent and CXCR4-dependent CCF assays, all stable cell lines, inducible expression of gp160 to minimize cytotoxicity, robust luciferase reporter, and 384-well format. These assays have been validated using various known HIV entry inhibitors targeting various stages of the HIV entry/fusion process, including fusion inhibitors, gp120 inhibitors, CCR5 antagonists, CCR5 antibodies, and CXCR4 antagonists. IC50 data generated from this assay system were well correlated to that from the antiviral assays. The effects of DMSO on this assay system were assessed, and a 2- to 3-fold increase in luciferase activity was observed in the presence of 0.05% to 2% DMSO. Although cell-cell fusion efficiency was enhanced, no changes in drug response kinetics for entry inhibitors were found in the presence of 0.1% or 0.5% DMSO. This assay system has been successfully used for the identification and characterization of thousands of CCR5 inhibitors.  
 IT 461443-59-4, GW873140  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (GW873140 inhibited CCR5-dependent cell-cell fusion assays in HeLa-R5 and HeLa-X4 cell lines)  
 RN 461443-59-4 CAPLUS  
 CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 29 OF 59 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2006:117207 CAPLUS

DN 144:213021

TI Preparation of pseudopeptide phosphate prodrugs of HIV protease inhibitors

IN Degeoey, David A.; Flosi, William J.; Grampovnik, David J.; Klein, Larry L.; Kempf, Dale J.; Wang, Xiu C.

PA Abbott Laboratories, USA

SO PCT Int. Appl., 112 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006014282	A2	20060209	WO 2005-US23047	20050629
	WO 2006014282	A3	20060511		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	AU 2005270124	A1	20060209	AU 2005-270124	20050629
	CA 2571726	A1	20060209	CA 2005-2571726	20050629
	EP 1773850	A2	20070418	EP 2005-762529	20050629
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR			
	CN 101023090	A	20070822	CN 2005-80029924	20050629
	US 2007270383	A1	20071122	US 2005-170197	20050629
	KR 2007029244	A	20070313	KR 2007-700347	20070105
	IN 2007MN00181	A	20070720	IN 2007-MN181	20070205
PRAI	US 2004-585710P	P	20040706		
	WO 2005-US23047	W	20050629		

OS CASREACT 144:213021; MARPAT 144:213021

AB The invention discloses compds. A-L1-L2-OP03H2 (L1 is a bond, CO or CO2; L2 is (CR1R2)1-5, where R1, R2 are H or alkyl; A is a pseudopeptide moiety, e.g., I, attached through its oxygen atom), as well as their alkyl or arylalkyl esters, metal or quaternary ammonium salts, for use as prodrugs of HIV protease inhibitors. Thus, disodium N1-[(1S,3S,4S)-1-benzyl-5-phenyl-3-[(phosphonatooxy)methoxy]-4-[[[(1,3-thiazol-5-ylmethoxy)carbonyl]amino]pentyl]-N2-[[[(2-isopropyl-1,3-thiazol-4-yl)methyl](methyl)amino]carbonyl]-L-valinamide was prepared from the alc. (I-H) by treatment with Me sulfide and benzoyl peroxide in acetonitrile to form the 3-[(methylthio)methoxy] derivative, which was treated with phosphoric acid, mol. sieves and N-iodosuccinimide in THF and then with Na2S2O3 and Na2CO3.

IT 461443-59-4, GW873140

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(preparation of pseudopeptide phosphate prodrugs of HIV protease inhibitors)


RN 461443-59-4 CAPLUS

CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-

10/527,435


dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]- (CA INDEX NAME)

Absolute stereochemistry.



L20 ANSWER 30 OF 59 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2005:1256967 CAPLUS  
 DN 144:368023  
 TI CCR5: a target for therapeutic intervention of HIV-1 infection  
 AU Mitsuya, Hiroaki  
 CS Dep. of Infectious Diseases, Dep. of Hematology, School of Medicine,  
 Kumamoto University, Japan  
 SO Jikken Igaku (2005) 23(17), 2726-2731  
 CODEN: JIIGEF; ISSN 0288-5514  
 PB Yodosha  
 DT Journal; General Review  
 LA Japanese  
 AB A review on human immunodeficiency virus-1 (HIV-1) invasion inhibitors and  
 chemokine receptor antagonists, discussing (1) gp41 targeted inhibitors  
 T-20 and T-1249 and CD4 binding inhibitors PRO542 and TNX-355 and  
 anti-CXCR4 agents, (2) CCR5 antagonists maraviroc, aplaviroc, vicravivroc  
 and TAK-652 and (3) structural anal. of CCR5 and CCR5 antagonist binding.  
 IT 461443-59-4, AK602  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)  
 (CCR5 as a target for therapeutic intervention of HIV-1 infection)  
 RN 461443-59-4 CAPLUS  
 CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-  
 dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]- (CA INDEX NAME)

Absolute stereochemistry.



L20 ANSWER 31 OF 59 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2005:1131007 CAPLUS  
 DN 144:141709  
 TI Emerging drug targets for antiretroviral therapy  
 AU Reeves, Jacqueline D.; Piefer, Andrew J.  
 CS Department of Microbiology, University of Pennsylvania, Philadelphia, PA, USA  
 SO Drugs (2005), 65(13), 1747-1766  
 CODEN DRUGAY; ISSN: 0012-6667  
 PB Adis International Ltd.  
 DT Journal; General Review  
 LA English  
 AB A review. Current targets for antiretroviral therapy (ART) include the viral enzymes reverse transcriptase and protease. The use of a combination of inhibitors targeting these enzymes can reduce viral load for a prolonged period and delay disease progression. However, complications of ART, including the emergence of viruses resistant to current drugs, are driving the development of new antiretroviral agents targeting not only the reverse transcriptase and protease enzymes but novel targets as well. Indeed, enfuvirtide, an inhibitor targeting the viral envelope protein (Env) was recently approved for use in combination therapy in individuals not responding to current antiretroviral regimens. Emerging drug targets for ART include: (i) inhibitors that directly or indirectly target Env; (ii) the HIV enzyme integrase; and (iii) inhibitors of maturation that target the substrate of the protease enzyme. Env mediates entry of HIV into target cells via a multistep process that presents three distinct targets for inhibition by viral and cellular-specific agents. First, attachment of virions to the cell surface via nonspecific interactions and CD4 binding can be blocked by inhibitors that include cyanovirin-N, cyclotriazadisulfonamide analogs, PRO 2000, TNX 355 and PRO 542. In addition, BMS 806 can block CD4-induced conformational changes. Secondly, Env interactions with the co-receptor mols. can be targeted by CCR5 antagonists including SCH-D, maraviroc (UK 427857) and aplaviroc (GW 873140), and the CXCR4 antagonist AMD 070. Thirdly, fusion of viral and cellular membranes can be inhibited by peptides such as enfuvirtide and tifuvirtide (T 1249). The development of entry inhibitors has been rapid, with an increasing number entering clin. trials. Moreover, some entry inhibitors are also being evaluated as candidate microbicides to prevent mucosal transmission of HIV. The integrase enzyme facilitates the integration of viral DNA into the host cell genome. The uniqueness and specificity of this reaction makes integrase an attractive drug target. However, integrase inhibitors have been slow to reach clin. development, although recent contenders, including L 870810, show promise. Inhibitors that target viral maturation via a unique mode of action, such as PA 457, also have potential. In addition, recent advances in our understanding of cellular pathways involved in the life cycle of HIV have also identified novel targets that may have potential for future antiretroviral intervention, including interactions between the cellular proteins APOBEC3G and TSG101, and the viral proteins Vif and p6, resp. In summary, a number of antiretroviral agents in development make HIV entry, integration and maturation emerging drug targets. A multifaceted approach to ART, using combinations of inhibitors that target different steps of the viral life cycle, has the best potential for long-term control of HIV infection. Furthermore, the development of microbicides targeting HIV holds promise for reducing HIV transmission events.  
 IT 461443-59-4, GW 873140


10/527,435

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(CCR5 antagonist GW 873140 showed potential in therapy of human  
immunodeficiency virus infected patient through targeting Env  
interactions with co-receptor mols.)

RN 461443-59-4 CAPLUS


CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-  
dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 222 THERE ARE 222 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 32 OF 59 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2005:1016895 CAPLUS  
 DN 143:415586  
 TI G-Protein-Coupled Receptor Affinity Prediction Based on the Use of a  
 Profiling Dataset: QSAR Design, Synthesis, and Experimental Validation  
 AU Rolland, Catherine; Gozalbes, Rafael; Nicolaie, Eric; Paugam,  
 Marie-France; Coussy, Laurent; Barbosa, Frederique; Horvath, Dragos;  
 Revah, Frederic  
 CS Cerep, Rueil-Malmaison, 92500, Fr.  
 SO Journal of Medicinal Chemistry (2005), 48(21), 6563-6574  
 CODEN: JMCMAR; ISSN: 0022-2623  
 PB American Chemical Society  
 DT Journal  
 LA English  
 AB A QSAR model accounting for "average" G-protein-coupled receptor (GPCR)  
 binding was built from a large set of exptl. standardized binding data  
 (1939 compds. systematically tested over 40 different GPCRs) and applied  
 to the design of a library of "GPCR-predicted" compds. Three hundred and  
 sixty of these compds. were randomly selected and tested in 21 GPCR  
 binding assays. Positives were defined by their ability to inhibit by  
 more than 70% the binding of reference compds. at 10  $\mu$ M. A 5.5-fold  
 enrichment in positives was observed when comparing the "GPCR-predicted"  
 compds. with 600 randomly selected compds. predicted as "non-GPCR" from a  
 general collection. The model was efficient in predicting strongest  
 binders, since enrichment was greater for higher cutoffs. Significant  
 enrichment was also observed for peptidic GPCRs and receptors not included to  
 develop the QSAR model, suggesting the usefulness of the model to design  
 ligands binding with newly identified GPCRs, including orphan ones.  
 IT 868056-95-5  
 RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic  
 use); BIOL (Biological study); USES (Uses)  
 (QSAR design, synthesis, and exptl. validation of G-protein-coupled  
 receptor affinity prediction based on use of a profiling dataset)  
 RN 868056-95-5 CAPLUS  
 CN Benzoic acid, 4-[4-[[1-butyl-3-(cyclohexylhydroxymethyl)-2,5-dioxo-1,4,9-  
 triazaspiro[5.5]undec-9-yl]methyl]phenoxy]- (CA INDEX NAME)



RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 33 OF 59 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2005:958485 CAPLUS

DN 144:100402

TI Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adults

AU Lalezari, Jacob; Thompson, Melanie; Kumar, Priny; Piliero, Peter; Davey, Richard; Patterson, Kristine; Shachoy-Clark, Anne; Adkison, Kimberly; Demarest, James; Lou, Yu; Berrey, Michelle; Piscitelli, Stephen

CS Quest Clinical Research, San Francisco, CA, USA

SO AIDS (Hagerstown, MD, United States) (2005), 19(14), 1443-1448

CODEN: AIDSET; ISSN: 0269-9370

PB Lippincott Williams & Wilkins

DT Journal

LA English

AB Objective: 873140 is a spirodiketopiperazine CCR5 antagonist with prolonged receptor binding and potent antiviral activity in vitro. This study evaluated plasma HIV RNA, safety, and pharmacokinetics following short-term monotherapy in HIV-infected adults. Design: Double-blind, randomized, placebo-controlled multi-center trial. Methods: Treatment-naïve or experienced HIV-infected subjects with R5-tropic virus, CD4 cell count nadir > 200 + 106 cells/l, viral load > 5000 copies/mL and not receiving antiretroviral therapy for the preceding 12 wk were enrolled. Forty subjects were randomized to one of four cohorts (200 mg QD, 200 mg BID, 400 mg QD, 600 mg BID) with 10 subjects (eight active, two placebo) in each cohort, and received treatment for 10 days. Serial HIV RNA, pharmacokinetics, and safety evaluations were performed through day 24. Results: Of the 40 subjects, 21 were treatment-experienced; 35 were male, 20 were non-white, and eight were coinfecting with hepatitis C virus. Median baseline HIV RNA ranged from 4.26log10 to 4.46 log10. 873140 was generally well tolerated with no drug-related discontinuations. The most common adverse events were grade 1 gastrointestinal complaints that generally resolved within 1-3 days on therapy. No clin. significant abnormalities were observed on ECG or in laboratory parameters. Mean log changes in HIV RNA at nadir, and the percentage of subjects with > 1 log10 decrease were -0.12 (0%) for placebo, -0.46 (17%) for 200 mg once daily, -1.23 (75%) for 200 mg twice daily, -1.03 (63%) for 400 mg once daily, and -1.66 (100%) for 600 mg twice daily. An Emax relationship was observed between the area under the 873140 plasma concentration-time curve and change in HIV RNA. Conclusions: 873140 demonstrated potent antiretroviral activity and was well tolerated. These results support further evaluation in Phase 2b/3 studies.

IT 461023-63-2

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(CCR5 antagonist 873140 was safe, well tolerated and effective in HIV-infected patient)


RN 461023-63-2 CAPLUS

CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



10/527,435



● HCl

RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 34 OF 59 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2005:698347 CAPLUS  
 DN 143:194248  
 TI Therapeutic combinations containing an amino acid amide HIV protease inhibitor  
 IN Hammond, Jennifer Lou; Patick, Amy Karen  
 PA Agouron Pharmaceuticals, Inc., USA  
 SO U.S. Pat. Appl. Publ., 25 pp.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005171038	A1	20050804	US 2005-46260	20050128
	AU 2005216710	A1	20050909	AU 2005-216710	20050117
	CA 2555171	A1	20050909	CA 2005-2555171	20050117
	WO 2005082362	A1	20050909	WO 2005-IB101	20050117
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP	1713470	A1	20061025	EP 2005-702264	20050117
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
BR	2005006493	A	20070213	BR 2005-6493	20050117
CN	1938017	A	20070328	CN 2005-80010030	20050117
JP	2007519704	T	20070719	JP 2006-550331	20050117
NO	2006003483	A	20060830	NO 2006-3483	20060731
MX	2006PA08632	A	20060904	MX 2006-PA8632	20060731
IN	2006DN04522	A	20070824	IN 2006-DN4522	20060804
PRAI	US 2004-540749P	P	20040130		
	US 2004-615000P	P	20041001		
	WO 2005-IB101	W	20050117		

OS CASREACT 143:194248

AB The invention is related to methods for treating an HIV infection by using a therapeutically effective amount of a combination of compds., including I and its related N-amide derivs. The invention is also related to compns. comprising certain compds. useful as inhibitors of the HIV protease enzyme and at least one addnl. therapeutic agent. In an XTT dye reduction method, I in combination with ritonavir acted synergistically against HIV-1 infection.


IT 461443-59-4, GW 873140

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (combination therapy agent; compns. comprising an amino acid amide HIV protease inhibitor)

RN 461443-59-4 CAPLUS

CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]- (CA INDEX NAME)

Absolute stereochemistry.




L20 ANSWER 35 OF 59 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2005:641882 CAPLUS  
 DN 143:153711  
 TI Preparation of amino acid hydrazide derivatives as HIV protease inhibitors  
 IN Randolph, John T.; Chen, Hui-ju; Degoey, David A.; Flentge, Charles A.;  
 Flosi, William J.; Grampovnik, David J.; Huang, Peggy P.; Hutchinson,  
 Douglas K.; Kempf, Dale J.; Klein, Larry L.; Yeung, Ming C.  
 PA USA  
 SO U.S. Pat. Appl. Publ., 155 pp.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005159469	A1	20050721	US 2004-10177	20041210
PRAI	US 2003-528679P	P	20031211		
OS	MARPAT 143:153711				

AB The invention relates to amino acid hydrazide derivs. I [X-Y is CH<sub>2</sub>(CH<sub>2</sub>)<sub>1-2</sub>, CH:CH or C(:Z')(CH<sub>2</sub>)<sub>1-2</sub>; Z, Z' are O, S or NH; R<sub>1</sub>, R<sub>2</sub>, R<sub>5</sub> are independently (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, etc.; R<sub>3</sub> is H, alkyl, aryl, etc.; R<sub>4</sub> is an amino acid or acyl residue of defined structure], including pharmaceutically-acceptable salts, stereoisomers, esters or prodrugs, having HIV protease inhibitory activity. Thus, hydrazide I [X-Y is CH<sub>2</sub>CH<sub>2</sub>; Z is O; R<sub>1</sub> is CMeEt; R<sub>2</sub> is PhCH<sub>2</sub>; R<sub>3</sub> is 4-(2-pyridyl)benzyl; R<sub>4</sub> is N-carbomethoxy-tert-leucine (all-S stereo)] was prepared by a multistep sequence involving peptide coupling in the final step. Compds. of the invention showed EC<sub>50</sub> values 1-100 nM against wild-type HIV.

IT 461443-59-4  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (preparation of amino acid hydrazide derivs. as HIV protease inhibitors)  
 RN 461443-59-4 CAPLUS  
 CN Benzoic acid, 4-[4-[[ (3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]- (CA INDEX NAME)


Absolute stereochemistry.



L20 ANSWER 36 OF 59 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2005:590606 CAPLUS  
 DN 143:125797  
 TI Pharmacokinetics and short-term safety of 873140, a novel CCR5 antagonist, in healthy adult subjects  
 AU Adkison, Kimberly K.; Shachoy-Clark, Anne; Fang, Lei; Lou, Yu; O'Mara, Kathy; Berrey, M. Michelle; Piscitelli, Stephen C.  
 CS GlaxoSmithKline, Research Triangle Park, NC, USA  
 SO Antimicrobial Agents and Chemotherapy (2005), 49(7), 2802-2806  
 CODEN: AMACCQ; ISSN: 0066-4804  
 PB American Society for Microbiology  
 DT Journal  
 LA English  
 AB 873140 Is a novel CCR5 antagonist with potent in vitro anti-human immunodeficiency virus (HIV) activity. This study was a double-blind, randomized, placebo-controlled, single- and repeat-dose escalation investigation of the safety, pharmacokinetics, and food effect of 873140 in 70 adult subjects. During single-dose escalation, three cohorts (each composed of 10 subjects, with 8 subjects receiving the active drug and 2 subjects receiving the placebo [8 active and 2 placebo]) received doses of 50, 200, 400, 800, and 1,200 mg after an overnight fast, or 400 mg plus a standard high-fat breakfast in an alternating panel design. During repeat-dose escalation, four cohorts (each with 8 active and 2 placebo) received doses of 200, 400, 600, or 800 mg every 12 h (BID) for 8 days. Laboratory safety tests, vital signs, and electrocardiograms (ECGs) were performed at regular intervals, and blood samples were obtained for pharmacokinetics. Single and repeat doses of 50 mg to 800 mg were well tolerated, with no serious adverse events and no grade 3 or 4 adverse events. The mild-to-moderate side effects were primarily gastrointestinal and included abdominal cramping, nausea, and diarrhea. No specific trends in laboratory parameters or clin. significant ECG changes were noted. Plasma 873140 concns. increased rapidly; the median time to maximum concentration of drug in serum was 1.75 to 5 h. The median area under the plasma concentration-time profile (AUC) and the maximum concentration of drug in serum (Cmax) ranged from 127 ng · h/mL and 24 ng/mL at 200 mg BID to 329 ng · h/mL and 100 ng/mL at 800 mg BID, resp. Food consumption increased the AUC and Cmax by a mean of 1.7- and 2.2-fold, resp. The pharmacokinetic and safety profile supports the continued investigation of 873140 with HIV-infected subjects.  
 IT 461023-63-2  
 RL: PKT (Pharmacokinetics); BIOL (Biological study)  
 (pharmacokinetics and short-term safety of 873140, a novel CCR5 antagonist, in healthy adult subjects)  
 RN 461023-63-2 CAPLUS  
 CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/527,435



● HCl

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 37 OF 59 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2005:588945 CAPLUS  
 DN 143:133695  
 TI Preparation of amino acid hydrazide derivatives as HIV protease inhibitors  
 IN Randolph, John T.; Chen, Hui-Ju; Degoey, David A.; Flentge, Charles A.;  
 Flosi, William J.; Grampovnik, David J.; Huang, Peggy P.; Hutchinson,  
 Douglas K.; Kempf, Dale J.; Klein, Larry L.; Yeung, Ming C.  
 PA Abbott Laboratories, USA  
 SO PCT Int. Appl., 281 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005061487	A1	20050707	WO 2004-US37711	20041110
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2549228	A1	20050707	CA 2004-2549228	20041110
	EP 1697348	A1	20060906	EP 2004-810778	20041110
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
	JP 2007516255	T	20070621	JP 2006-543825	20041110
	MX 2006PA06609	A	20060831	MX 2006-PA6609	20060609
PRAI	US 2003-733227	A	20031211		
	WO 2004-US37711	W	20041110		

OS MARPAT 143:133695

AB The invention relates to amino acid hydrazide derivs. I [X-Y is CH<sub>2</sub>(CH<sub>2</sub>)<sub>1-2</sub>, CH:CH or C(:Z')(CH<sub>2</sub>)<sub>1-2</sub>; Z, Z' are O, S or NH; R<sub>1</sub>, R<sub>2</sub>, R<sub>5</sub> are independently (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, etc.; R<sub>3</sub> is H, alkyl, aryl, etc.; R<sub>4</sub> is an amino acid or acyl residue of defined structure], including pharmaceutically-acceptable salts, stereoisomers, esters or prodrugs, having HIV protease inhibitory activity. Thus, hydrazide I [X-Y is CH<sub>2</sub>CH<sub>2</sub>; Z is O; R<sub>1</sub> is CMeEt; R<sub>2</sub> is PhCH<sub>2</sub>; R<sub>3</sub> is 4-(2-pyridyl)benzyl; R<sub>4</sub> is N-carbomethoxy-tert-leucine (all-S stereo)] was prepared by a multistep sequence involving peptide coupling in the final step. Compds. of the invention showed EC<sub>50</sub> values 1-100 nM against wild-type HIV.


IT 461443-59-4, GW873140

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (preparation of amino acid hydrazide derivs. as HIV protease inhibitors)

RN 461443-59-4 CAPLUS

CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 5

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT



L20 ANSWER 38 OF 59 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2005:588404 CAPLUS  
 DN 143:133693  
 TI Preparation of amino acid derivatives as HIV protease inhibitors  
 IN Degoey, David A.; Flentge, Charles A.; Flosi, William J.; Grampovnik, David J.; Kempf, Dale J.; Klein, Larry L.; Yeung, Ming C.; Randolph, John T.; Wang, Xiu C.; Yu, Su  
 PA USA  
 SO U.S. Pat. Appl. Publ., 279 pp.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005148623	A1	20050707	US 2004-8713	20041209
PRAI	US 2003-528974P	P	20031211		
OS	MARPAT 143:133693				


AB The invention relates to amino acid derivs. A-NHCHR6CHR5CHR4CHR3NHCOCHR2NHCO2R1 [A is an amino acid or acyl residue of defined structure; R1, R2, R3, R6 are independently (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl or heteroaryl; R4, R5 are H (not both), OH or substituted hydroxyl], including pharmaceutically-acceptable salts, prodrugs or stereoisomers, having HIV protease inhibitory activity. Thus, Me (1S,4R,6S,7S,10S)-7-benzyl-1,10-di-tert-butyl-6-hydroxy-2,9,12-trioxo-4-[4-(2-pyridinyl)benzyl]-13-oxa-3,8,11-triazatetradec-1-ylcarbamate was prepared by a multistep procedure, which includes the reaction of intermediate tert-Bu (1S,2S,4R)-4-amino-1-benzyl-2-hydroxy-5-[4-(2-pyridinyl)phenyl]pentylcarbamate with N-protected L-tert-leucine. Compds. of the invention showed EC50 values in the range 0.7 nM to >3.2  $\mu$ M against wild-type HIV.

IT 461443-59-4  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (preparation of amino acid derivs. as HIV protease inhibitors)

RN 461443-59-4 CAPLUS

CN Benzoic acid, 4-[4-[[ (3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]- (CA INDEX NAME)


Absolute stereochemistry.



L20 ANSWER 39 OF 59 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2005:536932 CAPLUS  
 DN 143:125633  
 TI The appealing story of HIV entry inhibitors: from discovery of biological mechanisms to drug development  
 AU Castagna, Antonella; Biswas, Priscilla; Beretta, Alberto; Lazzarin, Adriano  
 CS Clinic of Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy  
 SO Drugs (2005), 65(7), 879-904  
 CODEN: DRUGAY; ISSN: 0012-6667  
 PB Adis International Ltd.  
 DT Journal; General Review  
 LA English  
 AB A review. Current therapeutic intervention in HIV infection relies upon 20 different drugs. Despite the impressive efficacy shown by these drugs, we are confronted with an unexpected frequency of adverse effects, such as mitochondrial toxicity and lipodystrophy, and resistance, not only to individual drugs but to entire drug classes. Thus, there is now a great need for new antiretroviral drugs with reduced toxicity, increased activity against drug-resistant viruses and a greater capacity to reach tissue sanctuaries of the virus. Two different HIV mols. have been selected as targets of drug inhibition so far: reverse transcriptase and protease. Drugs that target the interactions between the HIV envelope and the cellular receptor complex are a 'new entry' into the scenario of HIV therapy and have recently raised great interest because of their activity against multidrug-resistant viruses. There are several compds. that are at different developmental stages in the pipeline to counter HIV entry, among them: (i) the attachment inhibitor dextrin-2-sulfate; (ii) the inhibitors of the glycoprotein (gp) 120/CD4 interaction PRO 542, TNX 355 and BMS 488043; (iii) the co-receptor inhibitors subdivided in those targeting CCR5 (SCH 417690 [SCH D], UK 427857 GW 873140, PRO 140, TAK 220, AMD 887) and those targeting CXCR4 (AMD 070, KRH 2731); and (iv) the fusion inhibitors; enfuvirtide (T-20) and tifuvirtide (T-1249). The story, of the first of these drugs, enfuvirtide, which has successfully completed phase III clin. trials, has been approved by the US FDA and by the European Medicines Agency, and is now com. available worldwide, is an example of how the knowledge of basic mol. mechanisms can rapidly translate into the development of clin. effective mols.  
 IT 461443-59-4, GW 873140  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (addition of co-receptor CCR5 inhibitor GW 873140 to therapeutic armamentarium against HIV-1 offers new hope for treating HIV infected patient)  
 RN 461443-59-4 CAPLUS  
 CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]- (CA INDEX NAME)

Absolute stereochemistry.

10/527,435



RE.CNT 198 THERE ARE 198 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 40 OF 59 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2005:527407 CAPLUS

DN 143:59982

TI Preparation of HIV protease inhibitors, in particular imidazolidine derivatives

IN Flentge, Charles A.; Chen, Hui-Ju; Degoe, David A.; Flosi, William J.; Grampovnik, David J.; Huang, Peggy P.; Kempf, Dale J.; Klein, Larry L.; Krueger, Allan C.; Madigan, Darold L.; Randolph, John T.; Sun, Minghua; Yeung, Ming C.; Zhao, Chen

PA USA

SO U.S. Pat. Appl. Publ., 287 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005131042	A1	20050616	US 2003-733915	20031211
	CA 2549389	A1	20050707	CA 2004-2549389	20041110
	WO 2005061450	A2	20050707	WO 2004-US37745	20041110
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1709037	A2	20061011	EP 2004-810802	20041110
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
	JP 2007513944	T	20070531	JP 2006-543826	20041110
	MX 2006PA06610	A	20060831	MX 2006-PA6610	20060609
PRAI	US 2003-733915	A	20031211		
	WO 2004-US37745	W	20041110		

OS MARPAT 143:59982

AB Title compds. of formula ANH(CHR)(CHR1)(CHR2)NR3S(O2)R4 (I) [wherein A = alkylcarbonyl, arylsulfonyl, 1,3-substituted 2-oxoimidazolidinyl, 2,4-dioxoimidazolidinyl, etc.; X, Y = independently O, S, NH; R = (un)substituted alk(en)yl, cycloalk(en)yl, hetero/arylalkyl, etc.; R1 = OH and derivs., OPO3H and derivs., OSO2H and derivs., etc.; R2 = H; R3 = halo/alkyl, halo/alkenyl, (un)substituted cycloalk(en)yl, aryl; R4 = (un)substituted cycloalk(en)yl, heterocyclyl, hetero/aryl] were prepared as HIV protease inhibitors. For example, II was prepared, in 62% yield, by coupling acid III (preparation given) with amine IV (preparation given). I showed

antiviral activity against Wild-Type HIV with EC50 in the range of 1 nM to 100 nM.

IT 461443-59-4, GW873140

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(combination therapy; preparation of HIV protease inhibitors, in particular imidazolidine derivs.)


RN 461443-59-4 CAPLUS

CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-

10/527,435

dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]- (CA INDEX NAME)

Absolute stereochemistry.



L20 ANSWER 41 OF 59 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2005:527398 CAPLUS  
 DN 143:78485  
 TI Preparation of amino acid derivatives as HIV protease inhibitors  
 IN Degoey, David A.; Flentge, Charles A.; Flosi, William J.; Grampovnik,  
 David J.; Kempf, Dale J.; Klein, Larry L.  
 PA USA  
 SO U.S. Pat. Appl. Publ., 204 pp.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005131017	A1	20050610	US 2003-733946	20031211
	CA 2549098	A1	20050630	CA 2004-2549098	20041209
	WO 2005058841	A2	20050630	WO 2004-US41658	20041209
	WO 2005058841	A3	20060309		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				
	CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,				
	GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,				
	LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,				
	NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,				
	TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,				
	AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,				
	EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,				
	RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,				
	MR, NE, SN, TD, TG				
EP	1697344	A2	20060906	EP 2004-813910	20041209
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
	IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK,				
	BA, HR, IS, YU				
JP	2007516260	T	20070621	JP 2006-544070	20041209
MX	2006PA06612	A	20060831	MX 2006-PA6612	20060609
PRAI	US 2003-733946	A	20031211		
	WO 2004-US41658	W	20041209		

OS CASREACT 143:78485; MARPAT 143:78485

AB The invention relates to amino acid derivs. A-NHCHR6CHR5CHR4CHR3NHCOCHR2NHCO2R1 [A is an amino acid or acyl residue of defined structure; R1, R2, R3, R6 are independently (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl or heteroaryl; R4, R5 are H (not both), OH or substituted hydroxyl], including pharmaceutically-acceptable salts, stereoisomers, esters or prodrugs, having HIV protease inhibitory activity. Thus, Me (1S,4R,6S,7S,10S)-7-benzyl-1,10-di-tert-butyl-6-hydroxy-2,9,12-trioxo-4-[4-(2-pyridinyl)benzyl]-13-oxa-3,8,11-triazatetradec-1-ylcarbamate was prepared by a multistep procedure, which includes the reaction of intermediate tert-Bu (1S,2S,4R)-4-amino-1-benzyl-2-hydroxy-5-[4-(2-pyridinyl)phenyl]pentylcarbamate with N-protected L-tert-leucine. Compds. of the invention showed EC50 values 0.7-300 nM against wild-type HIV.


IT 461443-59-4, GW873140

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (preparation of amino acid derivs. as HIV protease inhibitors)

RN 461443-59-4 CAPLUS

CN Benzoic acid, 4-[4-[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]- (CA INDEX NAME)


Absolute stereochemistry.



L20 ANSWER 42 OF 59 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2005:311526 CAPLUS  
 DN 142:456334  
 TI The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor  
 AU Watson, Christian; Jenkinson, Stephen; Kazmierski, Wieslaw; Kenakin, Terry  
 CS Assay Development and Compound Profiling, GlaxoSmithKline Research and Development, Research Triangle Park, NC, USA  
 SO Molecular Pharmacology (2005), 67(4), 1268-1282  
 CODEN: MOPMA3; ISSN: 0026-895X  
 PB American Society for Pharmacology and Experimental Therapeutics  
 DT Journal  
 LA English  
 AB 4-{[4-({(3R)-1-Butyl-3-[(R)-cyclohexyl(hydroxy)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl}phenyl]oxy}benzoic acid hydrochloride (873140) is a potent noncompetitive allosteric antagonist of the CCR5 receptor (pK<sub>B</sub> = 8.6±0.07; 95% CI, 8.5 to 8.8) with concomitantly potent antiviral effects for HIV-1. In this article, the receptor-based mechanism of action of 873140 is compared with four other noncompetitive allosteric antagonists of CCR5. Although (Z)-(4-bromophenyl){1'-[(2,4-dimethyl-1-oxido-3-pyridinyl)carbonyl]-4'-methyl-1,4'-bipiperidin-4-yl}methanone O-ethyloxime (Sch-C; SCH 351125), 4,6-dimethyl-5-{[4-methyl-4-((3S)-3-methyl-4-[(1R)-2-(methyloxy)-1-[4-(trifluoromethyl)phenyl]ethyl]-1-piperazinyl)-1-piperidinyl]carbonyl}pyrimidine (Sch-D; SCH 417,690), 4,4-difluoro-N-[(1S)-3-{(3-endo)-3-[3-methyl-5-(1-methylethyl)-4H-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1]oct-8-yl}-1-phenylpropyl)cyclohexanecarboxamide (UK-427,857), and N,N-dimethyl-N-[4-[[[2-(4-methylphenyl)-6,7-dihydro-5H-benzocyclo-hepten-8-yl]carbonyl]amino]benzyl]tetrahydro-2H-pyran-4-aminium chloride (TAK779) blocked the binding of both chemokines 125I-MIP-1 $\alpha$  (also known as 125I-CCL3, 125I-LD78) and 125I-RANTES (125I-CCL5), 873140 was an ineffectual antagonist of 125I-RANTES (regulated on activation normal T cell expressed and secreted) binding (but did block binding of 125I-MIP-1 $\alpha$ ). Furthermore, 873140 blocked the calcium response effects of CCR5 activation by CCL5 (RANTES) (as did the other antagonists), indicating a unique divergence of blockade of function and binding with this antagonist. The antagonism of CCR5 by 873140 is saturable and probe-dependent, consistent with an allosteric mechanism of action. The blockade of CCR5 by 873140 was extremely persistent with a rate constant for reversal of <0.004 h<sup>-1</sup> (t<sub>1/2</sub> > 136 h). Coadministration studies of 873140 with the four other allosteric antagonists yielded data that are consistent with the notion that all five of these antagonists bind to a common allosteric site on the CCR5 receptor. Although these ligands may have a common binding site, they do not exert the same allosteric effect on the receptor, as indicated by their differential effects on the binding of 125I-RANTES. This idea is discussed in terms of using these drugs sequentially to overcome HIV viral resistance in the clinic.  
 IT 461023-63-2  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (873140; CCR5 receptor-based mechanism of action of compound 873140, a potent allosteric noncompetitive HIV entry inhibitor)  
 RN 461023-63-2 CAPLUS  
 CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



Absolute stereochemistry.




● HCl

RE.CNT 54 THERE ARE 54 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 43 OF 59 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2005:233058 CAPLUS  
 DN 142:366839  
 TI Potent anti-R5 human immunodeficiency virus type 1 effects of a CCR5 antagonist, AK602/ONO4128/GW873140, in a novel human peripheral blood mononuclear cell nonobese diabetic-SCID, interleukin-2 receptor  $\gamma$ -chain-knocked-out AIDS mouse model  
 AU Nakata, Hirotomo; Maeda, Kenji; Miyakawa, Toshikazu; Shibayama, Shiro; Matsuo, Masayoshi; Takaoka, Yoshikazu; Ito, Mamoru; Koyanagi, Yoshio; Mitsuya, Hiroaki  
 CS Department of Infectious Diseases, Kumamoto University Graduate School of Medicine, Kumamoto, 860-8556, Japan  
 SO Journal of Virology (2005), 79(4), 2087-2096  
 CODEN: JOVIAM; ISSN: 0022-538X  
 PB American Society for Microbiology  
 DT Journal  
 LA English  
 AB We established human peripheral blood mononuclear cell (PBMC)-transplanted R5 human immunodeficiency virus type 1 isolate JR-FL (HIV-1JR-FL)-infected, nonobese diabetic-SCID, interleukin 2 receptor  $\gamma$ -chain-knocked-out (NOG) mice, in which massive and systemic HIV-1 infection occurred. The susceptibility of the implanted PBMC to the infectivity and cytopathic effect of R5 HIV-1 appeared to stem from hyperactivation of the PBMC, which rapidly proliferated and expressed high levels of CCR5. When a novel spirodiketopiperazine-containing CCR5 inhibitor, AK602/ONO4128/GW873140 (mol. weight, 614), was administered to the NOG mice 1 day after R5 HIV-1 inoculation, the replication and cytopathic effects of R5 HIV-1 were significantly suppressed. In saline-treated mice (n = 7), the mean human CD4+/CD8+ cell ratio was 0.1 on day 16 after inoculation, while levels in mice (n = 8) administered AK602 had a mean value of 0.92, comparable to levels in uninfected mice (n = 7). The mean number of HIV-RNA copies in plasma in saline-treated mice were .apprx.106/mL on day 16, while levels in AK602-treated mice were 1.27+103/mL (P = 0.001). AK602 also significantly suppressed the number of proviral DNA copies and serum p24 levels (P = 0.001). These data suggest that the present NOG mouse system should serve as a small-animal AIDS model and warrant that AK602 be further developed as a potential therapeutic for HIV-1 infection.  
 IT 461443-59-4, AK602  
 RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (anti-R5 HIV1 activity of CCR5 antagonist, AK602, in novel PBMC diabetic-SCID, IL-2R-knocked-out AIDS mouse model)  
 RN 461443-59-4 CAPLUS  
 CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]- (CA INDEX NAME)

Absolute stereochemistry.

10/527,435




RE.CNT 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 44 OF 59 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2005:160977 CAPLUS  
 DN 142:246180  
 TI Pharmaceutical compositions comprising CCR5 antagonists  
 IN Peled, Amnon; Wald, Ori; Galun, Eithan  
 PA Hadasit Medical Research Services & Development Ltd., Israel  
 SO PCT Int. Appl., 36 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005016226	A2	20050224	WO 2004-IL743	20040812
	WO 2005016226	A3	20060803		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	IL 2003-157398	A	20030814	no US appln in patent family	
AB	A pharmaceutical composition comprising at least one CCR5 antagonist, such as anti-CCR5 antibodies, modified chemokines or a fraction thereof, peptides derived from such chemokines, and small organic mols., e.g., TAK 220, SCH C, SCH D, AK 602 or UK 427857, and a pharmaceutically acceptable carrier is useful for reducing liver inflammation and liver damage caused by HCV infection. The pharmaceutical composition comprising CCR5 antagonists is useful for administration together with combined interferon- $\alpha$ and ribavirin therapy.				
IT	461443-59-4, AK 602 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (compns. comprising CCR5 antagonists for treatment of liver diseases)				
RN	461443-59-4 CAPLUS				
CN	Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]- (CA INDEX NAME)				

Absolute stereochemistry.



L20 ANSWER 45 OF 59 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2005:74120 CAPLUS

DN 142:176697

TI Preparation of spiro compounds for the modulation of chemokine receptor activity

IN Chan, Chun Kong; Zhang, Ming-Qiang; Moinet, Christophe; Proulx, Melanie; Reddy, Thumkunta Jagadeeswar; Courchesne, Marc

PA Virochem Pharma Inc., Can.

SO PCT Int. Appl., 338 pp.

CODEN: PIXXD2

DT Patent

same as # 54

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005007656	A1	20050127	WO 2004-CA1048	20040716
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2573951	A1	20050127	CA 2004-2573951	20040716
	EP 1776362	A1	20070425	EP 2004-761573	20040716
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, HR, LT, LV, MK				
	US 2005075326	A1	20050407	US 2004-893583	20040719
PRAI	US 2003-487973P	P	20030718		
	WO 2004-CA1048	W	20040716		

OS MARPAT 142:176697

AB The title compds. I [Y, Z and X = CH<sub>2</sub>, CO, CR<sub>4</sub>R<sub>5</sub>; W = H, alkyl, alkenyl, aryl, etc.; R<sub>1</sub> = H, OH, alkyl, etc.; R<sub>2</sub> = alkyl, alkenyl, alkynyl, aryl, heterocyclyl; R<sub>3</sub> = H, alkyl, alkenyl, alkynyl, aryl; R<sub>4</sub>, R<sub>5</sub> = H, alkyl, alkenyl, alkynyl, aryl] and their pharmaceutically acceptable salts, useful for the modulation of CCR5 chemokine receptor activity and the treatment or prevention of diseases associated therewith, were prepared E.g., a multi-step synthesis of II.HCl, starting from tert-Bu 1-oxo-2,8-diaza-spiro[4.5]decane-8-carboxylate and 4-bromobenzyl bromide, was given. The compds. I have been found to have activity in binding to the CCR5 receptor, generally with an IC<sub>50</sub> values of < 25 μM. Certain compds. I have also been tested in an assay for HIV activity, and generally having an IC<sub>50</sub> values of < 1 μM.

IT 461443-59-4, Ak602

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(co-drug; preparation of spiro compds. for treating diseases associated with CCR5 chemokine receptor activity in combination with other agents)

RN 461443-59-4 CAPLUS

CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]- (CA INDEX NAME)

Absolute stereochemistry.

10/527,435



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 46 OF 59 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2005:14522 CAPLUS  
 DN 142:86614  
 TI Compositions for down-regulation of CCR5 expression and reducing HIV entry  
 into T-cells  
 IN Redfield, Robert R.; Amoroso, Anthony; Davis, Charles E.; Heredia, Alonsa  
 PA University of Maryland Biotechnology Institute, USA  
 SO PCT Int. Appl., 58 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English same as # 22  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005001027	A2	20050106	WO 2004-US15681	20040517
	WO 2005001027	A3	20060126		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2004251228	A1	20050106	AU 2004-251228	20040517
	CA 2526122	A1	20050106	CA 2004-2526122	20040517
	EP 1627048	A2	20060222	EP 2004-752660	20040517
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR			
	CN 1805740	A	20060719	CN 2004-80016720	20040517
	BR 2004010360	A	20060801	BR 2004-10360	20040517
	MX 2005PA12352	A	20060711	MX 2005-PA12352	20051116
	US 2006154857	A1	20060713	US 2005-281195	20051116
	IN 2005DN05654	A	20071130	IN 2005-DN5654	20051206
PRAI	US 2003-471453P	P	20030516		
	WO 2004-US15681	W	20040517		
AB	The present invention relates to the downregulation of surface receptor CCR5 expression through manipulation of the cell cycle in activated lymphocytes by administering a composition that arrests the G1 phase of the cell cycle, thereby reducing receptor sites for entry of HIV into T cells, and thus, the effects of HIV. Further, a composition is disclosed that includes a G1 phase arresting agent and an antiviral agent, wherein the combination synergistically enhances the activity of the antiviral agent.				
IT	461443-59-4, Ak602 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (compsn. for down-regulation of CCR5 expression and reducing HIV entry into T-cells)				
RN	461443-59-4 CAPLUS				
CN	Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]- (CA INDEX NAME)				

Absolute stereochemistry.





L20 ANSWER 47 OF 59 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2004:996006 CAPLUS  
 DN 141:406151  
 TI Effector cell function inhibitor  
 IN Sugiyama, Tetsuya; Kasano, Miki  
 PA Ono Pharmaceutical Co., Ltd., Japan  
 SO PCT Int. Appl., 114 pp.  
 CODEN: PIXXD2

DT Patent  
 LA Japanese  
 FAN.CNT 1

common inventors

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004098638	A1	20041118	WO 2004-JP6197	20040428
	W:				
	AE, AG, AL, AM, AN, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1623721	A1	20060208	EP 2004-730075	20040428
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	US 2007270429	A1	20071122	US 2007-555611	20070314
PRAI	JP 2003-128193	A	20030506		
	WO 2004-JP6197	W	20040428		

no 102(e) date

ODP

OS MARPAT 141:406151

AB An effector cell function inhibitor comprised of CCR5-antagonist. The effector cell function inhibitor comprised of CCR5-antagonist is capable of inhibiting the function of effector cells playing an important roll in disease generation, etc., so that it is useful in the prevention and/or treatment of, for example, transplant rejections (rejection of solid organ graft, rejection of pancreatic cell transplant in diabetes, graft-vs.-host disease (GVHD), etc.), autoimmune diseases (arthritis, chronic arthritic rheumatism, multiple sclerosis, ulcerative colitis, etc.), allergoses (asthma, etc.), ischemic diseases (ischemia reperfusion lesion, etc.), cancer or cancer metastasis, etc.

IT 461023-63-2 676451-07-3 676455-06-4


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(pharmacol. of cyclohexyldioxotriazaspiroundecaylmethylphenoxybenzoate analogs as CCR5 antagonists and effector cell function inhibitors)

RN 461023-63-2 CAPLUS

CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676451-07-3 CAPLUS  
 CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxymethyl]phenyl]methyl]-3-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676455-06-4 CAPLUS  
 CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenyl]methyl]-3-methoxy-, monohydrochloride (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/527,435

L20 ANSWER 48 OF 59 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2004:875343 CAPLUS  
 DN 142:147626  
 TI GW-873140  
 AU McIntyre, J. A.; Castaner, J.  
 CS Prous Science, Barcelona, 08080, Spain  
 SO Drugs of the Future (2004), 29(7), 677-679  
 CODEN: DRFUD4; ISSN: 0377-8282  
 PB Prous Science  
 DT Journal; General Review  
 LA English  
 AB A review. The human immunodeficiency virus (HIV) is a highly mutative virus, representing a challenge for researchers in terms of the development of effective therapeutic strategies against HIV and AIDS. HIV entry inhibitors block the fusion of HIV with host cells and are not compromised by the process of viral resistance, implicit with many anti-HIV therapies. The R5 viral strain is the most prevalent viral type isolated from asymptomatic individuals and its coreceptor CCR5 is blocked by GW-873140 (Ono-4128, AK-602). GW-873140 demonstrated potent activity against a wide spectrum of laboratory and primary HIV R5 isolates, and anti-HIV activity was observed for up to 24 h following binding to CCR5. This was also demonstrated in a phase I study in healthy adult subjects, with prolonged CCR5 receptor occupancy despite plasma levels of GW-873140 at or below the assay detection limit. The drug was well tolerated in this study and is entering phase II testing.  
 IT 461443-59-4P, GW873140  
 RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (GW-873140 for treatment of HIV infection)  
 RN 461443-59-4 CAPLUS  
 CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

TI Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro

AU Maeda, Kenji; Nakata, Hiroto; Koh, Yasuhiro; Miyakawa, Toshikazu; Ogata, Hiromi; Takaoka, Yoshikazu; Shibayama, Shiro; Sagawa, Kenji; Fukushima, Daikichi; Moravek, Joseph; Koyanagi, Yoshio; Mitsuya, Hiroaki

CS Dep. Hematol., Kumamoto Univ. Sch. Med., Kumamoto, 860-8556, Japan

SO Journal of Virology (2004), 78(16), 8654-8662

CODEN: JOVIAM; ISSN: 0022-538X

PB American Society for Microbiology

DT Journal

LA English

AB We identified a novel spirodiketopiperazine (SDP) derivative, AK602/ONO4128/GW873140, which specifically blocked the binding of macrophage inflammatory protein 1 $\alpha$  (MIP-1 $\alpha$ ) to CCR5 with a high affinity (Kd of  $\approx$ 3 nM), potently blocked human immunodeficiency virus type 1 (HIV-1) gp120/CCR5 binding and exerted potent activity against a wide spectrum of laboratory and primary R5 HIV-1 isolates, including multidrug-resistant HIV-1 (HIV-1MDR) (50% inhibitory concentration values of 0.1 to 0.6 nM) in vitro. AK602 competitively blocked

the

binding to CCR5 expressed on Chinese hamster ovary cells of two monoclonal antibodies, 45523, directed against multidomain epitopes of CCR5, and 45531, specific against the C-terminal half of the second extracellular loop (ECL2B) of CCR5. AK602, despite its much greater anti-HIV-1 activity than other previously published CCR5 inhibitors, including TAK-779 and SCH-C, preserved RANTES (regulated on activation normal T-cell expressed and secreted) and MIP-1 $\beta$  binding to CCR5+ cells and their functions, including CC-chemokine-induced chemotaxis and CCR5 internalization, while TAK-779 and SCH-C fully blocked the CC-chemokine/CCR5 interactions. Pharmacokinetic studies revealed favorable oral bioavailability in rodents. These data warrant further development of AK602 as a potential therapeutic for HIV-1 infection.

IT 461443-59-4, AK 602


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(ONO 4128, GW 873140; spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro)

RN 461443-59-4 CAPLUS

CN Benzoic acid, 4-[4-[[ (3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]- (CA INDEX NAME)

Absolute stereochemistry.



10/527,435

RE.CNT 36      THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 50 OF 59 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2004:531388 CAPLUS  
 DN 141:82353  
 TI Antagonist and agonist binding to strong binding site of chemokine receptor  
 IN XX Watanabe, Noriki; Takeda, Kazuhiko; Tada, Hideaki; Fukushima, Daikichi  
 PA Ono Pharmaceutical Co., Ltd., Japan  
 SO PCT Int. Appl., 88 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA Japanese  
 FAN.CNT 1


common inventors

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004054616	A1	20040701	NO 2003-JP15973	20031212
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003289329	A1	20040709	AU 2003-289329	20031212
EP 1570860	A1	20050907	EP 2003-780739	20031212
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2006251651	A1	20061109	US 2005-538364	20050613
PRAI JP 2002-363013	A	20021213		
WO 2003-JP15973	W	20031212		
AB	An antagonist or an agonist binding to the strong binding site of CCR5; a preventive and/or a remedy for allergic diseases, inflammatory diseases, immune diseases and/or cancerous diseases containing the same; a method of screening a compound binding to the strong binding site of CCR5; a preventive and/or a remedy for allergic diseases, inflammatory diseases, immune diseases and/or cancerous diseases containing the antagonist or the agonist selected by the screening method; an antagonist or an agonist binding to the strong binding site of a chemokine receptor; a preventive and/or a remedy for allergic diseases, inflammatory diseases, immune diseases and/or cancerous diseases containing the same; a method of screening a compound binding to the strong binding site of a chemokine receptor; and a preventive and/or a remedy for allergic diseases, inflammatory diseases, immune diseases and/or cancerous diseases containing the antagonist or the agonist selected by the screening method. These antagonists or agonists are useful as preventives and/or remedies for allergic diseases, inflammatory diseases, immune diseases and/or cancerous diseases.			
IT	461023-23-4 461023-63-2 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (antagonists and agonists binding to strong binding site of chemokine receptors as antiinflammatory, immunosuppressants, and antitumor agents)			
RN	461023-23-4 CAPLUS			
CN	Benzamide, 4-[4-[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-			

10/527,435

1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-, monohydrochloride (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 461023-63-2 CAPLUS  
CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT



L20 ANSWER 51 OF 59 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2004:333850 CAPLUS  
 DN 140:355836  
 TI High-mannose oligosaccharide cluster conjugated with immunogenic protein  
 for use as HIV vaccines  
 IN Wang, Lai-xi  
 PA University of Maryland Biotechnology Institute, Off. of Research Admin./  
 Tech. Dev., USA  
 SO PCT Int. Appl., 68 pp.  
 CODEN: PIXXD2  
 DT Patent same as # 54  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	---	-----	-----
PI	WO 2004033663	A2	20040422	WO 2003-US32496	20031014
	WO 2004033663	A3	20060316		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				
	HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,				
	LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG,				
	PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR,				
	TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,				
	KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,				
	FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,				
	BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2504755	A1	20040422	CA 2003-2504755	20031014
	AU 2003282821	A1	20040504	AU 2003-282821	20031014
	EP 1572963	A2	20050914	EP 2003-774819	20031014
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
	IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	US 2005244424	A1	20051103	US 2005-531124	20050630
PRAI	US 2002-417764P	P	20021011		
	WO 2003-US32496	W	20031014		

AB The present invention relates to a constructed oligosaccharide cluster, optionally bonded to an immunogenic protein, that can be administered to a subject to induce an immune response for increasing production of 2G12 and/or used in assays as reactive sites for determining compds. that inactivate and/or bind the high-mannose oligosaccharide cluster. The high-mannose oligosaccharide cluster comprises  $\geq 2$  high-mannose oligosaccharides attached a scaffolding framework of monosaccharide, cyclic peptide, cyclic organic compound or 11-bis-maleimidetetraethyleneglycol. The high-mannose oligosaccharide that mimics high-mannose N-glycan of HIV-1 gp120 comprises Man9, Man8, Man7, Man6, Man5 or a combination thereof. The high-mannose oligosaccharide of the invention is derived from soybean agglutinin or chemical synthesized. The immunogenic protein is keyhole limpet hemocyanin, tetanus toxoid, diphtheria toxoid, bovine serum albumin, ovalbumin, thyroglobulin, myoglobin, cholera toxin  $\beta$ -subunit, Ig. and/or tuberculosis purified protein derivative Compns. comprising these clusters, methods of using these clusters and compns. are disclosed.


IT 461443-59-4, AK 602  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (high-mannose oligosaccharide cluster conjugated with immunogenic protein for use as HIV vaccines)

RN 461443-59-4 CAPLUS  
 CN Benzoic acid, 4-[4-[[ (3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-

10/527,435

dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]- (CA INDEX NAME)

Absolute stereochemistry.



L20 ANSWER 52 OF 59 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2004:267337 CAPLUS  
 DN 140:309368  
 TI Novel crystals of triazaspiro[5.5]undecane derivative  
 IN Takaoka, Yoshikazu; Okamoto, Masaki; Genba, Yuichi  
 PA Ono Pharmaceutical Co., Ltd., Japan  
 SO PCT Int. Appl., 96 pp.  
 CODEN: PIXXD2

DT Patent  
 LA Japanese  
 FAN CNT 1

Common inventors  
 no 102(e) date

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004026874	A1	20040401	WO 2003-JP11835	20030917
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003271057	A1	20040408	AU 2003-271057	20030917
	EP 1541573	A1	20050615	EP 2003-751273	20030917
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	US 2006052407	A1	20060309	US 2005-527193	20050310
PRAI	JP 2002-272079	A	20020918		
	WO 2003-JP11835	W	20030917		

AB Claimed are crystals of non-solvated (3R)-1-butyl-2,5-dioxo-3-((1R)-1-hydroxy-1-cyclohexylmethyl)-9-(4-(4-carboxyphenoxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane hydrochloride. These crystals have a potent antagonism to chemokine/chemokine receptors. Owing to these characteristics, they are useful in producing preventives and/or remedies for various inflammatory diseases, etc. Formulations containing the above crystals are given.

IT 461023-63-2P


RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of crystals of triazaspiro[5.5]undecane derivative with chemokine antagonist activity)

RN 461023-63-2 CAPLUS

CN Benzoic acid, 4-[4-[[ (3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

IT 461443-59-4P 676449-48-2P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of crystals of triazaspiro[5.5]undecane derivative with  
 chemokine  
 antagonist activity)  
 RN 461443-59-4 CAPLUS  
 CN Benzoic acid, 4-[4-[[ (3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-  
 dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 676449-48-2 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-  
 cyclohexylhydroxymethyl]-9-(phenylmethyl)-, (3R)-, monomethanesulfonate  
 (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 676449-46-0  
 CMF C26 H39 N3 O3

Absolute stereochemistry.


10/527,435



CM 2

CRN 75-75-2

CMF C H4 O3 S



RE.CNT 8

THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 53 OF 59 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2004:267336 CAPLUS  
 DN 140:303699  
 TI Preparation of triazaspiro[5.5]undecane derivatives as chemokine receptor  
 CCR5 antagonists and drugs comprising the same as the active ingredients  
 IN Takaoka, Yoshikazu; Nishizawa, Rena; Shibayama, Shiro; Sagawa, Kenji;  
 Matsuo, Masayoshi  
 PA Ono Pharmaceutical Co., Ltd., Japan  
 SO PCT Int. Appl., 288 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA Japanese  
 FAN.CNT 1

Applicant's WO

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004026873	A1	20040401	WO 2003-JP11834	20030917
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2497903	A1	20040401	CA 2003-2497903	20030917
AU 2003272879	A1	20040408	AU 2003-272879	20030917
EP 1541574	A1	20050615	EP 2003-753933	20030917
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003014304	A	20050726	BR 2003-14304	20030917
CN 1688577	A	20051026	CN 2003-824386	20030917
MX 2005PA02771	A	20050606	MX 2005-PA2771	20050311
US 2005267114	A1	20051201		20050311
NO 2005001379	A	20050617	NO 2005-1379	20050316
ZA 2005002222	A	20050930	ZA 2005-2222	20050316
PRAI JP 2002-270849	A	20020918		
WO 2003-JP11834	W	20030917		

OS MARPAT 140:303699

AB The title compds. [I; R1 = (a) each (un)substituted and partially or completely saturated C3-15 mono-, di-, or tricarbo-cyclic aryl or 3- to 15-membered mono-, di-, or triheterocyclic aryl latter containing heteroatoms selected from 1-4 N atoms, 1 or 2 O atoms, and/or 1 or 2 S atoms, or (b) C1-8 alkyl, C2-4 alkenyl, or C2-4 alkynyl each substituted by 1-3 substituents selected from each (un)substituted HO, acyl, NH2, CONH2, acylamino, sulfonylamino, :NH, and :NOH; R2 = H, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, each (un)substituted Ph, pyridinyl, or C3-8 cycloalkyl, group (b); R3, R4 = (i) H, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, or (ii) C1-8 alkyl, C2-8 alkenyl, or C2-8 alkynyl each substituted by 1-5 substituents selected from group (a), HO, and tetrahydropyran-4-ylidene], quaternary ammonium salts, N-oxides, or salts thereof are prepared These compds. are useful in preventing and/or treating various inflammatory diseases (asthma, nephritis, nephropathy, hepatitis, arthritis, rheumatoid arthritis, rhinitis, conjunctivitis, ulcerative colitis, etc.), immune diseases (autoimmune disease, transplant rejection, immune suppression, psoriasis, multiple sclerosis, etc.), infection with human

immunodeficiency virus (acquired immune deficiency syndrome), allergic diseases (atopic dermatitis, urticaria, allergic bronchopulmonary aspergillosis, allergic eosinophilic gastroenteritis, etc.), ischemic reperfusion injury, acute respiratory distress syndrome, shock accompanying bacterial infection, diabetes, cancer metastasis, etc. (no data). They are improved in bioavailability when administered orally, metabolic stability, liver or systemic clearance, or affinity for chemokine receptor CCR compared to prior art compds. and exhibit very low toxicity. Thus, 1-benzyl-4-piperidone, (2R,3R)-2-(tert-butoxycarbonylamino)-3-cyclohexyl-3-hydroxypropanoic acid, n-butylamine, and 2-(morpholin-4-yl)ethyl isocyanide were stirred in MeOH at 50° overnight to give, after workup, 1-benzyl-4-[2-(morpholin-4-yl)ethylaminocarbonyl]-4-[N-butyl-N-[(2R,3R)-2-amino-3-hydroxy-3-cyclohexylpropanoyl]amino]piperidine which was stirred in AcOH at 70° for 1 h to give, after workup, (3R)-1-butyl-2,5-dioxo-3-[(1R)-1-hydroxy-1-cyclohexylmethyl]-9-phenylmethyl-1,4,9-triazaspiro[5.5]undecane (II). A tablet and an ampule formulation containing specific compound I were described.

IT 461023-03-0P 461023-63-2P 676449-46-0P  
 676449-47-1P 676449-48-2P 676449-49-3P  
 676449-52-8P 676449-57-3P 676449-58-4P  
 676449-59-5P 676449-60-8P 676449-61-9P  
 676449-62-0P 676449-63-1P 676449-66-4P  
 676449-67-5P 676449-80-2P 676449-86-8P  
 676449-87-9P 676449-88-0P 676449-89-1P  
 676449-93-7P 676449-95-9P 676450-01-4P  
 676450-05-8P 676450-06-9P 676450-07-0P  
 676450-08-1P 676450-11-6P 676450-12-7P  
 676450-13-8P 676450-16-1P 676450-17-2P  
 676450-18-3P 676450-19-4P 676450-22-9P  
 676450-24-1P 676450-25-2P 676450-26-3P  
 676450-28-5P 676450-30-9P 676450-32-1P  
 676450-33-2P 676450-34-3P 676450-35-4P  
 676450-36-5P 676450-38-7P 676450-39-8P  
 676450-40-1P 676450-41-2P 676450-42-3P  
 676450-43-4P 676450-44-5P 676450-45-6P  
 676450-46-7P 676450-47-8P 676450-49-0P  
 676450-50-3P 676450-52-5P 676450-55-8P  
 676450-57-0P 676450-59-2P 676450-60-5P  
 676450-62-7P 676450-64-9P 676450-70-7P  
 676450-72-9P 676450-73-0P 676450-74-1P  
 676450-76-3P 676450-77-4P 676450-80-9P  
 676450-81-0P 676450-82-1P 676450-83-2P  
 676450-84-3P 676450-85-4P 676450-86-5P  
 676450-87-6P 676450-88-7P 676450-89-8P  
 676450-90-1P 676450-91-2P 676450-92-3P  
 676450-93-4P 676450-94-5P 676450-95-6P  
 676450-96-7P 676450-97-8P 676450-98-9P  
 676450-99-0P 676451-00-6P 676451-01-7P  
 676451-03-9P 676451-04-0P 676451-05-1P  
 676451-06-2P 676451-07-3P 676451-08-4P  
 676451-09-5P 676451-10-8P 676451-11-9P  
 676451-12-0P 676451-13-1P 676451-14-2P  
 676451-15-3P 676451-16-4P 676451-18-6P  
 676451-20-0P 676451-21-1P 676451-28-8P  
 676451-30-2P 676451-32-4P 676451-33-5P  
 676451-35-7P 676451-37-9P 676451-39-1P

676451-41-5P 676451-43-7P 676451-45-9P  
 676451-47-1P 676451-49-3P 676451-51-7P  
 676451-53-9P 676451-54-0P 676451-55-1P  
 676451-56-2P 676451-57-3P 676451-58-4P  
 676451-59-5P 676451-60-8P 676451-61-9P  
 676451-62-0P 676451-63-1P 676451-64-2P  
 676451-65-3P 676451-66-4P 676451-67-5P  
 676451-68-6P 676451-69-7P 676451-70-0P  
 676451-71-1P 676451-72-2P 676451-73-3P  
 676451-74-4P 676451-75-5P 676451-76-6P  
 676451-77-7P 676451-78-8P 676451-79-9P  
 676451-80-2P 676451-81-3P 676451-82-4P  
 676451-83-5P 676451-84-6P 676451-85-7P  
 676451-86-8P 676451-87-9P 676451-88-0P  
 676451-89-1P 676451-90-4P 676451-91-5P  
 676451-92-6P 676451-93-7P 676451-94-8P  
 676451-95-9P 676451-96-0P 676451-97-1P  
 676451-98-2P 676451-99-3P 676452-00-9P  
 676452-01-0P 676452-02-1P 676452-03-2P  
 676452-04-3P 676452-05-4P 676452-06-5P  
 676452-07-6P 676452-08-7P 676452-09-8P  
 676452-10-1P 676452-11-2P 676452-12-3P  
 676452-13-4P 676452-14-5P 676452-15-6P  
 676452-16-7P 676452-17-8P 676452-18-9P  
 676452-19-0P 676452-20-3P 676452-21-4P  
 676452-22-5P 676452-23-6P 676452-24-7P  
 676452-25-8P 676452-26-9P 676452-27-0P  
 676452-28-1P 676452-29-2P 676452-30-5P  
 676452-31-6P 676452-32-7P 676452-33-8P  
 676452-34-9P 676452-35-0P 676452-36-1P  
 676452-37-2P 676452-38-3P 676452-39-4P  
 676452-40-7P 676452-41-8P 676452-43-0P  
 676452-45-2P 676452-46-3P 676452-47-4P  
 676452-48-5P 676452-49-6P 676452-50-9P  
 676452-51-0P 676452-52-1P 676452-53-2P  
 676452-54-3P 676452-55-4P 676452-56-5P  
 676452-57-6P 676452-58-7P 676452-59-8P  
 676452-60-1P 676452-61-2P 676452-62-3P  
 676452-63-4P 676452-64-5P 676452-65-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)


(preparation of triazaspiro[5.5]undecane derivs. as chemokine receptor CCR5  
 antagonists and drugs)

RN 461023-03-0 CAPLUS

CN Methanesulfonamide, N-[4-[4-[[ (3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-  
 2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]phenyl]-,  
 monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.






● HCl

RN 461023-63-2 CAPLUS  
 CN Benzoic acid, 4-[4-[[ (3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 676449-46-0 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-(phenylmethyl)-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 676449-47-1 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-(phenylmethyl)-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676449-48-2 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-(phenylmethyl)-, (3R)-, monomethanesulfonate (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 676449-46-0  
 CMF C26 H39 N3 O3

Absolute stereochemistry.




CM 2

CRN 75-75-2  
 CMF C H4 O3 S



RN 676449-49-3 CAPLUS  
 CN Methanesulfonamide, N-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676449-52-8 CAPLUS  
 CN Benzamide, 4-[4-[[ (3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]-3,5-dimethylphenoxy]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676449-57-3 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[(4-methoxyphenyl)methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676449-58-4 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[(4-methylphenyl)methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676449-59-5 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[(4-hydroxyphenyl)methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676449-60-8 CAPLUS  
 CN Benzoic acid, 4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676449-61-9 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[[4-(dimethylamino)phenyl]methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676449-62-0 CAPLUS  
 CN Benzenesulfonamide, 4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]-N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676449-63-1 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[[4-(2-hydroxyethyl)phenyl]methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676449-66-4 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-9-[(4-chlorophenyl)methyl]-3-[(R)-cyclohexylhydroxymethyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676449-67-5 CAPLUS  
 CN Benzonitrile, 4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676449-80-2 CAPLUS

CN Methanesulfonamide, N-[4-[4-[[ (3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]phenyl]-N-ethyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676449-86-8 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[[4-(cyclohexyloxy)phenyl]methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676449-87-9 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[[4-(phenylmethyl)phenyl]methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676449-88-0 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[[4-(2-phenylethenyl)phenyl]methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry unknown.




● HCl

RN 676449-89-1 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[(3-phenoxyphenyl)methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






● HCl

RN 676449-93-7 CAPLUS  
 CN Benzamide, 4-[[ (3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]-N-[2-(dimethylamino)ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●2 HCl

RN 676449-95-9 CAPLUS  
 CN Ethanesulfonamide, N-[4-[4-[[ (3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676450-01-4 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[[4-(2-phenylethyl)phenyl]methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676450-05-8 CAPLUS  
 CN Benzamide, 4-[[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenyl]methyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676450-06-9 CAPLUS  
 CN Benzoic acid, 4-[[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676450-07-0 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[[4-(2-phenylcyclopropyl)phenyl]methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676450-08-1 CAPLUS  
 CN Benzenesulfonamide, N-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenyl]-4-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676450-11-6 CAPLUS

CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676450-12-7 CAPLUS

CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]benzoyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676450-13-8 CAPLUS

CN Benzamide, 4-[4-[[ (3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]benzoyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676450-16-1 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[[ (3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676450-17-2 CAPLUS  
 CN Benzoic acid, 4-[[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676450-18-3 CAPLUS  
 CN Benzoic acid, 4-[[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]methyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676450-19-4 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[[4-(1H-imidazol-1-yl)phenyl]methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676450-22-9 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[[4'-hydroxy[1,1'-biphenyl]-3-yl]methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/527,435



● HCl

RN 676450-24-1 CAPLUS  
CN Benzoic acid, 4-[[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenyl]methoxy]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676450-25-2 CAPLUS  
CN Benzamide, 4-[[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenyl]methoxy]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.






● HCl

RN 676450-26-3 CAPLUS

CN Benzoic acid, 4-[[[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]benzoyl]amino]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676450-28-5 CAPLUS

CN Acetamide, N-[4-[[[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenyl]methyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676450-30-9 CAPLUS  
 CN Benzamide, 4-[[[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]benzoyl]amino]methyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



● HCl


PAGE 1-B

—NHMe

RN 676450-32-1 CAPLUS  
 CN Benzamide, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-N-(cyclopropylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



● HCl

PAGE 1-B




RN 676450-33-2 CAPLUS

CN Benzamide, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-N-2-butynyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



● HCl


PAGE 1-B



RN 676450-34-3 CAPLUS

CN Benzoic acid, 4-[[3-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676450-35-4 CAPLUS

CN Benzamide, 4-[[3-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]methyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676450-36-5 CAPLUS

CN Benzamide, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676450-38-7 CAPLUS  
 CN Benzoic acid, 4-[4-[[ (3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-3-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676450-39-8 CAPLUS  
 CN Benzamide, 4-[4-[[ (3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-N-cyclopentyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676450-40-1 CAPLUS

CN Benzoic acid, 4-[[[3-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenyl]methoxy]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676450-41-2 CAPLUS

CN Glycine, N-[4-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]benzoyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



● HCl


PAGE 1-B

—CO<sub>2</sub>H

RN 676450-42-3 CAPLUS

CN Benzoic acid, 4-[4-[[ (3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-3-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676450-43-4 CAPLUS

CN Benzamide, 4-[4-[[ (3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-3-methoxy-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676450-44-5 CAPLUS

CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-3-chloro-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676450-45-6 CAPLUS

CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]-2-chlorophenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.






● HCl

RN 676450-46-7 CAPLUS

CN 1,3-Benzenedicarboxylic acid, 5-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676450-47-8 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 9-[[4-[(4-bromophenyl)methoxy]phenyl]methyl]-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676450-49-0 CAPLUS

CN Benzamide, 4-[[ (3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]-N-[(4-fluorophenyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676450-50-3 CAPLUS

CN Benzamide, 4-[4-[[ (3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-N,3-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676450-52-5 CAPLUS

CN Benzamide, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-3-chloro-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676450-55-8 CAPLUS

CN Benzeneacetamide, 4-bromo-N-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676450-57-0 CAPLUS

CN Benzamide, 4-[4-[[ (3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]-2-chlorophenoxy]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676450-59-2 CAPLUS

CN Benzamide, 4-[[ (3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]-N-(2-pyridinylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 676450-60-5 CAPLUS

CN Benzoic acid, 4-[2-bromo-4-[[ (3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676450-62-7 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[[4-(1H-1,2,4-triazol-1-yl)phenyl]methyl]-, dihydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 676450-64-9 CAPLUS

CN Benzoic acid, 4-[4-[[ (3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]-2-(trifluoromethyl)phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676450-70-7 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-9-[[4-[(4-chlorophenyl)methoxy]-3-methoxyphenyl]methyl]-3-[(R)-cyclohexylhydroxymethyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676450-72-9 CAPLUS

CN Benzamide, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]-2-(trifluoromethyl)phenoxy]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676450-73-0 CAPLUS

CN Benzoic acid, 4-[[[[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenyl]methyl]amino]carbonyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676450-74-1 CAPLUS  
 CN 1,4-Benzenedicarboxamide, N-[[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenyl)methyl]-N'-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



● HCl


PAGE 1-B

—NHMe

RN 676450-76-3 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-9-[[4-[(2-chloro-6-fluorophenyl)methoxy]phenyl)methyl]-3-[(R)-cyclohexylhydroxymethyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






● HCl

RN 676450-77-4 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[[ (3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676450-80-9 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid, 3'-[[ (3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676450-81-0 CAPLUS

CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-3,5-dimethoxy-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676450-82-1 CAPLUS

CN Benzoic acid, 3-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676450-83-2 CAPLUS

CN Benzenecarboximidamide, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-N-hydroxy-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/527,435



● 2 HCl

RN 676450-84-3 CAPLUS  
 CN Benzoic acid, 4-[4-[[ (3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-2-hydroxy-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676450-85-4 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[[4-[4-(2,5-dihydro-5-thioxo-1,2,4-oxadiazol-3-yl)phenoxy]phenyl]methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676450-86-5 CAPLUS  
 CN Benzoic acid, 4-[[[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenyl]amino]carbonyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676450-87-6 CAPLUS  
 CN Benzoic acid, 4-[[[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]benzoyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676450-88-7 CAPLUS  
 CN Benzoic acid, 4-[[[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]benzoyl]amino]-3-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676450-89-8 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[[4-[4-(1H-tetrazol-5-yl)phenoxy]phenyl]methyl]-, dihydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 676450-90-1 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[[4-[4-(2,5-dihydro-5-oxo-1,2,4-thiadiazol-3-yl)phenoxy]phenyl]methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676450-91-2 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[[4-[[4-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)phenoxy]phenyl]methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676450-92-3 CAPLUS  
 CN Benzoic acid, 3-[[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]benzoyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676450-93-4 CAPLUS

CN Benzoic acid, 4-[2-[[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenyl]amino]-2-oxoethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676450-94-5 CAPLUS

CN Benzoic acid, 2-[[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]benzoyl]amino]-5-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676450-95-6 CAPLUS

CN Benzoic acid, 4-[[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenyl)methyl]-3-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676450-96-7 CAPLUS

CN	Benzoic acid, 4-[[[[[4-[[ (3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenyl)methyl]amino]carbonyl]-3-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)
----	--

Absolute stereochemistry.






● HCl

RN 676450-97-8 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[[4-(2,4-dimethoxyphenoxy)phenyl]methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676450-98-9 CAPLUS

CN Benzoic acid, 4-[[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]methyl]-3-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676450-99-0 CAPLUS

CN Benzoic acid, 4-[[[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]benzoyl]methylamino]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676451-00-6 CAPLUS

CN Benzonitrile, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-3-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676451-01-7 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[[4-[[4-(2-oxido-3H-1,2,3,5-oxathiadiazol-4-yl)phenoxy]phenyl]methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676451-03-9 CAPLUS

CN Benzoic acid, 4-[[[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]benzoyl]amino]methyl]-3-methoxy]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676451-04-0 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[[4-(4-hydroxy-2-methoxyphenoxy)phenyl]methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676451-05-1 CAPLUS

CN Benzamide, 4-[[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-3-methoxy-N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676451-06-2 CAPLUS

CN Methanesulfonamide, N-[4-[4-[[ (3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-3-methoxyphenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676451-07-3 CAPLUS

CN Benzoic acid, 4-[4-[[ (3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-3-ethoxy-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676451-08-4 CAPLUS  
 CN Benzamide, 4-[4-[[ (3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-2-hydroxy-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676451-09-5 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[[4-(3,5-dimethoxyphenoxy)phenyl]methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676451-10-8 CAPLUS  
 CN Acetamide, N-[4-[4-[[ (3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-3-methoxyphenyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676451-11-9 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[[4-[4-(1,1-dimethylethyl)phenoxy]phenyl]methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676451-12-0 CAPLUS  
 CN Benzoic acid, 3-[[4-[[ (3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenyl]methyl]-2-(1-oxopropoxy)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676451-13-1 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[[4-(2-methoxyphenoxy)phenyl]methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl


RN 676451-14-2 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[[4-[4-(trifluoromethoxy)phenoxy]phenyl]methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/527,435



● HCl

RN 676451-15-3 CAPLUS  
 CN Benzoic acid, 4-[4-[[ (3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-3,5-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676451-16-4 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 9-[[4-(4-bromophenoxy)phenyl]methyl]-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676451-18-6 CAPLUS  
 CN Benzoic acid, 2-[4-[[ (3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-5-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676451-20-0 CAPLUS  
 CN Benzoic acid, 2-[4-[[ (3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676451-21-1 CAPLUS  
 CN Benzoic acid, 2-[4-[[ (3R)-3-[(R)-cyclohexylhydroxymethyl]-1-ethyl-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676451-28-8 CAPLUS

CN Benzoic acid, 4-[4-[[[(3R)-3-[(R)-cyclohexylhydroxymethyl]-1-methyl-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676451-30-2 CAPLUS

CN Benzamide, 4-[4-[[[(3R)-3-[(R)-cyclohexylhydroxymethyl]-1-[2-[(methylsulfonyl)amino]ethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676451-32-4 CAPLUS

CN Methanesulfonamide, N-[4-[[[(3R)-3-[(R)-cyclohexylhydroxymethyl]-1-methyl-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676451-33-5 CAPLUS

CN Methanesulfonamide, N-[4-[[[(3R)-3-[(R)-cyclohexylhydroxymethyl]-1-ethyl-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676451-35-7 CAPLUS

CN Methanesulfonamide, N-[4-[[[(3R)-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1-propyl-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676451-37-9 CAPLUS

CN Methanesulfonamide, N-[4-[4-[[[(3R)-3-[(R)-cyclohexylhydroxymethyl]-1-methyl-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676451-39-1 CAPLUS

CN Methanesulfonamide, N-[4-[4-[[[(3R)-3-[(R)-cyclohexylhydroxymethyl]-1-ethyl-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676451-41-5 CAPLUS

CN Methanesulfonamide, N-[4-[4-[[[(3R)-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1-propyl-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676451-43-7 CAPLUS

CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(1R)-1-hydroxy-2,2-dimethylpropyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/527,435




● HCl

RN 676451-45-9 CAPLUS

CN Benzamide, 4-[4-[[ (3R)-1-butyl-3-[(1R)-1-hydroxy-2,2-dimethylpropyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676451-47-1 CAPLUS

CN Benzoic acid, 4-[4-[[ (3R)-3-[(R)-cyclohexylhydroxymethyl]-1-(3-hydroxybutyl)-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676451-49-3 CAPLUS  
 CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-cycloheptylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676451-51-7 CAPLUS  
 CN Benzamide, 4-[4-[[[(3R)-1-butyl-3-[(R)-cycloheptylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.






● HCl

RN 676451-53-9 CAPLUS

CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-hydroxytricyclo[3.3.1.1<sup>3,7</sup>]dec-1-ylmethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676451-54-0 CAPLUS

CN Benzamide, 4-[4-[[[(3R)-1-butyl-3-[(R)-hydroxytricyclo[3.3.1.1<sup>3,7</sup>]dec-1-ylmethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676451-55-1 CAPLUS  
 CN Benzamide, 4-[4-[[ (3R)-1-butyl-3-[(R)-hydroxyphenylmethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676451-56-2 CAPLUS  
 CN Benzoic acid, 4-[4-[[ (3R)-1-butyl-3-[(R)-cyclopropylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676451-57-3 CAPLUS  
 CN Benzamide, 4-[4-[[ (3R)-1-butyl-3-[(R)-cyclopropylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/527,435



● HCl

RN	676451-58-4	CAPLUS
CN	Benzamide, 4-[4-[[ (3R)-1-butyl-3-[(1R)-2-ethyl-1-hydroxybutyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)	


Absolute stereochemistry.



● HCl

RN	676451-59-5	CAPLUS
CN	Benzoic acid, 4-[4-[[ (3R)-1-butyl-3-[(1R)-2-ethyl-1-hydroxybutyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)	


Absolute stereochemistry.



● HCl

RN 676451-60-8 CAPLUS  
 CN Benzamide, 4-[4-[[ (3R)-1-butyl-3-[(R)-3-furanylmethoxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676451-61-9 CAPLUS  
 CN Benzoic acid, 4-[4-[[ (3R)-1-butyl-3-[(R)-3-furanylmethoxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676451-62-0 CAPLUS  
 CN Benzamide, 4-[4-[[ (3R)-1-butyl-3-[(R)-(2,3-dihydro-1,4-benzodioxin-6-yl)methoxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



● HCl


PAGE 1-B

NHMe

RN 676451-63-1 CAPLUS

CN Benzoic acid, 4-[4-[[ (3R)-1-butyl-3-[(R)-(2,3-dihydro-1,4-benzodioxin-6-yl)hydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676451-64-2 CAPLUS

CN Benzoic acid, 4-[4-[[ (3R)-1-butyl-3-[(1R)-2-cyclohexyl-1-hydroxyethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676451-65-3 CAPLUS  
 CN Benzamide, 4-[4-[[[(3R)-1-butyl-3-[(1R)-2-cyclohexyl-1-hydroxyethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676451-66-4 CAPLUS  
 CN Benzoic acid, 4-[4-[[[(3R)-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1-(phenylmethyl)-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676451-67-5 CAPLUS  
 CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(1R)-1-hydroxy-3-phenylpropyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676451-68-6 CAPLUS  
 CN Benzamide, 4-[4-[[[(3R)-1-butyl-3-[(1R)-1-hydroxy-3-phenylpropyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676451-69-7 CAPLUS  
 CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(1R)-1-hydroxy-2-(tetrahydro-2H-pyran-4-yl)ethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676451-70-0 CAPLUS  
 CN Benzamide, 4-[4-[[ (3R)-1-butyl-3-[(1R)-1-hydroxy-2-(tetrahydro-2H-pyran-4-yl)ethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676451-71-1 CAPLUS  
 CN Benzoic acid, 4-[4-[[ (3R)-1-butyl-3-[(1R)-1-hydroxy-3-methylbutyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl



RN 676451-72-2 CAPLUS  
 CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclobutylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676451-73-3 CAPLUS  
 CN Benzamide, 4-[4-[[[(3R)-1-butyl-3-[(1R)-1-hydroxy-3-methylbutyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676451-74-4 CAPLUS  
 CN Benzamide, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclobutylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/527,435




● HCl

RN 676451-75-5 CAPLUS

CN Benzoic acid, 4-[4-[[ (3R)-1-butyl-3-[(1R)-1-hydroxy-2-methyl-2-phenylpropyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676451-76-6 CAPLUS

CN Benzamide, 4-[4-[[ (3R)-1-butyl-3-[(1R)-1-hydroxy-2-methyl-2-phenylpropyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676451-77-7 CAPLUS  
 CN Benzamide, 4-[4-[[ (3R)-1-butyl-3-[(R)-hydroxy(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676451-78-8 CAPLUS  
 CN Benzoic acid, 4-[4-[[ (3R)-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1-pentyl-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-3-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676451-79-9 CAPLUS  
 CN Benzoic acid, 4-[4-[[ (3R)-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1-pentyl-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676451-80-2 CAPLUS

CN Benzoic acid, 4-[4-[[ (3R)-1-butyl-3-[(1R)-2-ethyl-1-hydroxybutyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-3-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676451-81-3 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-9-[[4-(4-chlorophenoxy)phenyl]methyl]-3-[(R)-hydroxy(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676451-82-4 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-hydroxy(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)methyl]-9-[[4-(4-methoxyphenoxy)phenyl]methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676451-83-5 CAPLUS  
 CN Benzamide, 4-[4-[[[(3R)-1-butyl-3-[(R)-hydroxy(tetrahydro-2H-pyran-4-yl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-N-(cyclopropylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



PAGE 1-A

● HCl


PAGE 1-B



RN 676451-84-6 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-

hydroxy(tetrahydro-2H-pyran-4-yl)methyl]-9-[[4-(4-methoxyphenoxy)phenyl]methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676451-85-7 CAPLUS

CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(1R)-2-ethyl-1-hydroxybutyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676451-86-8 CAPLUS

CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(1R)-2-ethyl-1-hydroxybutyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenyl]methyl]-3-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676451-87-9 CAPLUS

CN Methanesulfonamide, N-[4-[[ (3R)-1-butyl-3-[(1R)-2-ethyl-1-hydroxybutyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676451-88-0 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-hydroxy(tetrahydro-2H-pyran-4-yl)methyl]-9-[(4-phenoxyphenyl)methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676451-89-1 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-9-[[4-(4-hydroxyphenoxy)phenyl]methyl]-3-[(R)-hydroxy(tetrahydro-2H-pyran-4-yl)methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676451-90-4 CAPLUS  
 CN Carbamic acid, [4-[[4-[[[(3R)-1-butyl-3-[(R)-hydroxy(tetrahydro-2H-pyran-4-yl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenyl]methyl]phenyl]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676451-91-5 CAPLUS  
 CN Benzoic acid, 4-[[4-[[[(3R)-1-butyl-3-[(1R)-2-ethyl-1-hydroxybutyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenyl]methoxy]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.






● HCl

RN 676451-92-6 CAPLUS

CN Benzenesulfonamide, 4-[4-[[ (3R)-1-butyl-3-[(1R)-2-ethyl-1-hydroxybutyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676451-93-7 CAPLUS

CN Benzeneacetamide, N-[4-[[ (3R)-1-butyl-3-[(1R)-2-ethyl-1-hydroxybutyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenyl]-4-fluoro-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676451-94-8 CAPLUS

CN Benzonitrile, 4-[4-[[[(3R)-1-butyl-3-[(R)-hydroxy(tetrahydro-2H-pyran-4-yl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676451-95-9 CAPLUS

CN Benzonitrile, 4-[4-[[[(3R)-1-butyl-3-[(R)-hydroxy(tetrahydro-2H-pyran-4-yl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-3-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676451-96-0 CAPLUS

CN Benzamide, 4-[[4-[[[(3R)-1-butyl-3-[(1R)-2-ethyl-1-hydroxybutyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenyl]methoxy]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676451-97-1 CAPLUS

CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(1R)-2-ethyl-1-hydroxybutyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-2-hydroxy-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/527,435




● HCl

RN 676451-98-2 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-9-[[4-(4-chlorophenoxy)phenyl]methyl]-3-[(R)-hydroxy(tetrahydro-2H-pyran-4-yl)methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676451-99-3 CAPLUS

CN Benzamide, 4-[4-[[[(3R)-1-butyl-3-[(R)-hydroxy(tetrahydro-2H-pyran-4-yl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-3-methoxy-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676452-00-9 CAPLUS  
 CN Benzamide, 4-[4-[[ (3R)-1-butyl-3-[(1R)-2-ethyl-1-hydroxybutyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-3-methoxy-N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676452-01-0 CAPLUS  
 CN Benzamide, 4-[4-[[ (3R)-1-butyl-3-[(1R)-2-ethyl-1-hydroxybutyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenyl]methyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676452-02-1 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(1R)-2-ethyl-1-hydroxybutyl]-9-[(4-methoxyphenyl)methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676452-03-2 CAPLUS  
 CN Benzamide, 4-[[4-[[[(3R)-1-butyl-3-[(1R)-2-ethyl-1-hydroxybutyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]methyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676452-04-3 CAPLUS  
 CN Acetamide, N-[4-[[4-[[[(3R)-1-butyl-3-[(1R)-2-ethyl-1-hydroxybutyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenyl]methyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/527,435



● HCl

RN 676452-05-4 CAPLUS  
CN Benzoic acid, 4-[4-[[ (3R)-1-butyl-3-[(1R)-2-ethyl-1-hydroxybutyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]benzoyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676452-06-5 CAPLUS  
CN Benzoic acid, 4-[4-[[ (3R)-1-butyl-3-[(1R)-2-ethyl-1-hydroxybutyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-3-chloro-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676452-07-6 CAPLUS

CN Acetamide, N-[4-[4-[[[(3R)-1-butyl-3-[(R)-hydroxy(tetrahydro-2H-pyran-4-yl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676452-08-7 CAPLUS

CN Benzamide, 4-[[4-[[[(3R)-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1-propyl-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenyl]methoxy]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.






● HCl

RN 676452-09-8 CAPLUS

CN Benzonitrile, 4-[4-[[[(3R)-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1-propyl-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-3-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676452-10-1 CAPLUS

CN Benzoic acid, 4-[4-[[[(3R)-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1-(phenylmethyl)-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-3-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676452-11-2 CAPLUS

CN Benzoic acid, 4-[[4-[[[(3R)-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1-(phenylmethyl)-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenyl)methyl]-3-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676452-12-3 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-9-[[4-(2,4-dimethoxyphenoxy)phenyl)methyl]-3-[(R)-hydroxy(tetrahydro-2H-pyran-4-yl)methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676452-13-4 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-9-[[4-(4-hydroxy-2-methoxyphenoxy)phenyl]methyl]-3-[(R)-hydroxy(tetrahydro-2H-pyran-4-yl)methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676452-14-5 CAPLUS

CN Benzamide, 4-[4-[[[(3R)-1-butyl-3-[(R)-hydroxy(tetrahydro-2H-pyran-4-yl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-3-chloro-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676452-15-6 CAPLUS

CN Benzamide, 4-[[ (3R)-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1-(phenylmethyl)-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676452-16-7 CAPLUS

CN Benzamide, 4-[4-[[ (3R)-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1-propyl-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-3-methoxy-N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676452-17-8 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-hydroxy(tetrahydro-2H-pyran-4-yl)methyl]-9-[[4-(4-methoxybenzoyl)phenyl]methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676452-18-9 CAPLUS  
 CN Benzamide, 4-[4-[[[(3R)-1-butyl-3-[(R)-hydroxy(tetrahydro-2H-pyran-4-yl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenyl]phenoxy]-N-[2-(diethylamino)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A




● HCl

PAGE 1-B



RN 676452-19-0 CAPLUS  
 CN Benzamide, 4-[[[4-[[[(3R)-1-butyl-3-[(R)-hydroxy(tetrahydro-2H-pyran-4-yl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenyl]methyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676452-20-3 CAPLUS  
 CN Benzamide, 4-[[[4-[[[(3R)-1-butyl-3-[(1R)-2-ethyl-1-hydroxybutyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]benzoyl]amino]methyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676452-21-4 CAPLUS

CN Benzamide, 4-[[[(3R)-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1-pentyl-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676452-22-5 CAPLUS

CN Benzoic acid, 4-[[[4-[[[(3R)-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1-pentyl-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]benzoyl]amino]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676452-23-6 CAPLUS

CN Glycine, N-[4-[4-[[ (3R)-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1-pentyl-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]benzoyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



● HCl

PAGE 1-B


—CO<sub>2</sub>H

RN 676452-24-7 CAPLUS

CN Benzeneacetamide, N-[4-[4-[[ (3R)-1-butyl-3-[(R)-cyclopentylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenyl]-4-fluoro-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.






● HCl

RN 676452-25-8 CAPLUS

CN Methanesulfonamide, N-[4-[[[(3R)-1-butyl-3-[(R)-cyclopentylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676452-26-9 CAPLUS

CN Benzamide, 4-[[4-[[[(3R)-1-butyl-3-[(R)-cyclopentylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]methyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676452-27-0 CAPLUS  
 CN Benzoic acid, 4-[[4-[[[(3R)-1-butyl-3-[(R)-cyclopentylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenyl]methoxy]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676452-28-1 CAPLUS  
 CN Benzoic acid, 4-[[4-[[[(3R)-1-butyl-3-[(R)-cyclopentylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenyl]methoxy]-3-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676452-29-2 CAPLUS

CN Benzoic acid, 2-[4-[[[(3R)-1-butyl-3-[(R)-cyclopentylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-5-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676452-30-5 CAPLUS

CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclopentylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/527,435



● HCl

RN 676452-31-6 CAPLUS  
CN Benzoic acid, 4-[[4-[[[(3R)-1-butyl-3-[(R)-cycloheptylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenyl]methoxy]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676452-32-7 CAPLUS  
CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-cycloheptylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-3-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/527,435




● HCl

RN 676452-33-8 CAPLUS

CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-cycloheptylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-3-chloro-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676452-34-9 CAPLUS

CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-cycloheptylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-3-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676452-35-0 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclopentylhydroxymethyl]-9-[(4-methoxyphenyl)methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676452-36-1 CAPLUS

CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclopentylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-3-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676452-37-2 CAPLUS

CN Methanesulfonamide, N-[4-[[[(3R)-1-butyl-3-[(R)-cycloheptylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676452-38-3 CAPLUS

CN Benzamide, 4-[[[(3R)-1-butyl-3-[(R)-cycloheptylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676452-39-4 CAPLUS

CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-cycloheptylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]benzoyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676452-40-7 CAPLUS

CN Benzoic acid, 4-[[4-[[[(3R)-1-butyl-3-[(R)-cycloheptylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]benzoyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.






● HCl

RN 676452-41-8 CAPLUS

CN Benzoic acid, 4-[[[4-[[[(3R)-1-butyl-3-[(R)-cycloheptylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenyl]methyl]-3-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676452-43-0 CAPLUS

CN Benzoic acid, 4-[[[4-[[[(3R)-1-butyl-3-[(R)-cycloheptylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]benzoyl]methylamino]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676452-45-2 CAPLUS

CN Benzamide, 4-[[4-[[[(3R)-1-butyl-3-[(R)-cyclopentylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenyl]methoxy]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676452-46-3 CAPLUS

CN Acetamide, N-[4-[[4-[[[(3R)-1-butyl-3-[(R)-cyclopentylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenyl]methyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676452-47-4 CAPLUS  
 CN Benzoic acid, 4-[[[4-[[[(3R)-1-butyl-3-[(R)-cycloheptylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]benzoyl]amino]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




● HCl

PAGE 1-B

—CO<sub>2</sub>H

RN 676452-48-5 CAPLUS  
 CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclopentylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-3-ethoxy-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676452-49-6 CAPLUS

CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclopentylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-2-hydroxy-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676452-50-9 CAPLUS

CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(1R)-2-ethyl-1-hydroxybutyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenyl]thio]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676452-51-0 CAPLUS

CN Glycine, N-[4-[4-[[ (3R)-1-butyl-3-[(R)-cycloheptylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]benzoyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



● HCl

PAGE 1-B


 $\text{CO}_2\text{H}$ 

RN 676452-52-1 CAPLUS

CN Benzoic acid, 4-[[[[[4-[(3R)-1-butyl-3-[(R)-cycloheptylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenyl)methyl]amino]carbonyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




● HCl

—CO<sub>2</sub>H

RN 676452-53-2 CAPLUS

CN Benzamide, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclopentylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-3-methoxy-N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676452-54-3 CAPLUS

CN Benzamide, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclopentylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-3-chloro-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676452-55-4 CAPLUS

CN Morpholine, 4-[4-[4-[[[(3R)-1-butyl-3-[(1R)-2-ethyl-1-hydroxybutyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]benzoyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676452-56-5 CAPLUS  
 CN Pyrrolidine, 1-[4-[4-[(3R)-1-butyl-3-[(1R)-2-ethyl-1-hydroxybutyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]benzoyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676452-57-6 CAPLUS  
 CN Benzamide, 4-[4-[[(3R)-1-butyl-3-[(1R)-2-ethyl-1-hydroxybutyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-N-(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676452-58-7 CAPLUS  
 CN Benzamide, 4-[4-[[ (3R)-1-butyl-3-[(1R)-2-ethyl-1-hydroxybutyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-N-(2-hydroxyethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



● HCl


PAGE 1-B

— OH

RN 676452-59-8 CAPLUS  
 CN Benzamide, 4-[4-[[ (3R)-1-butyl-3-[(1R)-2-ethyl-1-hydroxybutyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-N-(2-methoxyethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



● HCl




— OMe

RN 676452-60-1 CAPLUS

CN Morpholine, 4-[4-[4-[[ (3R)-1-butyl-3-[(1R)-2-ethyl-1-hydroxybutyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-3-methoxybenzoyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676452-61-2 CAPLUS

CN Pyrrolidine, 1-[4-[4-[[ (3R)-1-butyl-3-[(1R)-2-ethyl-1-hydroxybutyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-3-methoxybenzoyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676452-62-3 CAPLUS

CN Benzamide, 4-[4-[4-[[ (3R)-1-butyl-3-[(1R)-2-ethyl-1-hydroxybutyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-3-methoxy-N-(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/527,435




● HCl

RN 676452-63-4 CAPLUS  
 CN Benzamide, 4-[4-[[ (3R)-1-butyl-3-[(1R)-2-ethyl-1-hydroxybutyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-N-(2-hydroxyethyl)-3-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



● HCl


PAGE 1-B

—OH

RN 676452-64-5 CAPLUS  
 CN Benzamide, 4-[4-[[ (3R)-1-butyl-3-[(1R)-2-ethyl-1-hydroxybutyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-3-methoxy-N-(2-methoxyethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




● HCl

PAGE 1-B

— OMe

RN 676452-65-6 CAPLUS  
 CN Benzamide, 4-[[4-[[[(3R)-1-butyl-3-[(R)-hydroxy(tetrahydro-2H-pyran-4-yl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]methyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

IT 676452-66-7P 676452-67-8P 676452-68-9P  
 676452-69-0P 676452-70-3P 676452-71-4P  
 676452-72-5P 676452-73-6P 676452-74-7P  
 676452-75-8P 676452-76-9P 676452-77-0P  
 676452-78-1P 676452-79-2P 676452-80-5P

676452-81-6P 676452-82-7P 676452-83-8P  
676452-84-9P 676452-85-0P 676452-86-1P  
676452-87-2P 676452-88-3P 676452-89-4P  
676452-90-7P 676452-91-8P 676452-92-9P  
676452-93-0P 676452-94-1P 676452-95-2P  
676452-96-3P 676452-97-4P 676452-98-5P  
676452-99-6P 676453-00-2P 676453-01-3P  
676453-02-4P 676453-03-5P 676453-04-6P  
676453-05-7P 676453-06-8P 676453-08-0P  
676453-09-1P 676453-11-5P 676453-12-6P  
676453-13-7P 676453-14-8P 676453-15-9P  
676453-16-0P 676453-17-1P 676453-18-2P  
676453-19-3P 676453-20-6P 676453-21-7P  
676453-22-8P 676453-23-9P 676453-25-1P  
676453-26-2P 676453-27-3P 676453-55-7P  
676453-82-0P 676453-91-1P 676453-92-2P  
676453-93-3P 676453-94-4P 676453-95-5P  
676453-96-6P 676453-97-7P 676453-98-8P  
676453-99-9P 676454-00-5P 676454-01-6P  
676454-02-7P 676454-03-8P 676454-04-9P  
676454-05-0P 676454-06-1P 676454-07-2P  
676454-08-3P 676454-09-4P 676454-10-7P  
676454-11-8P 676454-12-9P 676454-13-0P  
676454-14-1P 676454-15-2P 676454-16-3P  
676454-17-4P 676454-18-5P 676454-19-6P  
676454-20-9P 676454-21-0P 676454-22-1P  
676454-27-6P 676454-28-7P 676454-29-8P  
676454-30-1P 676454-31-2P 676454-32-3P  
676454-33-4P 676454-34-5P 676454-35-6P  
676454-36-7P 676454-37-8P 676454-38-9P  
676454-39-0P 676454-40-3P 676454-41-4P  
676454-42-5P 676454-43-6P 676454-45-8P  
676454-46-9P 676454-47-0P 676454-50-5P  
676454-51-6P 676454-52-7P 676454-55-0P  
676454-56-1P 676454-57-2P 676454-58-3P  
676454-59-4P 676454-60-7P 676454-61-8P  
676454-62-9P 676454-63-0P 676454-64-1P  
676454-68-5P 676454-69-6P 676454-70-9P  
676454-71-0P 676454-78-7P 676454-79-8P  
676454-82-3P 676454-83-4P 676454-89-0P  
676454-90-3P 676454-91-4P 676454-92-5P  
676454-93-6P 676454-94-7P 676454-95-8P  
676454-96-9P 676455-00-8P 676455-02-0P  
676455-03-1P 676455-04-2P 676455-05-3P  
676455-06-4P 676455-07-5P 676455-08-6P  
676455-09-7P 676455-10-0P 676455-11-1P  
676455-12-2P 676455-13-3P 676455-14-4P  
676455-15-5P 676455-16-6P 676455-17-7P  
676455-18-8P 676455-19-9P 676455-20-2P  
676455-21-3P 676455-22-4P 676455-23-5P  
676455-24-6P 676455-25-7P 676455-26-8P  
676465-10-4P 676465-11-5P 676465-13-7P  
676465-15-9P 676465-17-1P 676465-18-2P  
676465-19-3P 676465-21-7P 676465-22-8P  
676465-23-9P 676465-24-0P 676465-25-1P  
676465-26-2P 676465-27-3P 676465-28-4P  
676465-29-5P 676465-30-8P 676465-31-9P

676465-32-0P 676465-33-1P 676465-34-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of triazaspiro[5.5]undecane derivs. as chemokine receptor CCR5 antagonists and drugs)

RN 676452-66-7 CAPLUS

CN Benzamide, 4-[[4-[[[(3R)-1-butyl-3-[(R)-hydroxy(tetrahydro-2H-pyran-4-yl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenyl]methoxy]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676452-67-8 CAPLUS

CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-hydroxy(tetrahydro-2H-pyran-4-yl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-3-chloro-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676452-68-9 CAPLUS

CN Acetamide, N-[4-[4-[[[(3R)-1-butyl-3-[(R)-hydroxy(tetrahydro-2H-pyran-4-yl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-3-

methoxyphenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676452-69-0 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 9-[[4-(4-bromophenoxy)phenyl)methyl]-1-butyl-3-[(R)-hydroxy(tetrahydro-2H-pyran-4-yl)methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676452-70-3 CAPLUS

CN Morpholine, 4-[4-[4-[[[(3R)-1-butyl-3-[(R)-hydroxy(tetrahydro-2H-pyran-4-yl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]benzoyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676452-71-4 CAPLUS  
 CN Pyrrolidine, 1-[4-[4-[[ (3R)-1-butyl-3-[(R)-hydroxy(tetrahydro-2H-pyran-4-yl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]benzoyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676452-72-5 CAPLUS  
 CN Acetamide, N-[4-[4-[[ (3R)-1-butyl-3-[(R)-hydroxy(tetrahydro-2H-pyran-4-yl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenyl]methyl]-3-chloro-5-methoxyphenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/527,435




● HCl

RN 676452-73-6 CAPLUS

CN Benzamide, 4-[4-[[ (3R)-1-butyl-3-[(R)-cyclopentylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-3-methoxy-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676452-74-7 CAPLUS

CN Benzamide, 4-[4-[[ (3R)-1-butyl-3-[(R)-hydroxy(tetrahydro-2H-pyran-4-yl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]benzoyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.






● HCl

RN 676452-75-8 CAPLUS

CN Benzamide, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclopentylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]benzoyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676452-76-9 CAPLUS

CN Benzamide, 4-[4-[[[(3R)-1-butyl-3-[(R)-hydroxy(tetrahydro-2H-pyran-4-yl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-N-(cyclopropylmethyl)-3-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



● HCl

PAGE 1-B




RN 676452-77-0 CAPLUS


CN Benzamide, 4-[[4-[[[(3R)-1-butyl-3-[(R)-hydroxy(tetrahydro-2H-pyran-4-yl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenyl]methyl]-N-(cyclopropylmethyl)-3-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




● HCl



RN 676452-78-1 CAPLUS  
 CN Benzamide, 4-[[4-[[[(3R)-1-butyl-3-[(R)-hydroxy(tetrahydro-2H-pyran-4-yl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenyl]methyl]-3-methoxy-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676452-79-2 CAPLUS  
 CN Morpholine, 4-[4-[4-[[[(3R)-1-butyl-3-[(R)-hydroxy(tetrahydro-2H-pyran-4-yl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-3-methoxybenzoyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676452-80-5 CAPLUS  
 CN Benzamide, 4-[4-[[[(3R)-1-butyl-3-[(R)-hydroxy(tetrahydro-2H-pyran-4-yl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-3-

methoxy-N-(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676452-81-6 CAPLUS

CN Benzamide, 4-[4-[[ (3R)-1-butyl-3-[(R)-hydroxy(tetrahydro-2H-pyran-4-yl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-3-methoxy-N-(2-methylpropyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676452-82-7 CAPLUS

CN Benzamide, 4-[4-[[ (3R)-1-butyl-3-[(R)-hydroxy(tetrahydro-2H-pyran-4-yl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-3-methoxy-N-(2-methoxyethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




● HCl

PAGE 1-B



RN 676452-83-8 CAPLUS  
 CN Benzamide, 4-[4-[[ (3R)-1-butyl-3-[(R)-hydroxy(tetrahydro-2H-pyran-4-yl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-N-(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676452-84-9 CAPLUS  
 CN Benzamide, 4-[4-[[ (3R)-1-butyl-3-[(R)-hydroxy(tetrahydro-2H-pyran-4-yl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-N-(2-methylpropyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676452-85-0 CAPLUS  
 CN Benzamide, 4-[4-[[ (3R)-1-butyl-3-[(R)-hydroxy(tetrahydro-2H-pyran-4-yl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-N-(2-methoxyethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



● HCl


PAGE 1-B



RN 676452-86-1 CAPLUS  
 CN Benzamide, 4-[4-[[ (3R)-1-butyl-3-[(R)-hydroxy(tetrahydro-2H-pyran-4-yl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-N-(2,2-dimethylpropyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



● HCl


PAGE 1-B

—CMe<sub>3</sub>

RN 676452-87-2 CAPLUS

CN Benzamide, 4-[[4-[[[(3R)-1-butyl-3-[(R)-hydroxy(tetrahydro-2H-pyran-4-yl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenyl]thio]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676452-88-3 CAPLUS

CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclopentylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-2-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676452-89-4 CAPLUS  
 CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-cycloheptylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-2-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676452-90-7 CAPLUS  
 CN Benzamide, 4-[4-[[[(3R)-1-butyl-3-[(R)-hydroxy(tetrahydro-2H-pyran-4-yl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-N-(2,2-dimethylpropyl)-3-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A



● HCl


PAGE 1-B

CMe<sub>3</sub>


RN 676452-91-8 CAPLUS  
 CN Benzamide, 4-[[4-[[[(3R)-1-butyl-3-[(R)-hydroxy(tetrahydro-2H-pyran-4-yl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenyl]methyl]-N-(cyclopropylmethyl)-, monohydrochloride (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




● HCl



RN 676452-92-9 CAPLUS  
 CN Benzamide, 4-[[4-[[[(3R)-1-butyl-3-[(R)-cyclopentylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenyl)methyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676452-93-0 CAPLUS  
 CN Methanesulfonamide, N-[4-[4-[[[(3R)-1-butyl-3-[(R)-cyclopentylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-3-methoxyphenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676452-94-1 CAPLUS  
 CN Methanesulfonamide, N-[4-[4-[[[(3R)-1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-3-

methoxyphenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676452-95-2 CAPLUS

CN Pyrrolidine, 1-[4-[4-[[[(3R)-1-butyl-3-[(R)-hydroxy(tetrahydro-2H-pyran-4-yl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-3-methoxybenzoyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676452-96-3 CAPLUS

CN Benzamide, 4-[[4-[[[(3R)-1-butyl-3-[(R)-hydroxy(tetrahydro-2H-pyran-4-yl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenyl]methyl]-3-chloro-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676452-97-4 CAPLUS  
 CN Benzamide, 4-[4-[[ (3R)-1-butyl-3-[(1R)-2-ethyl-1-hydroxybutyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]benzoyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676452-98-5 CAPLUS  
 CN Benzoic acid, 4-[4-[[ (3R)-1-butyl-3-[(1R)-2-ethyl-1-hydroxybutyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-3-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676452-99-6 CAPLUS

CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(1R)-2-ethyl-1-hydroxybutyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-2-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676453-00-2 CAPLUS

CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-hydroxy(tetrahydro-2H-pyran-4-yl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-3-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676453-01-3 CAPLUS

CN Benzoic acid, 4-[[4-[[[(3R)-1-butyl-3-[(1R)-2-ethyl-1-hydroxybutyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenyl]methyl]-3-chloro-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676453-02-4 CAPLUS

CN Benzamide, 4-[[4-[[[(3R)-1-butyl-3-[(1R)-2-ethyl-1-hydroxybutyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenyl]methyl]-3-chloro-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676453-03-5 CAPLUS

CN Acetamide, N-[4-[[4-[[ (3R)-1-butyl-3-[(1R)-2-ethyl-1-hydroxybutyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenyl]methyl]-3-chloro-5-methoxyphenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676453-04-6 CAPLUS

CN Methanesulfonamide, N-[4-[[4-[[ (3R)-1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenyl]methyl]-3-chlorophenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676453-05-7 CAPLUS

CN Benzoic acid, 4-[[4-[[[(3R)-1-butyl-3-[(R)-hydroxy(tetrahydro-2H-pyran-4-yl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenyl]methyl]-3-chloro-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676453-06-8 CAPLUS

CN Benzamide, 4-[[4-[[[(3R)-1-butyl-3-[(1R)-2-ethyl-1-hydroxybutyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenyl]methyl]-3-methoxy-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.






● HCl

RN 676453-08-0 CAPLUS

CN Benzamide, 4-[[4-[[[(3R)-1-butyl-3-[(1R)-2-ethyl-1-hydroxybutyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenyl]methyl]-N-(cyclopropylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676453-09-1 CAPLUS

CN Methanesulfonamide, N-[4-[4-[[[(3R)-1-butyl-3-[(1R)-2-ethyl-1-hydroxybutyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-3-methoxyphenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676453-11-5 CAPLUS

CN Methanesulfonamide, N-[4-[4-[[ (3R)-1-butyl-3-[(R)-hydroxy(tetrahydro-2H-pyran-4-yl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-3,5-dimethylphenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676453-12-6 CAPLUS

CN Benzoic acid, 4-[4-[[ (3R)-1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-3,5-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676453-13-7 CAPLUS

CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-hydroxy(tetrahydro-2H-pyran-4-yl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-3,5-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676453-14-8 CAPLUS

CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclopentylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-3,5-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676453-15-9 CAPLUS

CN Cyclopropaneacetamide, N-[4-[[4-[[ (3R)-1-butyl-3-[(R)-hydroxy(tetrahydro-2H-pyran-4-yl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenyl]methyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676453-16-0 CAPLUS

CN Propanamide, N-[4-[[4-[[ (3R)-1-butyl-3-[(R)-hydroxy(tetrahydro-2H-pyran-4-yl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenyl]methyl]phenyl]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676453-17-1 CAPLUS  
 CN Butanamide, N-[4-[4-[[ (3R)-1-butyl-3-[(R)-hydroxy(tetrahydro-2H-pyran-4-yl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenyl]methyl]phenyl]-3-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676453-18-2 CAPLUS  
 CN Cyclopropaneacetamide, N-[4-[4-[[ (3R)-1-butyl-3-[(R)-hydroxy(tetrahydro-2H-pyran-4-yl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676453-19-3 CAPLUS  
 CN Propanamide, N-[4-[4-[[[(3R)-1-butyl-3-[(R)-hydroxy(tetrahydro-2H-pyran-4-yl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]phenyl]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676453-20-6 CAPLUS  
 CN Butanamide, N-[4-[4-[[[(3R)-1-butyl-3-[(R)-hydroxy(tetrahydro-2H-pyran-4-yl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]phenyl]-3-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/527,435




● HCl

RN 676453-21-7 CAPLUS

CN Cyclopropaneacetamide, N-[4-[4-[(3R)-1-butyl-3-[(R)-hydroxy(tetrahydro-2H-pyran-4-yl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-3-methoxyphenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676453-22-8 CAPLUS

CN	Propanamide, N-[4-[4-[[ (3R)-1-butyl-3-[(R)-hydroxy(tetrahydro-2H-pyran-4-yl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-3-methoxyphenyl]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)
----	---

Absolute stereochemistry.




● HCl

RN 676453-23-9 CAPLUS

CN Butanamide, N-[4-[4-[[ (3R)-1-butyl-3-[(R)-hydroxy(tetrahydro-2H-pyran-4-yl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-3-methoxyphenyl]-3-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676453-25-1 CAPLUS

CN Methanesulfonamide, N-[4-[4-[[ (3R)-3-[(1R)-1-hydroxy-2-methylpropyl]-1-(2-methoxyethyl)-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]-3-methoxyphenoxy]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.






● HCl

RN 676453-26-2 CAPLUS

CN Methanesulfonamide, N-[4-[4-[[ (3R)-3-[(R)-cyclohexylhydroxymethyl]-1-(2-methoxyethyl)-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-3-methoxyphenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676453-27-3 CAPLUS

CN Methanesulfonamide, N-[4-[4-[[ (3R)-1-ethyl-3-[(1R)-1-hydroxy-2-methylpropyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-3-methoxyphenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/527,435




● HCl

RN 676453-55-7 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[[4-(4-methoxybenzoyl)phenyl]methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676453-82-0 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[[4-[(methoxyimino)phenylmethyl]phenyl]methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




● HCl

RN 676453-91-1 CAPLUS

CN Benzoic acid, 4-[4-[[ (3R)-1-(2-butynyl)-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676453-92-2 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-3-cyclohexen-1-ylhydroxymethyl]-9-[[4-[4-(methylamino)phenoxy]phenyl]methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676453-93-3 CAPLUS  
 CN Benzamide, 4-[4-[[ (3R)-1-butyl-3-[(R)-3-cyclopenten-1-ylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676453-94-4 CAPLUS  
 CN Benzamide, 4-[4-[[ (3R)-1-butyl-3-[(1R)-1-hydroxy-2-(tetrahydro-4H-pyran-4-ylidene)ethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676453-95-5 CAPLUS  
 CN Benzamide, 4-[4-[[[(3R)-1-butyl-3-[(S)-1,3-dithian-2-ylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676453-96-6 CAPLUS  
 CN Benzamide, 4-[4-[[[(3R)-1-butyl-3-[(R)-(2,6-dimethylphenyl)hydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676453-97-7 CAPLUS  
 CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-3-cyclopenten-1-ylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenyl)methyl]-3-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676453-98-8 CAPLUS

CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-3-cyclopenten-1-ylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-3-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676453-99-9 CAPLUS

CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-3-cyclopenten-1-ylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/527,435



● HCl

RN 676454-00-5 CAPLUS  
CN Benzoic acid, 4-[[4-[[[(3R)-1-butyl-3-[(R)-3-cyclopenten-1-ylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenyl]methoxy]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676454-01-6 CAPLUS  
CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-3-cyclopenten-1-ylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676454-02-7 CAPLUS  
 CN Benzenesulfonamide, 4-[4-[[[(3R)-1-butyl-3-[(R)-3-cyclopenten-1-ylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676454-03-8 CAPLUS  
 CN Benzeneacetamide, N-[4-[[[(3R)-1-butyl-3-[(R)-3-cyclopenten-1-ylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenyl]-4-fluoro-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl



RN 676454-04-9 CAPLUS  
 CN Benzamide, 4-[[4-[[[(3R)-1-butyl-3-[(R)-3-cyclopenten-1-ylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenyl]methoxy]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676454-05-0 CAPLUS  
 CN Acetamide, N-[4-[[4-[[[(3R)-1-butyl-3-[(R)-3-cyclopenten-1-ylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenyl]methyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676454-06-1 CAPLUS  
 CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-3-cyclopenten-1-ylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-2-hydroxy-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676454-07-2 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-3-cyclopenten-1-ylhydroxymethyl]-9-[[4-(4-methoxyphenoxy)phenyl]methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676454-08-3 CAPLUS  
 CN Benzamide, 4-[[4-[[[(3R)-1-butyl-3-[(R)-3-cyclopenten-1-ylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]methyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676454-09-4 CAPLUS

CN Benzoic acid, 2-[4-[[[(3R)-1-butyl-3-[(R)-3-cyclopenten-1-ylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-5-ethoxy-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676454-10-7 CAPLUS

CN Acetamide, N-[4-[4-[[[(3R)-1-butyl-3-[(R)-3-cyclopenten-1-ylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-3-methoxyphenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/527,435



● HCl

RN 676454-11-8 CAPLUS  
CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-3-cyclopenten-1-ylhydroxymethyl]-9-[[4-(2,4-dimethoxyphenoxy)phenyl]methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676454-12-9 CAPLUS  
CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-3-cyclopenten-1-ylhydroxymethyl]-9-[[4-(4-hydroxy-2-methoxyphenoxy)phenyl]methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676454-13-0 CAPLUS  
 CN Benzamide, 2-[4-[[[(3R)-1-butyl-3-[(R)-3-cyclopenten-1-ylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-N-[2-(dimethylamino)ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl

RN 676454-14-1 CAPLUS  
 CN Acetamide, N-[4-[4-[[[(3R)-1-butyl-3-[(R)-3-cyclopenten-1-ylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676454-15-2 CAPLUS  
 CN Methanesulfonamide, N-[4-[4-[(3R)-1-butyl-3-[(R)-3-cyclopenten-1-ylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676454-16-3 CAPLUS  
 CN Benzamide, 4-[4-[(3R)-1-butyl-3-[(R)-3-cyclopenten-1-ylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-3-chloro-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676454-17-4 CAPLUS

CN Benzamide, 4-[4-[[ (3R)-1-butyl-3-[(R)-3-cyclopenten-1-ylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-3-methoxy-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676454-18-5 CAPLUS

CN Benzamide, 4-[4-[[ (3R)-1-butyl-3-[(R)-3-cyclopenten-1-ylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-N-(cyclopropylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

PAGE 1-A

PAGE 1-B




RN 676454-19-6 CAPLUS

CN Benzamide, 4-[4-[[ (3R)-1-butyl-3-[(R)-3-cyclopenten-1-ylhydroxymethyl]-2,5-

dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]benzoyl]-N-methyl-,  
monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676454-20-9 CAPLUS

CN Benzamide, 4-[[4-[[[(3R)-1-butyl-3-[(R)-3-cyclopenten-1-ylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenyl)methyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676454-21-0 CAPLUS

CN Methanesulfonamide, N-[4-[4-[[[(3R)-1-butyl-3-[(R)-3-cyclopenten-1-ylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-3-methoxyphenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.






● HCl

RN 676454-22-1 CAPLUS

CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-3-cyclopenten-1-ylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-3,5-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676454-27-6 CAPLUS

CN Benzamide, 4-[4-[[[(3R)-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1-(2-propynyl)-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676454-28-7 CAPLUS  
 CN Benzamide, 4-[4-[[ (3R)-3-[(R)-cyclohexylhydroxymethyl]-1-[(1-oxido-3-pyridinyl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676454-29-8 CAPLUS  
 CN Benzamide, 4-[4-[[ (3R)-3-[(R)-cyclohexylhydroxymethyl]-1-[(1-oxido-2-pyridinyl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676454-30-1 CAPLUS  
 CN Benzamide, 4-[4-[[ (3R)-3-[(R)-cyclohexylhydroxymethyl]-1-[2-(dimethylamino)ethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-N-methyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 676454-31-2 CAPLUS  
 CN Benzamide, 4-[4-[[ (3R)-3-[(R)-cyclohexylhydroxymethyl]-1-ethyl-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/527,435



● HCl

RN 676454-32-3 CAPLUS  
CN Benzamide, 4-[4-[[ (3R)-3-[(R)-cyclohexylhydroxymethyl]-1-(cyclopropylmethyl)-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676454-33-4 CAPLUS  
CN Benzamide, 4-[4-[[ (3R)-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1-(2-phenylethyl)-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676454-34-5 CAPLUS

CN Benzamide, 4-[4-[[[(3R)-3-[(R)-cyclohexylhydroxymethyl]-1-methyl-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676454-35-6 CAPLUS

CN Benzamide, 4-[4-[[[(3R)-3-[(R)-cyclohexylhydroxymethyl]-1-(3-methylbutyl)-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676454-36-7 CAPLUS

CN Benzamide, 4-[4-[[[(3R)-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1-[2-(3-pyridinyl)ethyl]-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-N-methyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 676454-37-8 CAPLUS

CN Benzamide, 4-[4-[[[(3R)-3-[(R)-cyclohexylhydroxymethyl]-1-[2-(1-oxido-3-pyridinyl)ethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676454-38-9 CAPLUS  
 CN Carbamic acid, [2-[(3R)-3-[(R)-cyclohexylhydroxymethyl]-9-[[4-[4-[(methylamino)carbonyl]phenoxy]phenyl]methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-1-yl]ethyl]-, 2-propenyl ester, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676454-39-0 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 3-[(R)-cyclohexylhydroxymethyl]-1-ethyl-9-(phenylmethyl)-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676454-40-3 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 3-[(R)-cyclohexylhydroxymethyl]-1-methyl-9-(phenylmethyl)-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676454-41-4 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-1-propanamide, 3-[(R)-cyclohexylhydroxymethyl]-N-methyl-9-[[4-[4-[(methylamino)carbonyl]phenoxy]phenyl]methyl]-2,5-dioxo-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






● HCl

RN 676454-42-5 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-1-butanamide, 3-[(R)-cyclohexylhydroxymethyl]-N-methyl-9-[[4-[4-[(methylamino)carbonyl]phenoxy]phenyl]methyl]-2,5-dioxo-, monohydrochloride, (3R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676454-43-6 CAPLUS  
 CN Benzamide, 4-[4-[(3R)-1-(2-cyanoethyl)-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676454-45-8 CAPLUS

CN Benzamide, 4-[4-[[ (3R)-3-[(R)-cyclohexylhydroxymethyl]-1-hexyl-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676454-46-9 CAPLUS

CN Benzamide, 4-[4-[[ (3R)-3-[(R)-cyclohexylhydroxymethyl]-1-heptyl-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676454-47-0 CAPLUS  
 CN Benzamide, 4-[4-[[ (3R)-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1-(2,2,2-trifluoroethyl)-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676454-50-5 CAPLUS  
 CN Methanesulfonamide, N-[4-[[ (3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676454-51-6 CAPLUS

CN Benzamide, 4-[4-[[ (3R)-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1-pentyl-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676454-52-7 CAPLUS

CN Methanesulfonamide, N-[4-[4-[[ (3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]phenyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676454-55-0 CAPLUS

CN Benzamide, 4-[4-[[ (3R)-1-(2-butynyl)-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A

● HCl

RN 676454-56-1 CAPLUS

CN Benzamide, 4-[4-[[ (3R)-1-(3-butenyl)-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676454-57-2 CAPLUS

CN Benzamide, 4-[4-[[ (3R)-3-[(R)-cyclohexylhydroxymethyl]-1-(2-ethylbutyl)-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676454-58-3 CAPLUS

CN Benzamide, 4-[4-[[ (3R)-3-[(R)-cyclohexylhydroxymethyl]-1-(3-methoxypropyl)-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676454-59-4 CAPLUS  
 CN Benzamide, 4-[4-[[ (3R)-3-[(R)-cyclohexylhydroxymethyl]-1-(2-ethoxyethyl)-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676454-60-7 CAPLUS  
 CN Benzamide, 4-[4-[[ (3R)-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1-(2,2,3,3,3-pentafluoropropyl)-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676454-61-8 CAPLUS  
 CN Benzamide, 4-[4-[[ (3R)-1-(cyclobutylmethyl)-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676454-62-9 CAPLUS  
 CN Benzamide, 4-[4-[[ (3R)-1-(2E)-2-butenyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.






● HCl

RN 676454-63-0 CAPLUS  
 CN Benzamide, 4-[4-[[ (3R)-3-[(R)-cyclohexylhydroxymethyl]-1-[(2-methylcyclopropyl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676454-64-1 CAPLUS  
 CN Benzamide, 4-[4-[[ (3R)-1-butyl-3-[(R)-hydroxy(tetrahydro-2H-thiopyran-4-yl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676454-68-5 CAPLUS  
 CN Benzamide, 4-[4-[[ (3R)-1-(2-aminoethyl)-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676454-69-6 CAPLUS  
 CN Carbamic acid, [2-[(3R)-3-[(R)-cyclohexylhydroxymethyl]-9-[[4-[4-[(methylamino)carbonyl]phenoxy]phenyl]methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-1-yl]ethyl]-, 2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/527,435



RN 676454-70-9 CAPLUS

CN Benzamide, 4-[4-[[ (3R)-1-[2-(acetylamino)ethyl]-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676454-71-0 CAPLUS

CN Benzamide, 4-[4-[[ (3R)-1-(2-aminoethyl)-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 676454-78-7 CAPLUS

CN Methanesulfonamide, N-[4-[4-[[ (3R)-3-[(R)-cyclohexylhydroxymethyl]-1-ethyl-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-3-methoxyphenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676454-79-8 CAPLUS

CN Methanesulfonamide, N-[4-[4-[[ (3R)-1-ethyl-3-[(R)-hydroxy(tetrahydro-2H-pyran-4-yl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-3-methoxyphenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676454-82-3 CAPLUS

CN Methanesulfonamide, N-[4-[4-[[ (3R)-3-[(R)-cyclohexylhydroxymethyl]-1-(2-hydroxyethyl)-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-3-methoxyphenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676454-83-4 CAPLUS

CN Methanesulfonamide, N-[4-[4-[[ (3R)-1-(2-butynyl)-3-[(R)-hydroxy(tetrahydro-2H-pyran-4-yl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-3-methoxyphenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A

● HCl

RN 676454-89-0 CAPLUS

CN Benzamide, 4-[4-[[ (3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-3-chloro-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 676454-90-3 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[[4-[[4-(2,5-dihydro-5-oxo-1,2,4-thiadiazol-3-yl)phenoxy]phenyl]methyl]-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 676454-91-4 CAPLUS

CN Benzamide, 4-[4-[[ (3R)-1-butyl-3-[(1R)-2-ethyl-1-hydroxybutyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-3-methoxy-N-(2-methoxyethyl)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

— OMe

RN 676454-92-5 CAPLUS

CN Methanesulfonamide, N-[4-[4-[[ (3R)-1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-3-methoxyphenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 676454-93-6 CAPLUS

CN Pyrrolidine, 1-[4-[4-[[ (3R)-1-butyl-3-[(R)-hydroxy(tetrahydro-2H-pyran-4-yl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-3-methoxybenzoyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 676454-94-7 CAPLUS

CN Methanesulfonamide, N-[4-[4-[[ (3R)-1-butyl-3-[(1R)-2-ethyl-1-hydroxybutyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-3-methoxyphenyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 676454-95-8 CAPLUS

CN Butanamide, N-[4-[4-[[ (3R)-1-butyl-3-[(R)-hydroxy(tetrahydro-2H-pyran-4-yl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-

yl)methyl]phenyl)methyl]phenyl]-3-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 676454-96-9 CAPLUS

CN Butanamide, N-[4-[[4-[[ (3R)-1-butyl-3-[(R)-hydroxy(tetrahydro-2H-pyran-4-yl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenyl)methyl]-3-methoxyphenyl]-3-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 676455-00-8 CAPLUS

CN Benzamide, 4-[4-[[ (3R)-1-butyl-3-[(R)-3-cyclohexen-1-ylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 676455-02-0 CAPLUS

CN Benzamide, 4-[4-[[ (3R)-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1-pentyl-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.






RN 676455-03-1 CAPLUS


CN Benzamide, 4-[4-[[ (3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-N-(cyclopropylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 676455-04-2 CAPLUS

CN Benzoic acid, 4-[4-[[ (3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-3-methoxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 676455-05-3 CAPLUS

CN Benamide, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-3-methoxy-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 676455-06-4 CAPLUS

CN Benzoic acid, 4-[[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenyl]methyl]-3-methoxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 676455-07-5 CAPLUS

CN Benamide, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-3-methoxy-N,N-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 676455-08-6 CAPLUS

CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-3-ethoxy- (CA INDEX NAME)

INDEX NAME)


Absolute stereochemistry.



RN 676455-09-7 CAPLUS

CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-3,5-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 676455-10-0 CAPLUS

CN Benzoic acid, 4-[4-[[[(3R)-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1-pentyl-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-3-methoxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 676455-11-1 CAPLUS

CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(1R)-2-ethyl-1-hydroxybutyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-3-methoxy- (CA INDEX NAME)

Absolute stereochemistry.




RN 676455-12-2 CAPLUS


CN Benzamide, 4-[4-[[ (3R)-1-butyl-3-[(R)-hydroxy(tetrahydro-2H-pyran-4-yl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-N-(cyclopropylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 676455-13-3 CAPLUS


CN Benzamide, 4-[4-[[ (3R)-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1-propyl-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-3-methoxy-N,N-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 676455-14-4 CAPLUS  
 CN Benzoic acid, 4-[4-[[ (3R)-1-butyl-3-[(R)-cycloheptylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-3-methoxy- (CA INDEX NAME)

Absolute stereochemistry.




RN 676455-15-5 CAPLUS  
 CN Benzoic acid, 4-[4-[[ (3R)-1-butyl-3-[(R)-cyclopentylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-3-methoxy- (CA INDEX NAME)

Absolute stereochemistry.



RN 676455-16-6 CAPLUS  
 CN Benzoic acid, 4-[4-[[ (3R)-1-butyl-3-[(R)-cyclopentylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-3-ethoxy- (CA INDEX NAME)

Absolute stereochemistry.




RN 676455-17-7 CAPLUS  
 CN Benzamide, 4-[4-[[ (3R)-1-butyl-3-[(R)-hydroxy (tetrahydro-2H-pyran-4-

yl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-N-(cyclopropylmethyl)-3-methoxy- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 676455-18-8 CAPLUS

CN Benzamide, 4-[[4-[[[(3R)-1-butyl-3-[(R)-hydroxy(tetrahydro-2H-pyran-4-yl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenyl)methyl]-3-methoxy-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 676455-19-9 CAPLUS

CN Benzamide, 4-[[4-[[[(3R)-1-butyl-3-[(R)-hydroxy(tetrahydro-2H-pyran-4-yl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-3-methoxy-N-(1-methylethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 676455-20-2 CAPLUS

CN Benzamide, 4-[4-[[ (3R)-1-butyl-3-[(R)-hydroxy(tetrahydro-2H-pyran-4-yl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-3-methoxy-N-(2-methylpropyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 676455-21-3 CAPLUS

CN Benzamide, 4-[4-[[ (3R)-1-butyl-3-[(R)-hydroxy(tetrahydro-2H-pyran-4-yl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-N-(2,2-dimethylpropyl)-3-methoxy- (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



—CMe<sub>3</sub>


RN 676455-22-4 CAPLUS  
 CN Propanamide, N-[4-[4-[[ (3R)-1-butyl-3-[(R)-hydroxy(tetrahydro-2H-pyran-4-yl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]phenyl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 676455-23-5 CAPLUS  
 CN Butanamide, N-[4-[4-[[ (3R)-1-butyl-3-[(R)-hydroxy(tetrahydro-2H-pyran-4-yl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]phenyl]-3-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 676455-24-6 CAPLUS  
 CN Propanamide, N-[4-[4-[[ (3R)-1-butyl-3-[(R)-hydroxy(tetrahydro-2H-pyran-4-yl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-3-methoxyphenyl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.






RN 676455-25-7 CAPLUS

CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-3-cyclopenten-1-ylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-3-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 676455-26-8 CAPLUS

CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-3-cyclopenten-1-ylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-3-ethoxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 676465-10-4 CAPLUS

CN Benzoic acid, 4-[4-[[[(3S)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676465-11-5 CAPLUS  
 CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(S)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676465-13-7 CAPLUS  
 CN Benzenemethanesulfonamide, N-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenyl]-4-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676465-15-9 CAPLUS  
 CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-2-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676465-17-1 CAPLUS  
 CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676465-18-2 CAPLUS  
 CN Benzoic acid, 4-[3-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]benzoyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676465-19-3 CAPLUS

CN Benzamide, 4-[4-[[ (3R)-1-butyl-3-[(1R)-2-ethyl-1-hydroxybutyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-3-methoxy-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676465-21-7 CAPLUS

CN Benzamide, 4-[4-[[ (3R)-1-(3-butynyl)-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676465-22-8 CAPLUS

CN Methanesulfonamide, N-[4-[4-[(3R)-1-butyl-3-[(1S)-1-hydroxy-2-methylpropyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-3-methoxyphenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 676465-23-9 CAPLUS

CN Benzamide, 4-[4-[(3R)-1-butyl-3-[(R)-hydroxy(trans-4-methoxycyclohexyl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676465-24-0 CAPLUS  
 CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-hydroxy(trans-4-methoxycyclohexyl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676465-25-1 CAPLUS  
 CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-hydroxy(trans-4-methylcyclohexyl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676465-26-2 CAPLUS  
 CN Benzamide, 4-[4-[[ (3R)-1-butyl-3-[(R)-hydroxy(trans-4-methylcyclohexyl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676465-27-3 CAPLUS  
 CN Benzamide, 4-[4-[[ (3R)-1-butyl-3-[(R)-hydroxy(cis-4-hydroxycyclohexyl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676465-28-4 CAPLUS  
 CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-hydroxy(cis-4-hydroxycyclohexyl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 676465-29-5 CAPLUS  
 CN Benzamide, 4-[4-[[[(3R)-1-butyl-3-[(R)-hydroxy(cis-4-methylcyclohexyl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.






● HCl

RN 676465-30-8 CAPLUS  
 CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-(cis-4-ethoxycyclohexyl)hydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676465-31-9 CAPLUS  
 CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-(trans-4-ethoxycyclohexyl)hydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676465-32-0 CAPLUS  
 CN Benzamide, 4-[4-[[ (3R)-1-butyl-3-[(R)-(cis-4-ethoxycyclohexyl)hydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676465-33-1 CAPLUS  
 CN Benzamide, 4-[4-[[ (3R)-1-butyl-3-[(R)-(trans-4-ethoxycyclohexyl)hydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 676465-34-2 CAPLUS  
 CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-hydroxy(cis-4-methylcyclohexyl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 54 OF 59 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2004:252478 CAPLUS  
 DN 140:264479  
 TI G1-phase arresting compounds for inducing increased levels of  
 $\beta$ -chemokines  
 IN Redfield, Robert R.; Amoroso, Anthony; Davis, Charles E.; Heredia, Alonsa  
 PA University of Maryland Biotechnology, USA  
 SO PCT Int. Appl., 76 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004024683	A2	20040325	WO 2003-US28697	20030912
	WO 2004024683	A3	20040701		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2498934	A1	20040325	CA 2003-2498934	20030912
	AU 2003266152	A1	20040430	AU 2003-266152	20030912
	EP 1545539	A2	20050629	EP 2003-795698	20030912
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	US 2006099170	A1	20060511	US 2005-527904	20050707
PRAI	US 2002-410714P	P	20020913		
	WO 2003-US28697	W	20030912		

AB The present invention relates to methods for inducing increased levels and availability of  $\beta$ -chemokines by administering to a subject at least 1 G1-phase arresting compound, wherein the increased levels and availability of  $\beta$ -chemokines block chemokine/viral receptors thereby preventing or treating viral infections. The secretion of the  $\beta$ -chemokines by peripheral blood mononuclear cells in response to the activation started before lymphocytes entered the DNA synthesis phase of the cell cycle (S phase), reaches a peak by day 3 or 7 and then declined to low levels. The antiviral activity is due the presence of the  $\beta$ -chemokines RANTES, and MIP proteins.

IT 461443-59-4

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(G1-phase arresting compds. for inducing increased levels of  $\beta$ -chemokines)

RN 461443-59-4 CAPLUS

CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]- (CA INDEX NAME)

Absolute stereochemistry.

10/527,435



L20 ANSWER 55 OF 59 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2004:252197 CAPLUS  
 DN 140:281350  
 TI Spiro compounds for inhibiting the first-pass effect  
 IN Harris, James W.  
 PA Bioavailability System, LLC, USA  
 SO U.S. Pat. Appl. Publ., 133 pp., Cont.-in-part of U.S. Ser. No. 793,416.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004058982	A1	20040325	US 2003-422848	20030425
	US 6248776	B1	20010619	US 1999-251467	19990217
	US 6476066	B1	20021105	US 2001-793416	20010227
	US 2005214366	A1	20050929	US 2005-81024	20050316
	US 7230027	B2	20070612		
	US 2007244188	A1	20071018	US 2007-696198	20070404
PRAI	US 1999-251467	A3	19990217		
	US 2001-793416	A2	20010227		
	US 1997-56382P	P	19970826		
	US 1997-997259	A2	19971223		
	US 2003-422848	B1	20030425		
	US 2005-81024	A1	20050316		

OS MARPAT 140:281350

AB Compns., methods, etc. for addressing the first-pass effect are presented.  
 An example compound prepared was I. Also processing citrus oils to obtain the  
 compds. is given as examples as well as assessment of human cytochrome P  
 450-mediated biotransformation.


IT 461443-59-4

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (spiro compds. for inhibiting the first-pass effect)

RN 461443-59-4 CAPLUS

CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-  
 dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]- (CA INDEX NAME)

Absolute stereochemistry.



L20 ANSWER 56 OF 59 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2003:334910 CAPLUS

DN 138:331734

TI Drugs comprising combination of triazaspiro[5.5]undecane derivative with cytochrome p450 isozyme 3a4 inhibitor and/or P-glycoprotein inhibitor

IN Imawaka, Haruo; Shibayama, Shiro; Takaoka, Yoshikazu

PA Ono Pharmaceutical Co., Ltd., Japan

SO PCT Int. Appl., 183 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003035074	A1	20030501	WO 2002-JP2552	20020318
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2461545	A1	20030501	CA 2002-2461545	20020318
	AU 2002238945	A1	20030506	AU 2002-238945	20020318
	EP 1438962	A1	20040721	EP 2002-705299	20020318
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	CN 1571671	A	20050126	CN 2002-820391	20020318
	BR 2002013372	A	20050201	BR 2002-13372	20020318
	HU 2005000028	A2	20050428	HU 2005-28	20020318
	NO 2004001618	A	20040722	NO 2004-1618	20040421
	MX 2004PA03816	A	20040730	MX 2004-PA3816	20040422
	ZA 2004003086	A	20050511	ZA 2004-3086	20040422
PRAI	JP 2001-324435	A	20011023		
	WO 2002-JP2552	W	20020318		

OS MARPAT 138:331734

AB Drugs comprising a combination of triazaspiro[5.5]undecane derivs. represented by the following general formula (I): I wherein each symbol is as will be defined hereinafter; quaternary ammonium salts thereof, N-oxides of the same or nontoxic salts of the same with at least one cytochrome P 450 isoenzyme 3A4 inhibitor and/or at least one P-glycoprotein inhibitor. The drugs comprising such a combination, wherein the bioavailability of the compds. represented by the general formula I is elevated, are efficaciously usable as oral preps. in treating various diseases.

IT 461443-59-4

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU


(Therapeutic use); BIOL (Biological study); USES (Uses)

(drugs comprising combination of triazaspiro[5.5]undecane derivative with cytochrome P 450 isoenzyme 3a4 inhibitor and/or P-glycoprotein inhibitor)

RN 461443-59-4 CAPLUS

CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT



L20 ANSWER 57 OF 59 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2002:736255 CAPLUS  
 DN 137:263065  
 TI Preparation of triazaspiro[5.5]undecane derivatives as active ingredients  
 in remedies for inflammatory diseases  
 IN Habashita, Hiromu; Hamano, Shinichi; Shibayama, Shiro; Takaoka, Yoshikazu  
 PA Ono Pharmaceutical Co., Ltd., Japan  
 SO PCT Int. Appl., 379 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA Japanese  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002074770	A1	20020926	WO 2002-JP2554	20020318
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2440264	A1	20020926	CA 2002-2440264	20020318
	AU 2002238947	A1	20021003	AU 2002-238947	20020318
	AU 2002238947	B2	20071018		
	EP 1378510	A1	20040107	EP 2002-705301	20020318
	EP 1378510	B1	20060607		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2002008167	A	20040309	BR 2002-8167	20020318
	CN 1518551	A	20040804	CN 2002-810082	20020318
	JP 3558079	B2	20040825	JP 2002-573779	20020318
	HU 2004000229	A2	20040830	HU 2004-229	20020318
	NZ 528249	A	20050324	NZ 2002-528249	20020318
	EP 1619194	A2	20060125	EP 2005-105154	20020318
	EP 1619194	A3	20060607		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
	RU 2269528	C2	20060210	RU 2003-128067	20020318
	AT 328884	T	20060615	AT 2002-705301	20020318
	PT 1378510	T	20060929	PT 2002-705301	20020318
	ES 2266452	T3	20070301	ES 2002-2705301	20020318
	TW 254047	B	20060501	TW 2002-91105129	20020319
	ZA 2003007167	A	20041101	ZA 2003-7167	20030912
	NO 2003004148	A	20031114	NO 2003-4148	20030917
	MX 2003PA08529	A	20040630	MX 2003-PA8529	20030919
	US 2004082584	A1	20040429	US 2003-472555	20030922
	US 7053090	B2	20060530		
	JP 2004196822	A	20040715	JP 2004-66592	20040310
	US 2005215557	A1	20050929	US 2005-135272	20050524
	US 7262193	B2	20070828		
PRAI	JP 2001-79610	A	20010319		
	JP 2001-160251	A	20010529		
	EP 2002-705301	A3	20020318		
	JP 2002-573779	A3	20020318		

WO 2002-JP2554 W 20020318  
 US 2003-472555 A1 20030922

OS MARPAT 137:263065

AB Title compds. [I; R1 = arylalkyl, nitrogen-containing-heterocyclalkyl; R2 = alkyl, alkynyl; R3 = H, alkyl; R4 = H, alkyl; R3R4 = CHR; R = alkyl; R5 = H, alkyl], quaternary ammonium salts thereof, N-oxides thereof, nontoxic salts thereof, and drugs containing the same as the active ingredient are prepared Title compds. I, inhibiting the effects of chemokine/chemokine receptor, are useful in preventing and/or treating various inflammatory diseases, asthma, atopic dermatitis, urticaria, allergic diseases, nephritis, nephropathy, hepatitis, arthritis, rheumatoid arthritis, tumor metastasis control, etc. Thus, the title compound II was prepared from (2R,3R)-2-(tert-butoxycarbonylamino)-3-hydroxy-4-methylpentanoic acid, n-butylamine, N-benzyl-4-piperidone, and benzylisonitrile via intramol. cyclocondensation.

IT 461019-79-4P 461023-63-2P 461024-09-9P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of triazaspiro[5.5]undecane derivs. as active ingredients in remedies for inflammatory diseases)

RN 461019-79-4 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-9-(phenylmethyl)-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 461023-63-2 CAPLUS

CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 461024-09-9 CAPLUS  
 CN Benzoic acid, 4-[4-[[ (3R)-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1-propyl-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

IT 461019-99-8P 461020-01-9P 461020-03-1P  
 461020-05-3P 461020-07-5P 461020-09-7P  
 461020-11-1P 461020-13-3P 461020-15-5P  
 461020-17-7P 461020-23-5P 461020-25-7P  
 461020-27-9P 461020-29-1P 461020-31-5P  
 461020-41-7P 461020-43-9P 461020-60-0P  
 461020-66-6P 461020-68-8P 461020-82-6P  
 461020-84-8P 461020-98-4P 461021-00-1P  
 461021-04-5P 461021-06-7P 461021-14-7P  
 461021-18-1P 461022-95-7P 461022-99-1P  
 461023-01-8P 461023-02-9P 461023-03-0P  
 461023-04-1P 461023-05-2P 461023-06-3P  
 461023-07-4P 461023-08-5P 461023-09-6P  
 461023-17-6P 461023-22-3P 461023-23-4P  
 461023-24-5P 461023-25-6P 461023-26-7P  
 461023-39-2P 461023-42-7P 461023-44-9P  
 461023-50-7P 461023-54-1P 461023-57-4P  
 461023-59-6P 461023-64-3P 461023-65-4P  
 461023-67-6P 461023-86-9P 461023-88-1P  
 461023-90-5P 461023-92-7P 461023-93-8P  
 461023-96-1P 461023-98-3P 461023-99-4P  
 461024-00-0P 461024-01-1P 461024-03-3P  
 461024-04-4P 461024-06-6P 461024-08-8P  
 461024-42-0P 461024-43-1P 461024-44-2P  
 461024-45-3P 461024-46-4P 461024-47-5P  
 461024-49-7P 461024-54-4P 461024-60-2P  
 461024-61-3P 461024-62-4P 461024-63-5P  
 461024-64-6P 461024-69-1P 461036-49-7P  
 461441-44-1P 461441-45-2P 461441-46-3P  
 461441-56-5P 461441-57-6P 461441-58-7P  
 461441-60-1P 461441-61-2P 461441-62-3P  
 461441-63-4P 461441-64-5P 461441-65-6P  
 461441-66-7P 461441-67-8P 461441-68-9P  
 461441-69-0P 461441-72-5P 461441-73-6P  
 461441-74-7P 461441-75-8P 461441-76-9P

461441-81-6P 461441-82-7P 461441-90-7P  
 461441-93-0P 461441-94-1P 461442-01-3P  
 461442-02-4P 461442-03-5P 461442-04-6P  
 461442-08-0P 461442-09-1P 461442-10-4P  
 461442-11-5P 461442-12-6P 461442-16-0P  
 461443-05-0P 461443-07-2P 461443-08-3P  
 461443-09-4P 461443-10-7P 461443-11-8P  
 461443-12-9P 461443-13-0P 461443-14-1P  
 461443-15-2P 461443-16-3P 461443-24-3P  
 461443-29-8P 461443-30-1P 461443-31-2P  
 461443-32-3P 461443-33-4P 461443-38-9P  
 461443-39-0P 461443-40-3P 461443-45-8P  
 461443-46-9P 461443-50-5P 461443-53-8P  
 461443-55-0P 461443-59-4P 461443-60-7P  
 461443-61-8P 461443-62-9P 461443-63-0P  
 461443-73-2P 461443-75-4P 461443-76-5P  
 461443-78-7P 461443-79-8P 461443-81-2P  
 461443-82-3P 461443-84-5P 461443-85-6P  
 461443-87-8P 461443-89-0P 461443-93-6P  
 461443-95-8P 461443-98-1P 461444-02-0P  
 461444-04-2P 461444-29-1P 461444-30-4P  
 461444-31-5P 461444-32-6P 461444-33-7P  
 461444-34-8P 461444-36-0P 461444-40-6P  
 461444-43-9P 461444-44-0P 461444-45-1P  
 461444-46-2P 461444-47-3P 461444-50-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of triazaspiro[5.5]undecane derivs. as active ingredients in remedies for inflammatory diseases)

RN 461019-99-8 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-9-[[4-(4-methoxyphenoxy)phenyl]methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 461020-01-9 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-9-[[4-(3-methoxyphenoxy)phenyl]methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 461020-03-1 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-9-[[4-(4-fluorophenoxy)phenyl]methyl]-3-[(1R)-1-hydroxy-2-methylpropyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 461020-05-3 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-9-[[4-(4-chlorophenoxy)phenyl]methyl]-3-[(1R)-1-hydroxy-2-methylpropyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 461020-07-5 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 9-[(4-benzoylphenyl)methyl]-1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 461020-09-7 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-9-[[4-(hydroxyphenylmethyl)phenyl]methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 461020-11-1 CAPLUS  
 CN Morpholine, 4-[4-[4-[[ (3R)-1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]benzoyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/527,435



● HCl

RN 461020-13-3 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-9-[[4-[(6-methyl-3-pyridinyl)oxy]phenyl]methyl]-, dihydrochloride, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●2 HCl

RN 461020-15-5 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-9-[[4-[(1-oxido-3-pyridinyl)oxy]phenyl]methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 461020-17-7 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-9-[[4-[(4-hydroxy-1-piperidinyl)methyl]phenyl]methyl]-, dihydrochloride, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl

RN 461020-23-5 CAPLUS  
 CN Benzenesulfonamide, 4-[4-[[ (3R)-1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 461020-25-7 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-9-[[4-[4-(methylthio)phenoxy]phenyl]methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/527,435



● HCl

RN 461020-27-9 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-9-[[4-[4-(methylsulfonyl)phenoxy]phenyl]methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 461020-29-1 CAPLUS  
 CN Benzonitrile, 4-[4-[[4-[(3R)-1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 461020-31-5 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-9-[[4-(phenylthio)phenyl]methyl]-, monohydrochloride, (3R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 461020-41-7 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-9-[[4-[(6-methyl-1-oxido-3-pyridinyl)oxy]phenyl]methyl]-, monohydrochloride, (3R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 461020-43-9 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-9-[[4-(4-hydroxyphenoxy)phenyl]methyl]-, monohydrochloride, (3R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/527,435



● HCl

RN 461020-60-0 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-9-[[4-[4-(methoxymethyl)phenoxy]phenyl]methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 461020-66-6 CAPLUS  
 CN Benzamide, 4-[4-[[4-[(3R)-1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 461020-68-8 CAPLUS  
 CN Benzamide, 4-[4-[[ (3R)-1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 461020-82-6 CAPLUS  
 CN Benzamide, 4-[4-[[ (3R)-1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-N-[2-(dimethylamino)ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A


● 2 HCl

PAGE 1-B

—NMe<sub>2</sub>

RN 461020-84-8 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-9-[[4-(3-pyridinyloxy)phenyl]methyl]-, dihydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 461020-98-4 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-9-[[4-(cyclohexyloxy)phenyl]methyl]-3-[(1R)-1-hydroxy-2-methylpropyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 461021-00-1 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-9-[[4-[(tetrahydro-2H-pyran-4-yl)oxy]phenyl]methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 461021-04-5 CAPLUS  
 CN Benzamide, 4-[[[(3R)-1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]-N-cyclohexyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 461021-06-7 CAPLUS  
 CN Pyrrolidine, 1-[4-[4-[[[(3R)-1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]benzoyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 461021-14-7 CAPLUS  
 CN Benzamide, 4-[4-[[[(3R)-1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-N-(2-hydroxyethyl)-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 461021-18-1 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-9-[[4-[4-(hydroxymethyl)phenoxy]phenyl]methyl]-3-[(1R)-1-hydroxy-2-methylpropyl]-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 461022-95-7 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[(4-phenoxyphenyl)methyl]-, hydrochloride (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 461022-99-1 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[[4-(4-fluorophenoxy)phenyl]methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 461023-01-8 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-9-[[4-(4-chlorophenoxy)phenyl]methyl]-3-[(R)-cyclohexylhydroxymethyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl


RN 461023-02-9 CAPLUS

CN Benzonitrile, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/527,435



● HCl

RN 461023-03-0 CAPLUS  
 CN Methanesulfonamide, N-[4-[4-[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 461023-04-1 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[[4-[(6-methyl-3-pyridinyl)oxy]phenyl]methyl]-, dihydrochloride, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl

RN 461023-05-2 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[[4-(1-methylethyl)phenyl]methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 461023-06-3 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[[4-[4-(methylsulfonyl)phenoxy]phenyl]methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 461023-07-4 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[[4-[(tetrahydro-2H-pyran-4-yl)oxy]phenyl]methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/527,435



● HCl

RN 461023-08-5 CAPLUS  
CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 9-[(4-benzoylphenyl)methyl]-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-, monohydrochloride, (3R)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 461023-09-6 CAPLUS  
CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[[4-(hydroxyphenylmethyl)phenyl]methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 461023-17-6 CAPLUS

CN Methanesulfonamide, N-[4-[[ (3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenyl]-N-(methylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 461023-22-3 CAPLUS

CN Benzamide, 4-[[ (3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 461023-23-4 CAPLUS

CN Benamide, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-, monohydrochloride (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 461023-24-5 CAPLUS

CN Benzenesulfonamide, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 461023-25-6 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[[4-[(6-methyl-1-oxido-3-pyridinyl)oxy]phenyl]methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 461023-26-7 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[[4-(4-hydroxyphenoxy)phenyl]methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 461023-39-2 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[[4-(4-methoxyphenoxy)phenyl]methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 461023-42-7 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[[4-(3-methoxyphenoxy)phenyl]methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 461023-44-9 CAPLUS  
 CN Benzamide, 4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]-N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 461023-50-7 CAPLUS  
 CN Benzamide, 4-[4-[[ (3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-N-[2-(dimethylamino)ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




● 2 HCl

PAGE 1-B



RN 461023-54-1 CAPLUS  
 CN Morpholine, 4-[4-[4-[[ (3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]benzoyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 461023-57-4 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[[4-[(1-oxido-3-pyridinyl)oxy]phenyl)methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)



Absolute stereochemistry.




● HCl

RN 461023-59-6 CAPLUS

CN Benzamide, 4-[4-[[ (3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 461023-64-3 CAPLUS

CN Benzamide, 4-[[ (3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]-N-[(4-methoxyphenyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 461023-65-4 CAPLUS  
 CN Benzamide, 4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]-N-(3-methoxypropyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 461023-67-6 CAPLUS  
 CN Pyrrolidine, 1-[4-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]benzoyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/527,435



● HCl

RN	461023-86-9	CAPLUS
CN	Benzamide, 4-[[ (3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]-N-cyclohexyl-, monohydrochloride (9CI) (CA INDEX NAME)	

Absolute stereochemistry.




● HCl

RN	461023-88-1	CAPLUS
CN	Benzamide, 4-[4-[[ (3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-N-(2-hydroxyethyl)-, monohydrochloride (9CI) (CA INDEX NAME)	

Absolute stereochemistry.

PAGE 1-A



● HCl


PAGE 1-B



RN 461023-90-5 CAPLUS

CN Methanesulfonamide, N-[4-[4-[[[(3S)-1-butyl-3-[(S)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 461023-92-7 CAPLUS

CN Benzamide, 4-[4-[[[(3R)-1-butyl-3-[(R)-hydroxy(tetrahydro-2H-pyran-4-yl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/527,435



● HCl

RN 461023-93-8 CAPLUS  
 CN Benzamide, 4-[[ (3R)-1-butyl-3-[(R)-hydroxy(tetrahydro-2H-pyran-4-yl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]-N-[(4-methoxyphenyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 461023-96-1 CAPLUS  
 CN Methanesulfonamide, N-[4-[4-[[ (3R)-1-butyl-3-[(R)-hydroxy(tetrahydro-2H-pyran-4-yl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 461023-98-3 CAPLUS  
 CN Benzamide, 4-[[[(3R)-1-butyl-3-[(R)-cyclopentylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]-N-[(4-methoxyphenyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 461023-99-4 CAPLUS  
 CN Benzamide, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclopentylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 461024-00-0 CAPLUS  
 CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclopentylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 461024-01-1 CAPLUS  
 CN Benzamide, 4-[4-[[ (3R)-3-[(1R)-1-hydroxy-2-methylpropyl]-2,5-dioxo-1-propyl-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 461024-03-3 CAPLUS  
 CN Benzamide, 4-[4-[[ (3R)-3-[(1R)-1-hydroxy-2-methylpropyl]-2,5-dioxo-1-propyl-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]-N-[(4-methoxyphenyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 461024-04-4 CAPLUS  
 CN Benzamide, 4-[4-[[ (3R)-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1-propyl-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 461024-06-6 CAPLUS  
 CN Benzamide, 4-[[ (3R)-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1-propyl-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]-N-[(4-methoxyphenyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 461024-08-8 CAPLUS  
 CN Benzoic acid, 4-[4-[[ (3R)-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1-propyl-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.






● HCl

RN 461024-42-0 CAPLUS  
 CN Propanamide, N-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenyl]-2-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 461024-43-1 CAPLUS  
 CN Acetamide, N-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenyl]-2-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 461024-44-2 CAPLUS  
 CN Benzeneacetamide, N-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 461024-45-3 CAPLUS  
 CN Benzeneacetamide, N-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenyl]-4-fluoro-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 461024-46-4 CAPLUS  
 CN Benzoic acid, 4-[[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]benzoyl]amino]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 461024-47-5 CAPLUS

CN Benzoic acid, 4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]-, (4-methoxyphenyl)methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 461024-49-7 CAPLUS

CN Benzoic acid, 4-[4-[[[(3S)-1-butyl-3-[(S)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 461024-54-4 CAPLUS  
 CN Benzamide, 4-[4-[[ (3S)-1-butyl-3-(hydroxymethyl)-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 461024-60-2 CAPLUS  
 CN Benzamide, 4-[4-[[ (3R)-3-[(R)-cyclohexylhydroxymethyl]-1-[(4-methoxyphenyl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 461024-61-3 CAPLUS

CN Benzamide, 4-[4-[[ (3R)-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1-(phenylmethyl)-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 461024-62-4 CAPLUS

CN Benzamide, 4-[4-[[ (3R)-3-[(R)-cyclohexylhydroxymethyl]-1-(2-methoxyethyl)-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 461024-63-5 CAPLUS

CN Benzamide, 4-[4-[[ (3R)-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1-(2-pyridinylmethyl)-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-N-methyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 461024-64-6 CAPLUS

CN Benzamide, 4-[4-[[ (3R)-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1-(3-pyridinylmethyl)-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-N-methyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 461024-69-1 CAPLUS

CN Benzamide, 4-[4-[[ (3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-N-hydroxy-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 461036-49-7 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[[4-[4-(methylsulfinyl)phenoxy]phenyl]methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/527,435




● HCl

RN 461441-44-1 CAPLUS

CN	Benzoic acid, 4-[4-[[ (3R)-1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)
----	---

Absolute stereochemistry.




● HCl

RN 461441-45-2 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-9-[[4-(4-methylphenoxy)phenyl]methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl



RN 461441-46-3 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-9-[[4-[[4-methoxyphenyl)methyl]amino]phenyl]methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 461441-56-5 CAPLUS  
 CN Benzamide, 4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]-N-methyl-N-[2-(2-pyridinyl)ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl

RN 461441-57-6 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[[4-[4-(hydroxymethyl)phenoxy]phenyl]methyl]-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 461441-58-7 CAPLUS

CN Benzoic acid, 4-[4-[[ (3R)-1-butyl-3-[(R)-hydroxy(tetrahydro-2H-pyran-4-yl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 461441-60-1 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-9-[[4-(4-methoxyphenoxy)phenyl]methyl]-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 461441-61-2 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-9-[[4-(3-methoxyphenoxy)phenyl]methyl]-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 461441-62-3 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-9-[[4-(4-fluorophenoxy)phenyl]methyl]-3-[(1R)-1-hydroxy-2-methylpropyl]-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 461441-63-4 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-9-[[4-(4-chlorophenoxy)phenyl]methyl]-3-[(1R)-1-hydroxy-2-methylpropyl]-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 461441-64-5 CAPLUS


CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 9-[(4-benzoylphenyl)methyl]-1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 461441-65-6 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-9-[[4-(hydroxyphenylmethyl)phenyl]methyl]-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 461441-66-7 CAPLUS  
 CN Morpholine, 4-[4-[4-[(3R)-1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 461441-67-8 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-9-[[4-[(6-methyl-3-pyridinyl)oxy]phenyl]methyl]-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 461441-68-9 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-9-[[4-[(1-oxido-3-pyridinyl)oxy]phenyl]methyl]-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 461441-69-0 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-9-[[4-[(4-hydroxy-1-piperidinyl)methyl]phenyl]methyl]-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 461441-72-5 CAPLUS

CN Benzenesulfonamide, 4-[4-[[[(3R)-1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 461441-73-6 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-9-[[4-[4-(methylthio)phenoxy]phenyl]methyl]-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 461441-74-7 CAPLUS

CN	1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-9-[[4-[4-(methylsulfonyl)phenoxy]phenyl]methyl]-, (3R)- (CA INDEX NAME)	(CA
----	---	-----


Absolute stereochemistry.



RN 461441-75-8 CAPLUS


CN Benzonitrile, 4-[4-[[ (3R)-1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 461441-76-9 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-9-[[4-(phenylthio)phenyl]methyl]-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 461441-81-6 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-9-[[4-[(6-methyl-1-oxido-3-pyridinyl)oxy]phenyl]methyl]-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 461441-82-7 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-9-[[4-(4-hydroxyphenoxy)phenyl]methyl]-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 461441-90-7 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-9-[[4-[4-(methoxymethyl)phenoxy]phenyl]methyl]-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 461441-93-0 CAPLUS

CN Benzamide, 4-[4-[[ (3R)-1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 461441-94-1 CAPLUS

CN Benzamide, 4-[4-[[ (3R)-1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.






RN 461442-01-3 CAPLUS

CN Benzamide, 4-[4-[[ (3R)-1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-N-[2-(dimethylamino)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—NMe<sub>2</sub>

RN 461442-02-4 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-9-[[4-(3-pyridinyloxy)phenyl]methyl]-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 461442-03-5 CAPLUS

CN Benzoic acid, 4-[4-[[ (3R)-1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 461442-04-6 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-9-[[4-(4-methylphenoxy)phenyl]methyl]-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 461442-08-0 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-9-[[4-(cyclohexyloxy)phenyl]methyl]-3-[(1R)-1-hydroxy-2-methylpropyl]-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 461442-09-1 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-9-[[4-[(tetrahydro-2H-pyran-4-yl)oxy]phenyl]methyl]-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 461442-10-4 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-9-[[4-[[4-methoxyphenyl)methyl]amino]phenyl]methyl-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 461442-11-5 CAPLUS

CN Benzamide, 4-[[4-[[4-methoxyphenyl)methyl]amino]phenyl]methyl]-N-cyclohexyl-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 461442-12-6 CAPLUS

CN Pyrrolidine, 1-[4-[4-[[4-methoxyphenyl)methyl]amino]phenyl]methyl]-N-cyclohexyl-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 461442-16-0 CAPLUS

CN	Benzamide, 4-[4-[[ (3R)-1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-N-(2-hydroxyethyl)- (CA INDEX NAME)
----	--


Absolute stereochemistry.



RN 461443-05-0 CAPLUS

CN	1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[(4-phenoxyphenyl)methyl]-, (3R)- (CA INDEX NAME)	
----	--	--


Absolute stereochemistry.



RN 461443-07-2 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[[4-(4-fluorophenoxy)phenyl]methyl]-, (3R)-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 461443-08-3 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-9-[[4-(4-chlorophenoxy)phenyl]methyl]-3-[(R)-cyclohexylhydroxymethyl]-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 461443-09-4 CAPLUS

CN Benzonitrile, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 461443-10-7 CAPLUS

CN Methanesulfonamide, N-[4-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 461443-11-8 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[[4-[(6-methyl-3-pyridinyl)oxy]phenyl]methyl]-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 461443-12-9 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[[4-(1-methylethyl)phenyl]methyl]-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 461443-13-0 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[[4-[4-(methylsulfinyl)phenoxy]phenyl]methyl]-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 461443-14-1 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[[4-[(tetrahydro-2H-pyran-4-yl)oxy]phenyl]methyl]-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 461443-15-2 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 9-[(4-benzoylphenyl)methyl]-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 461443-16-3 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[[4-(hydroxyphenylmethyl)phenyl]methyl]-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 461443-24-3 CAPLUS

CN Methanesulfonamide, N-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenyl]-N-(methylsulfonyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 461443-29-8 CAPLUS

CN Benzamide, 4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 461443-30-1 CAPLUS

CN Benzamide, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]- (CA INDEX NAME)

Absolute stereochemistry.






RN 461443-31-2 CAPLUS

CN Benzenesulfonamide, 4-[4-[[ (3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 461443-32-3 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[[4-[(6-methyl-1-oxido-3-pyridinyl)oxy]phenyl]methyl]-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 461443-33-4 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[[4-(4-hydroxyphenoxy)phenyl]methyl]-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 461443-38-9 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[[4-(4-methoxyphenoxy)phenyl]methyl]-, (3R)-(CA INDEX NAME)


Absolute stereochemistry.



RN 461443-39-0 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[[4-(3-methoxyphenoxy)phenyl]methyl]-, (3R)-(CA INDEX NAME)


Absolute stereochemistry.



RN 461443-40-3 CAPLUS

CN Benzamide, 4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]-N,N-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 461443-45-8 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[[4-[(4-(dimethylamino)phenyl)methyl]phenoxy]phenyl]methyl]-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 461443-46-9 CAPLUS

CN Benzamide, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-N-[2-(dimethylamino)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 461443-50-5 CAPLUS

CN Morpholine, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-

dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]benzoyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 461443-53-8 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[[4-[(1-oxido-3-pyridinyl)oxy]phenyl]methyl]-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 461443-55-0 CAPLUS

CN Benamide, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-N-methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 461443-59-4 CAPLUS

CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 461443-60-7 CAPLUS

CN Benzamide, 4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]-N-[(4-methoxyphenyl)methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 461443-61-8 CAPLUS

CN Benzamide, 4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]-N-(3-methoxypropyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 461443-62-9 CAPLUS

CN Benzamide, 4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]-N-methyl-N-[2-(2-pyridinyl)ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 461443-63-0 CAPLUS

CN Pyrrolidine, 1-[4-[4-[[ (3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]benzoyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 461443-73-2 CAPLUS

CN Benzamide, 4-[[ (3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]-N-cyclohexyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 461443-75-4 CAPLUS

CN Benzamide, 4-[4-[[ (3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-N-(2-hydroxyethyl)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 461443-76-5 CAPLUS

CN Methanesulfonamide, N-[4-[4-[[ (3S)-1-butyl-3-[(S)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 461443-78-7 CAPLUS

CN Benzamide, 4-[4-[[ (3R)-1-butyl-3-[(R)-hydroxy(tetrahydro-2H-pyran-4-yl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 461443-79-8 CAPLUS

CN Benzamide, 4-[[ (3R)-1-butyl-3-[(R)-hydroxy(tetrahydro-2H-pyran-4-yl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]-N-[(4-

methoxyphenyl)methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 461443-81-2 CAPLUS

CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-hydroxy(tetrahydro-2H-pyran-4-yl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 461443-82-3 CAPLUS

CN Methanesulfonamide, N-[4-[4-[[[(3R)-1-butyl-3-[(R)-hydroxy(tetrahydro-2H-pyran-4-yl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 461443-84-5 CAPLUS

CN Benzamide, 4-[[[(3R)-1-butyl-3-[(R)-cyclopentylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]-N-[(4-methoxyphenyl)methyl]- (CA INDEX NAME)


Absolute stereochemistry.






RN 461443-85-6 CAPLUS  
 CN Benzamide, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclopentylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 461443-87-8 CAPLUS  
 CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclopentylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 461443-89-0 CAPLUS  
 CN Benzamide, 4-[4-[[[(3R)-3-[(1R)-1-hydroxy-2-methylpropyl]-2,5-dioxo-1-propyl-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 461443-93-6 CAPLUS

CN Benzamide, 4-[[[(3R)-3-[(1R)-1-hydroxy-2-methylpropyl]-2,5-dioxo-1-propyl-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]-N-[(4-methoxyphenyl)methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 461443-95-8 CAPLUS

CN Benzamide, 4-[4-[[[(3R)-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1-propyl-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 461443-98-1 CAPLUS

CN Benzamide, 4-[[[(3R)-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1-propyl-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]-N-[(4-methoxyphenyl)methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 461444-02-0 CAPLUS

CN Benzoic acid, 4-[4-[[[(3R)-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1-propyl-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 461444-04-2 CAPLUS

CN Benzoic acid, 4-[4-[[[(3R)-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1-propyl-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 461444-29-1 CAPLUS

CN Propanamide, N-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 461444-30-4 CAPLUS

CN Acetamide, N-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenyl]-2-methoxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 461444-31-5 CAPLUS

CN Benzeneacetamide, N-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 461444-32-6 CAPLUS

CN Benzeneacetamide, N-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenyl]-4-fluoro- (CA INDEX NAME)


Absolute stereochemistry.



RN 461444-33-7 CAPLUS

CN Benzoic acid, 4-[[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]benzoyl]amino]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 461444-34-8 CAPLUS

CN Benzoic acid, 4-[[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]-, (4-methoxyphenyl)methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 461444-36-0 CAPLUS

CN Benzoic acid, 4-[[4-[[[(3S)-1-butyl-3-[(S)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 461444-40-6 CAPLUS

CN Benzamide, 4-[4-[[ (3S)-1-butyl-3-(hydroxymethyl)-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 461444-43-9 CAPLUS

CN Benzamide, 4-[4-[[ (3R)-3-[(R)-cyclohexylhydroxymethyl]-1-[(4-methoxyphenyl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 461444-44-0 CAPLUS

CN Benzamide, 4-[4-[[ (3R)-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1-(phenylmethyl)-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 461444-45-1 CAPLUS

CN Benzamide, 4-[4-[[ (3R)-3-[(R)-cyclohexylhydroxymethyl]-1-(2-methoxyethyl)-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 461444-46-2 CAPLUS

CN Benzamide, 4-[4-[[ (3R)-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1-(2-pyridinylmethyl)-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 461444-47-3 CAPLUS

CN Benzamide, 4-[4-[[ (3R)-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1-(3-

pyridinylmethyl)-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-N-methyl-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 461444-50-8 CAPLUS

CN Benzamide, 4-[4-[[ (3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-N-hydroxy- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT



L20 ANSWER 58 OF 59 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2002:736254 CAPLUS

DN 137:263064

TI Preparation of triazaspiro[5.5]undecane derivatives as the active ingredients useful in prevention or as remedy for HIV infection

IN Mitsuya, Hiroaki; Maeda, Kenji; Shibayama, Shiro; Takaoka, Yoshikazu

PA Ono Pharmaceutical Co., Ltd., Japan

SO PCT Int. Appl., 680 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002074769	A1	20020926	WO 2002-JP2553	20020318
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2441162	A1	20020926	CA 2002-2441162	20020318
	AU 2002238946	A1	20021003	AU 2002-238946	20020318
	EP 1378509	A1	20040107	EP 2002-705300	20020318
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2002008229	A	20040309	BR 2002-8229	20020318
	HU 2004000241	A2	20040628	HU 2004-241	20020318
	CN 1533390	A	20040929	CN 2002-809833	20020318
	NZ 528270	A	20051028	NZ 2002-528270	20020318
	NO 2003004149	A	20031119	NO 2003-4149	20030917
	ZA 2003007318	A	20040729	ZA 2003-7318	20030918
	MX 2003PA08528	A	20040630	MX 2003-PA8528	20030919
	US 2004106619	A1	20040603	US 2003-472626	20030922
	US 7285552	B2	20071023		
PRAI	JP 2001-79611	A	20010319		
	WO 2002-JP2553	W	20020318		

OS MARPAT 137:263064

AB Title compds. [I; R1 = H, alkyl, alkenyl, alkynyl, COOH, SO<sub>2</sub>H, CONH<sub>2</sub>, CHO, heterocycle, aryl; R2 = alkyl, alkynyl; R3, R4 independently = H, alkyl, alkenyl, alkynyl, COOH, CONH<sub>2</sub>; R5 = H, alkyl, alkenyl, alkynyl], stereoisomers, quaternary ammonium salts thereof, N-oxides thereof and nontoxic salts of the same optionally combined with at least one preventive and/or remedy for HIV infection are prepared as preventives and/or remedies for HIV infection or preventives and/or remedies for AIDS caused by the infection. Thus, the title compound II·2HCl was prepared from N-(tert-butyloxycarbonyl)leucine, N-allyloxycarbonyl-4-piperidine, n-propylamine, and 3,5-dimethyl-1-phenyl-4-formyl-pyrazole via cyclization, on resin prepared from aminomethylated polystyrene hydrchloride.

IT 461019-79-4P 461023-63-2P 461024-09-9P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of triazaspiro[5.5]undecane derivs. as the active ingredients in prevention or remedy of HIV infection)

RN 461019-79-4 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-9-(phenylmethyl)-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 461023-63-2 CAPLUS

CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 461024-09-9 CAPLUS

CN Benzoic acid, 4-[4-[[[(3R)-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1-propyl-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

IT 342914-87-8P 343272-98-0P 343272-99-1P  
 343274-41-9P 343276-63-1P 343276-66-4P  
 343276-67-5P 343276-68-6P 343276-69-7P  
 343276-70-0P 343276-73-3P 343276-76-6P  
 343276-78-8P 343276-79-9P 343276-81-3P  
 343276-82-4P 343276-83-5P 343276-86-8P  
 343276-87-9P 343276-88-0P 343276-92-6P  
 343276-94-8P 343276-95-9P 343276-97-1P  
 343277-02-1P 343277-04-3P 343277-06-5P  
 343277-08-7P 343277-12-3P 343277-16-7P  
 461018-99-5P 461019-99-8P 461020-01-9P  
 461020-03-1P 461020-05-3P 461020-07-5P  
 461020-09-7P 461020-11-1P 461020-13-3P  
 461020-15-5P 461020-17-7P 461020-23-5P  
 461020-25-7P 461020-27-9P 461020-29-1P  
 461020-31-5P 461020-41-7P 461020-43-9P  
 461020-60-0P 461020-66-6P 461020-68-8P  
 461020-82-6P 461020-84-8P 461020-86-0P  
 461020-88-2P 461020-98-4P 461021-00-1P  
 461021-02-3P 461021-04-5P 461021-06-7P  
 461021-14-7P 461021-18-1P 461022-95-7P  
 461022-99-1P 461023-01-8P 461023-02-9P  
 461023-03-0P 461023-04-1P 461023-05-2P  
 461023-06-3P 461023-07-4P 461023-08-5P  
 461023-09-6P 461023-17-6P 461023-22-3P  
 461023-23-4P 461023-24-5P 461023-25-6P  
 461023-26-7P 461023-39-2P 461023-42-7P  
 461023-44-9P 461023-50-7P 461023-54-1P  
 461023-57-4P 461023-59-6P 461023-64-3P  
 461023-65-4P 461023-66-5P 461023-67-6P  
 461023-86-9P 461023-88-1P 461023-89-2P  
 461023-90-5P 461023-92-7P 461023-93-8P  
 461023-95-0P 461023-96-1P 461023-98-3P  
 461023-99-4P 461024-00-0P 461024-01-1P  
 461024-03-3P 461024-04-4P 461024-06-6P  
 461024-08-8P 461024-42-0P 461024-43-1P  
 461024-44-2P 461024-45-3P 461024-46-4P  
 461024-47-5P 461024-49-7P 461024-54-4P  
 461024-60-2P 461024-61-3P 461024-62-4P  
 461024-63-5P 461024-64-6P 461024-69-1P  
 461036-49-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU


(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)

(preparation of triazaspiro[5.5]undecane derivs. as the active ingredients  
in prevention or remedy of HIV infection)

RN 342914-87-8 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-  
cyclohexylhydroxymethyl]-9-(phenylmethyl)-, (3S)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 343272-98-0 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(1R)-1-hydroxy-2-  
methylpropyl]-9-[(4-phenoxyphenyl)methyl]-, hydrochloride (1:1), (3S)-  
(CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 343272-99-1 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(1S)-1-hydroxy-2-  
methylpropyl]-9-[(4-phenoxyphenyl)methyl]-, hydrochloride (1:1), (3R)-  
(CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 343274-41-9 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-(hydroxymethyl)-9-[(4-phenoxyphenyl)methyl]-, monohydrochloride, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 343276-63-1 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-9-[(4-phenoxyphenyl)methyl]-, monohydrochloride, (3R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 343276-66-4 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-9-[[4-(4-methylphenoxy)phenyl]methyl]-, monohydrochloride, (3R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 343276-67-5 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-9-[[4-(cyclohexyloxy)phenyl]methyl]-3-[(1R)-1-hydroxy-2-methylpropyl]-, monohydrochloride, (3R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 343276-68-6 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-9-[[4-[(tetrahydro-2H-pyran-4-yl)oxy]phenyl]methyl]-, monohydrochloride, (3R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 343276-69-7 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-9-[[4-(3-pyridinyloxy)phenyl]methyl]-, dihydrochloride, (3R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 343276-70-0 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-9-[[4-(1-methylethyl)phenyl]methyl]-, monohydrochloride, (3R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 343276-73-3 CAPLUS  
 CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-, monohydrochloride, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 343276-76-6 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[(4-phenoxyphenyl)methyl]-, monohydrochloride, (3R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 343276-78-8 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[[4-(1-methylethyl)phenyl]methyl]-, monohydrochloride, (3R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.






● HCl

RN 343276-79-9 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[[4-[(6-methyl-3-pyridinyl)oxy]phenyl]methyl]-, dihydrochloride, (3R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 343276-81-3 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[[4-(4-methoxyphenoxy)phenyl]methyl]-, monohydrochloride, (3R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 343276-82-4 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[[4-(4-fluorophenoxy)phenyl]methyl]-, monohydrochloride, (3R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 343276-83-5 CAPLUS  
 CN Methanesulfonamide, N-[4-[4-[[ (3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]phenyl]-, monohydrochloride, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 343276-86-8 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-(2-butynyl)-3-[(R)-cyclohexylhydroxymethyl]-9-[[4-(1-methylethyl)phenyl]methyl]-, monohydrochloride, (3R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 343276-87-9 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-(2-butynyl)-3-[(R)-cyclohexylhydroxymethyl]-9-[(4-phenoxyphenyl)methyl]-, monohydrochloride, (3R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 343276-88-0 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-(2-butynyl)-3-[(R)-cyclohexylhydroxymethyl]-9-[[4-(4-methylphenoxy)phenyl]methyl]-, monohydrochloride, (3R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 343276-92-6 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-(2-butynyl)-3-[(1R)-1-hydroxy-2-methylpropyl]-9-[[4-(4-methylphenoxy)phenyl]methyl]-, monohydrochloride, (3R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 343276-94-8 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-(2-butynyl)-3-[(1R)-1-hydroxy-2-methylpropyl]-9-[[4-(1-methylethyl)phenyl]methyl]-, monohydrochloride,

(3R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 343276-95-9 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-(2-butynyl)-3-[(1R)-1-hydroxy-2-methylpropyl]-9-[(4-phenoxyphenyl)methyl]-, monohydrochloride, (3R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 343276-97-1 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[(4-phenoxyphenyl)methyl]-, monohydrochloride, (3S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


10/527,435



● HCl

RN 343277-02-1 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(1S)-1-hydroxy-2-methylpropyl]-9-[(4-phenoxyphenyl)methyl]-, hydrochloride (1:1), (3S)- (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 343277-04-3 CAPLUS  
 CN Methanesulfonamide, N-[4-[4-[[[(3S)-1-butyl-3-[(1S)-1-hydroxy-2-methylpropyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 343277-06-5 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-9-[(4-phenoxyphenyl)methyl]-, hydrochloride (1:1), (3R)-(CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 343277-08-7 CAPLUS  
 CN Methanesulfonamide, N-[4-[4-[[ (3R)-1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 343277-12-3 CAPLUS  
 CN Methanesulfonamide, N-[4-[4-[[ (3R)-1-butyl-3-[(1S)-1-hydroxy-2-methylpropyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/527,435



● HCl

RN 343277-16-7 CAPLUS  
 CN Methanesulfonamide, N-[4-[4-[(3S)-1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 461018-99-5 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(1R)-1-hydroxyethyl]-9-[(4-phenoxyphenyl)methyl]-, monohydrochloride, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl



RN 461019-99-8 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-9-[[4-(4-methoxyphenoxy)phenyl]methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 461020-01-9 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-9-[[4-(3-methoxyphenoxy)phenyl]methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 461020-03-1 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-9-[[4-(4-fluorophenoxy)phenyl]methyl]-3-[(1R)-1-hydroxy-2-methylpropyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/527,435



● HCl

RN 461020-05-3 CAPLUS  
CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-9-[[4-(4-chlorophenoxy)phenyl]methyl]-3-[(1R)-1-hydroxy-2-methylpropyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 461020-07-5 CAPLUS  
CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 9-[(4-benzoylphenyl)methyl]-1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 461020-09-7 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-9-[[4-(hydroxyphenylmethyl)phenyl]methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 461020-11-1 CAPLUS

CN Morpholine, 4-[4-[4-[[ (3R)-1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]benzoyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 461020-13-3 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-9-[[4-[(6-methyl-3-pyridinyl)oxy]phenyl]methyl]-, dihydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/527,435



● 2 HCl

RN 461020-15-5 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-9-[[4-[(1-oxido-3-pyridinyl)oxy]phenyl]methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 461020-17-7 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-9-[[4-[(4-hydroxy-1-piperidinyl)methyl]phenyl]methyl]-, dihydrochloride, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl

RN 461020-23-5 CAPLUS  
 CN Benzenesulfonamide, 4-[4-[[ (3R)-1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 461020-25-7 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-9-[[4-[4-(methylthio)phenoxy]phenyl]methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 461020-27-9 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-9-[[4-[4-(methylsulfonyl)phenoxy]phenyl]methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/527,435



● HCl

RN 461020-29-1 CAPLUS  
 CN Benzonitrile, 4-[4-[[ (3R)-1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 461020-31-5 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-9-[[4-(phenylthio)phenyl]methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 461020-41-7 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-9-[[4-[(6-methyl-1-oxido-3-pyridinyl)oxy]phenyl]methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 461020-43-9 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-9-[[4-(4-hydroxyphenoxy)phenyl]methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 461020-60-0 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-9-[[4-[4-(methylsulfinyl)phenoxy]phenyl]methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/527,435



● HCl

RN 461020-66-6 CAPLUS  
 CN Benzamide, 4-[4-[[ (3R)-1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-, monohydrochloride (9CI)  
 (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 461020-68-8 CAPLUS  
 CN Benzamide, 4-[4-[[ (3R)-1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl



RN 461020-82-6 CAPLUS  
 CN Benzamide, 4-[4-[[ (3R)-1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-N-[2-(dimethylamino)ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




● 2 HCl

PAGE 1-B

—NMe<sub>2</sub>

RN 461020-84-8 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-9-[[4-(3-pyridinyloxy)phenyl]methyl]-, dihydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 461020-86-0 CAPLUS  
 CN Benzoic acid, 4-[4-[[ (3R)-1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/527,435



● 2 HCl

RN 461020-88-2 CAPLUS  
CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-9-[[4-(4-methylphenoxy)phenyl]methyl]-, dihydrochloride, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl

RN 461020-98-4 CAPLUS  
CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-9-[[4-(cyclohexyloxy)phenyl]methyl]-3-[(1R)-1-hydroxy-2-methylpropyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 461021-00-1 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-9-[[4-[(tetrahydro-2H-pyran-4-yl)oxy]phenyl]methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 461021-02-3 CAPLUS  
 CN Benzamide, 4-[[[(3R)-1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]-N-[(4-methoxyphenyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 461021-04-5 CAPLUS  
 CN Benzamide, 4-[[[(3R)-1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]-N-cyclohexyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 461021-06-7 CAPLUS  
 CN Pyrrolidine, 1-[4-[4-[(3R)-1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]benzoyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 461021-14-7 CAPLUS  
 CN Benzamide, 4-[4-[(3R)-1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-N-(2-hydroxyethyl)-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 461021-18-1 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-9-[[4-[4-(hydroxymethyl)phenoxy]phenyl]methyl]-3-[(1R)-1-hydroxy-2-methylpropyl]-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 461022-95-7 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[[4-(4-phenoxyphenyl)methyl]-, hydrochloride (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 461022-99-1 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[[4-(4-fluorophenoxy)phenyl]methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 461023-01-8 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-9-[[4-(4-chlorophenoxy)phenyl]methyl]-3-[(R)-cyclohexylhydroxymethyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 461023-02-9 CAPLUS

CN Benzonitrile, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenyl]methoxy]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/527,435



● HCl

RN 461023-03-0 CAPLUS  
 CN Methanesulfonamide, N-[4-[4-[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 461023-04-1 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[[4-[(6-methyl-3-pyridinyl)oxy]phenyl]methyl]-, dihydrochloride, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl

RN 461023-05-2 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[[4-(1-methylethyl)phenyl]methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 461023-06-3 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[[4-[4-(methylsulfonyl)phenoxy]phenyl]methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 461023-07-4 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[[4-[(tetrahydro-2H-pyran-4-yl)oxy]phenyl]methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/527,435



● HCl

RN 461023-08-5 CAPLUS  
CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 9-[(4-benzoylphenyl)methyl]-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-, monohydrochloride, (3R)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 461023-09-6 CAPLUS  
CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[[4-(hydroxyphenylmethyl)phenyl]methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 461023-17-6 CAPLUS

CN Methanesulfonamide, N-[4-[[ (3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenyl]-N-(methylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 461023-22-3 CAPLUS

CN Benzamide, 4-[[ (3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 461023-23-4 CAPLUS

CN Benzanide, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-, monohydrochloride (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 461023-24-5 CAPLUS

CN Benzenesulfonamide, 4-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 461023-25-6 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[[4-[(6-methyl-1-oxido-3-pyridinyl)oxy]phenyl]methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 461023-26-7 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[[4-(4-hydroxyphenoxy)phenyl]methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 461023-39-2 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[[4-(4-methoxyphenoxy)phenyl]methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 461023-42-7 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[[4-(3-methoxyphenoxy)phenyl]methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 461023-44-9 CAPLUS  
 CN Benzamide, 4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]-N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 461023-50-7 CAPLUS  
 CN Benzamide, 4-[4-[[ (3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-N-[2-(dimethylamino)ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




● 2 HCl

PAGE 1-B



RN 461023-54-1 CAPLUS  
 CN Morpholine, 4-[4-[4-[[ (3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]benzoyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 461023-57-4 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[[4-[(1-oxido-3-pyridinyl)oxy]phenyl]methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)

10/527,435

Absolute stereochemistry.




● HCl

RN 461023-59-6 CAPLUS

CN Benzamide, 4-[4-[[ (3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 461023-64-3 CAPLUS

CN Benzamide, 4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]-N-[(4-methoxyphenyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 461023-65-4 CAPLUS  
 CN Benzamide, 4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]-N-(3-methoxypropyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 461023-66-5 CAPLUS  
 CN Benzamide, 4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]-N-methyl-N-[2-(2-pyridinyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.






● HCl

RN 461023-67-6 CAPLUS

CN Pyrrolidine, 1-[4-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]benzoyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 461023-86-9 CAPLUS

CN Benzamide, 4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]-N-cyclohexyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 461023-88-1 CAPLUS  
 CN Benzamide, 4-[4-[[ (3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-N-(2-hydroxyethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



● HCl


PAGE 1-B



RN 461023-89-2 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[[4-[4-(hydroxymethyl)phenoxy]phenyl]methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/527,435




● HCl

RN 461023-90-5 CAPLUS

CN Methanesulfonamide, N-[4-[4-[[[(3S)-1-butyl-3-[(S)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 461023-92-7 CAPLUS

CN Benzamide, 4-[4-[[[(3R)-1-butyl-3-[(R)-hydroxy(tetrahydro-2H-pyran-4-yl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 461023-93-8 CAPLUS

CN Benzamide, 4-[[[(3R)-1-butyl-3-[(R)-hydroxy(tetrahydro-2H-pyran-4-yl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]-N-[(4-methoxyphenyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 461023-95-0 CAPLUS

CN Benzoic acid, 4-[[[(3R)-1-butyl-3-[(R)-hydroxy(tetrahydro-2H-pyran-4-yl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 461023-96-1 CAPLUS

CN Methanesulfonamide, N-[4-[4-[[[(3R)-1-butyl-3-[(R)-hydroxy(tetrahydro-2H-pyran-4-yl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 461023-98-3 CAPLUS  
 CN Benzamide, 4-[[ (3R)-1-butyl-3-[(R)-cyclopentylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]-N-[(4-methoxyphenyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 461023-99-4 CAPLUS  
 CN Benzamide, 4-[4-[[ (3R)-1-butyl-3-[(R)-cyclopentylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 461024-00-0 CAPLUS  
 CN Benzoic acid, 4-[4-[[ (3R)-1-butyl-3-[(R)-cyclopentylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 461024-01-1 CAPLUS  
 CN Benzamide, 4-[4-[[ (3R)-3-[(1R)-1-hydroxy-2-methylpropyl]-2,5-dioxo-1-propyl-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 461024-03-3 CAPLUS  
 CN Benzamide, 4-[[ (3R)-3-[(1R)-1-hydroxy-2-methylpropyl]-2,5-dioxo-1-propyl-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]-N-[(4-methoxyphenyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 461024-04-4 CAPLUS

CN Benzamide, 4-[4-[[ (3R)-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1-propyl-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 461024-06-6 CAPLUS

CN Benzamide, 4-[[ (3R)-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1-propyl-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]-N-[(4-methoxyphenyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 461024-08-8 CAPLUS

CN Benzoic acid, 4-[4-[[ (3R)-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1-propyl-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 461024-42-0 CAPLUS

CN Propanamide, N-[4-[[ (3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenyl]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl



RN 461024-43-1 CAPLUS  
 CN Acetamide, N-[4-[[ (3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenyl]-2-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 461024-44-2 CAPLUS  
 CN Benzeneacetamide, N-[4-[[ (3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 461024-45-3 CAPLUS  
 CN Benzeneacetamide, N-[4-[[ (3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenyl]-4-fluoro-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 461024-46-4 CAPLUS

CN Benzoic acid, 4-[[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]benzoyl]amino]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 461024-47-5 CAPLUS

CN Benzoic acid, 4-[[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]-, (4-methoxyphenyl)methyl ester, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 461024-49-7 CAPLUS  
 CN Benzoic acid, 4-[4-[[[(3S)-1-butyl-3-[(S)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 461024-54-4 CAPLUS  
 CN Benzamide, 4-[4-[[[(3S)-1-butyl-3-(hydroxymethyl)-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 461024-60-2 CAPLUS  
 CN Benzamide, 4-[4-[[ (3R)-3-[(R)-cyclohexylhydroxymethyl]-1-[(4-methoxyphenyl)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 461024-61-3 CAPLUS  
 CN Benzamide, 4-[4-[[ (3R)-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1-(phenylmethyl)-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 461024-62-4 CAPLUS  
 CN Benzamide, 4-[4-[[ (3R)-3-[(R)-cyclohexylhydroxymethyl]-1-(2-methoxyethyl)-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 461024-63-5 CAPLUS

CN Benzamide, 4-[4-[[ (3R)-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1-(2-pyridinylmethyl)-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-N-methyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 461024-64-6 CAPLUS

CN Benzamide, 4-[4-[[ (3R)-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1-(3-pyridinylmethyl)-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]-N-methyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 461024-69-1 CAPLUS

CN Benzamide, 4-[4-[[ (3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-N-hydroxy-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 461036-49-7 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[[4-[4-(methylsulfinyl)phenoxy]phenyl]methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 59 OF 59 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2001:416939 CAPLUS

DN 135:46203

TI Preparation and effect of triazaspiro[5.5]undecane derivatives as active ingredients in remedy for inflammatory diseases

IN Habashita, Hiromu; Hamano, Shinichi; Shibayam, Shiro; Takaoka, Yoshikazu

PA Ono Pharmaceutical Co., Ltd., Japan

SO PCT Int. Appl., 1149 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001040227	A1	20010607	WO 2000-JP8517	20001201
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2394679	A1	20010607	CA 2000-2394679	20001201
	AU 200116506	A	20010612	AU 2001-16506	20001201
	AU 780419	B2	20050317		
	EP 1236726	A1	20020904	EP 2000-979050	20001201
	EP 1236726	B1	20041201		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2000016111	A	20030325	BR 2000-16111	20001201
	HU 2003000641	A2	20030628	HU 2003-641	20001201
	TW 224597	B	20041201	TW 2000-89125555	20001201
	AT 283854	T	20041215	AT 2000-979050	20001201
	NZ 519183	A	20050225	NZ 2000-519183	20001201
	PT 1236726	T	20050429	PT 2000-979050	20001201
	ES 2233479	T3	20050616	ES 2000-979050	20001201
	RU 2265021	C2	20051127	RU 2002-117652	20001201
	ZA 2002004203	A	20030827	ZA 2002-4203	20020527
	NO 2002002609	A	20020726	NO 2002-2609	20020531
	NO 323631	B1	20070618		
	MX 2002PA05465	A	20031015	MX 2002-PA5465	20020531
	US 2004097511	A1	20040520	US 2003-148382	20030508
	US 7119091	B2	20061010		
PRAI	JP 1999-344967	A	19991203		
	JP 2000-18673	A	20000127		
	JP 2000-27968	A	20000204		
	JP 2000-147882	A	20000519		
	WO 2000-JP8517	W	20001201		
OS	MARPAT 135:46203				
AB	Title compds. [I; R1 = H, aryl, arylalkyloxycarbonyl, alkenyloxycarbonyl, heterocyclylalkyl, alkyl, alkenyl, alkynyl; R2 = alkyl, alkynyl; R3 = H; R4 = alkyl; R5 = H, alkyl], stereoisomers, quaternary ammonium salts thereof, N-oxides thereof and nontoxic salts thereof, are prepared via solid phase synthesis using divinylbenzene-polystyrene or divinylbenzene-Rink resin. Title compds. I, having controlling effects of				



chemokines/chemokine receptors, are useful in preventing and/or treating various inflammatory diseases, asthma, atopic dermatitis, urticaria, allergic diseases, nephritis, nephropathy, hepatitis, arthritis, rheumatoid arthritis, etc. Thus, the title compound II·HCl was prepared and biol. tested.

IT 342910-70-7P 342910-71-8P 342912-16-7P  
 342914-12-9P 342914-15-2P 342914-16-3P  
 342914-17-4P 342914-18-5P 342914-19-6P  
 342914-22-1P 342914-25-4P 342914-27-6P  
 342914-28-7P 342914-30-1P 342914-31-2P  
 342914-32-3P 342914-35-6P 342914-36-7P  
 342914-37-8P 342914-41-4P 342914-43-6P  
 342914-44-7P 342914-46-9P 342914-51-6P  
 342914-53-8P 342914-55-0P 342914-57-2P  
 342914-61-8P 342914-65-2P 342914-87-8P  
 343272-98-0P 343272-99-1P 343274-41-9P  
 343276-63-1P 343276-66-4P 343276-67-5P  
 343276-68-6P 343276-69-7P 343276-70-0P  
 343276-73-3P 343276-76-6P 343276-78-8P  
 343276-79-9P 343276-81-3P 343276-82-4P  
 343276-83-5P 343276-86-8P 343276-87-9P  
 343276-88-0P 343276-92-6P 343276-94-8P  
 343276-95-9P 343276-97-1P 343277-02-1P  
 343277-04-3P 343277-06-5P 343277-08-7P  
 343277-12-3P 343277-16-7P 343277-19-0P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation and effect of triazaspiro[5.5]undecane derivs. as active ingredients in inflammatory disease therapy)

RN 342910-70-7 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-9-[(4-phenoxyphenyl)methyl]-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 342910-71-8 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(1S)-1-hydroxy-2-methylpropyl]-9-[(4-phenoxyphenyl)methyl]-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 342912-16-7 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-(hydroxymethyl)-9-[(4-phenoxyphenyl)methyl]-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 342914-12-9 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-9-[(4-phenoxyphenyl)methyl]-, (3R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 342914-15-2 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-9-[[4-(4-methylphenoxy)phenyl]methyl]-, (3R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 342914-16-3 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-9-[[4-(cyclohexyloxy)phenyl]methyl]-3-[(1R)-1-hydroxy-2-methylpropyl]-, (3R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 342914-17-4 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-9-[[4-[(tetrahydro-2H-pyran-4-yl)oxy]phenyl]methyl]-, (3R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 342914-18-5 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-9-[[4-(3-pyridinyloxy)phenyl]methyl]-, (3R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 342914-19-6 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-9-[[4-(1-methylethyl)phenyl]methyl]-, (3R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 342914-22-1 CAPLUS

CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 342914-25-4 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[(4-phenoxyphenyl)methyl]-, (3R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 342914-27-6 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[[4-(1-methylethyl)phenyl]methyl]-, (3R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 342914-28-7 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[[4-[(6-methyl-3-pyridinyl)oxy]phenyl]methyl]-, (3R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 342914-30-1 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[[4-(4-methoxyphenoxy)phenyl]methyl]-, (3R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 342914-31-2 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[[4-(4-fluorophenoxy)phenyl]methyl]-, (3R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 342914-32-3 CAPLUS

CN Methanesulfonamide, N-[4-[4-[[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]phenyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 342914-35-6 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-(2-butynyl)-3-[(R)-cyclohexylhydroxymethyl]-9-[[4-(1-methylethyl)phenyl]methyl]-, (3R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 342914-36-7 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-(2-butynyl)-3-[(R)-cyclohexylhydroxymethyl]-9-[(4-phenoxyphenyl)methyl]-, (3R)-rel- (9CI)  
(CA INDEX NAME)


Relative stereochemistry.



RN 342914-37-8 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-(2-butynyl)-3-[(R)-cyclohexylhydroxymethyl]-9-[[4-(4-methylphenoxy)phenyl]methyl]-, (3R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 342914-41-4 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-(2-butynyl)-3-[(1R)-1-hydroxy-2-methylpropyl]-9-[[4-(4-methylphenoxy)phenyl]methyl]-, (3R)-rel- (9CI)  
(CA INDEX NAME)

Relative stereochemistry.




RN 342914-43-6 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-(2-butynyl)-3-[(1R)-1-hydroxy-2-methylpropyl]-9-[[4-(1-methylethyl)phenyl]methyl]-, (3R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.






RN 342914-44-7 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-(2-butynyl)-3-[(1R)-1-hydroxy-2-methylpropyl]-9-[(4-phenoxyphenyl)methyl]-, (3R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 342914-46-9 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[(4-phenoxyphenyl)methyl]-, (3S)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 342914-51-6 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(1S)-1-hydroxy-2-

methylpropyl]-9-[(4-phenoxyphenyl)methyl]-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 342914-53-8 CAPLUS

CN Methanesulfonamide, N-[4-[4-[[[(3S)-1-butyl-3-[(1S)-1-hydroxy-2-methylpropyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 342914-55-0 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-9-[(4-phenoxyphenyl)methyl]-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 342914-57-2 CAPLUS

CN Methanesulfonamide, N-[4-[4-[[[(3R)-1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 342914-61-8 CAPLUS

CN Methanesulfonamide, N-[4-[4-[[ (3R)-1-butyl-3-[(1S)-1-hydroxy-2-methylpropyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 342914-65-2 CAPLUS

CN Methanesulfonamide, N-[4-[4-[[ (3S)-1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 342914-87-8 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-(phenylmethyl)-, (3S)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 343272-98-0 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-9-[(4-phenoxyphenyl)methyl]-, hydrochloride (1:1), (3S)- (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 343272-99-1 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(1S)-1-hydroxy-2-methylpropyl]-9-[(4-phenoxyphenyl)methyl]-, hydrochloride (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 343274-41-9 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-(hydroxymethyl)-9-[(4-phenoxyphenyl)methyl]-, monohydrochloride, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 343276-63-1 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-9-[(4-phenoxyphenyl)methyl]-, monohydrochloride, (3R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 343276-66-4 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-9-[[4-(4-methylphenoxy)phenyl]methyl]-, monohydrochloride, (3R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 343276-67-5 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-9-[[4-(cyclohexyloxy)phenyl]methyl]-3-[(1R)-1-hydroxy-2-methylpropyl]-, monohydrochloride, (3R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 343276-68-6 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-9-[[4-[(tetrahydro-2H-pyran-4-yl)oxy]phenyl]methyl]-, monohydrochloride, (3R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 343276-69-7 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-9-[[4-(3-pyridinyloxy)phenyl]methyl]-, dihydrochloride, (3R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 343276-70-0 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-9-[[4-(1-methylethyl)phenyl]methyl]-, monohydrochloride, (3R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 343276-73-3 CAPLUS

CN Benzoic acid, 4-[4-[[[(3R)-1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-, monohydrochloride, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 343276-76-6 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[(4-phenoxyphenyl)methyl]-, monohydrochloride, (3R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 343276-78-8 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[[4-(1-methylethyl)phenyl]methyl]-, monohydrochloride, (3R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 343276-79-9 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[[4-[(6-methyl-3-pyridinyl)oxy]phenyl]methyl]-, dihydrochloride, (3R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.






● 2 HCl

RN 343276-81-3 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[[4-(4-methoxyphenoxy)phenyl]methyl]-, monohydrochloride, (3R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 343276-82-4 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[[4-(4-fluorophenoxy)phenyl]methyl]-, monohydrochloride, (3R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 343276-83-5 CAPLUS  
 CN Methanesulfonamide, N-[4-[4-[[ (3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]phenyl]-, monohydrochloride, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 343276-86-8 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-(2-butynyl)-3-[(R)-cyclohexylhydroxymethyl]-9-[[4-(1-methylethyl)phenyl]methyl]-, monohydrochloride, (3R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 343276-87-9 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-(2-butynyl)-3-[(R)-cyclohexylhydroxymethyl]-9-[(4-phenoxyphenyl)methyl]-, monohydrochloride, (3R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 343276-88-0 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-(2-butynyl)-3-[(R)-cyclohexylhydroxymethyl]-9-[[4-(4-methylphenoxy)phenyl]methyl]-, monohydrochloride, (3R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 343276-92-6 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-(2-butynyl)-3-[(1R)-1-hydroxy-2-methylpropyl]-9-[[4-(4-methylphenoxy)phenyl]methyl]-, monohydrochloride, (3R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 343276-94-8 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-(2-butynyl)-3-[(1R)-1-hydroxy-2-methylpropyl]-9-[[4-(1-methylethyl)phenyl]methyl]-, monohydrochloride, (3R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 343276-95-9 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-(2-butynyl)-3-[(1R)-1-hydroxy-2-methylpropyl]-9-[[4-(1-methylethyl)phenyl]methyl]-, monohydrochloride, (3R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 343276-97-1 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[(4-phenoxyphenyl)methyl]-, monohydrochloride, (3S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 343277-02-1 CAPLUS  
 CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(1S)-1-hydroxy-2-methylpropyl]-9-[(4-phenoxyphenyl)methyl]-, hydrochloride (1:1), (3S)- (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 343277-04-3 CAPLUS

CN Methanesulfonamide, N-[4-[4-[(3S)-1-butyl-3-[(1S)-1-hydroxy-2-methylpropyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 343277-06-5 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-9-[(4-phenoxyphenyl)methyl]-, hydrochloride (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 343277-08-7 CAPLUS  
 CN Methanesulfonamide, N-[4-[4-[[ (3R)-1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 343277-12-3 CAPLUS  
 CN Methanesulfonamide, N-[4-[4-[[ (3R)-1-butyl-3-[(1S)-1-hydroxy-2-methylpropyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 343277-16-7 CAPLUS  
 CN Methanesulfonamide, N-[4-[4-[[ (3S)-1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl]phenoxy]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/527,435




● HCl

RN 343277-19-0 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(1R)-1-hydroxyethyl]-9-[(4-phenoxyphenyl)methyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT



10/527,435

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

323.47

515.38

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-47.20

-47.20

STN INTERNATIONAL LOGOFF AT 23:55:48 ON 02 JAN 2008